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Abstract 
Burkholderia mallei is an intracellular, gram-negative bacterium which causes the disease 
Glanders in humans and mice. Little research has been performed to examine host immune 
responses to this organism. Therefore, the purpose of this work was to characterise host 
immunity to B. mallei by analysing splenic cellular and cytokine responses and systemic 
cytokine responses during intra-peritoneal infection in BALB/c mice. In summary, chronic 
B. mallei infection was characterised by an initial period of bacterial colonisation which 
was limited by the host immune system. This was followed by extensive bacterial 
replication within abscessed spleens. IFN-y was essential for controlling early infection 
and was accompanied by expression of type 1 cytokines and macrophage and neutrophil 
activation within 24 hours post-infection (p. i. ). The IFN-y response was induced 
predominantly in NK cells by IL-12 and IL-18 in vitro, further demonstrating the 
requirement for type 1 immunity to B. mallei infection. TNFa and Gr-1+ cells 
(predominantly neutrophils) were also important in innate host immune responses. T cells 
were not important during this phase but played an important role in adaptive immune 
responses to infection. Downregulation of immune responses occurred 72h p. i. followed by 
an additional period of macrophage and neutrophil activation 5-7 days p. i.. A 
heterogeneous infection developed 14-36 days p. i., with mice either forming abscesses or 
apparently clearing the infection. Abscesses were associated with high bacterial loads and 
inflammation: TNFa and T cells were involved in controlling the infection, although this 
did not prevent bacterial colonisation or eventual lethality 8 weeks p. i.. In conclusion, this 
data shows that early, type 1 immune responses are ultimately overcome leading to 
extensive replication of B. mallei within abscessed tissues. Maintenance of the type 1 cell- 
mediated immune responses observed during early infection is likely to be crucial for the 
development of effective therapies and vaccines against B. mallei. 
2 
Contents 
Abstract 
Contents 
Figures 
2 
3 
11 
Tables 15 
Declaration 17 
Acknowledgements 18 
Dedication 19 
Publications 20 
Abbreviations 21 
CHAPTER 1: INTRODUCTION 24 
1.1 Burkholderia mallei 25 
1.1.1 Introduction 26 
1.1.2 Epidemiology 27 
1.1.3 B. mallei and Biological Warfare 27 
1.1.4 Route of infection 28 
1.1.5 Incubation period 29 
1.1.6 Glanders: characteristics of the disease 30 
1.1.6.1 Natural infection 30 
1.1.6.2 Experimental infection 31 
1.1.7 Diagnosis 33 
1.1.8 Current treatments and prophylaxis 35 
3 
1.1.8.1 Pre-antibiotic treatments 
1.1.8.2 Antibiotic therapy 
1.1.8.3 Alternative Treatments 
1.1.9 Host responses to B. mallei infection 
1.2 Innate immune responses and inflammation 
1.2.1 Bacterial initiation of innate responses 
1.2.2 The Inflammatory response: Cells 
1.2.2.1 Neutrophils 42 
1.2.2.2 Macrophages 44 
1.2.2.3 Dendritic cells 44 
1.2.2.4 Natural Killer (NK) cells 45 
1.2.2.5 T cells 46 
1.2.3 The Inflammatory response: Inflammatory mediators 47 
1.2.3.1 Pro-inflammatory mediators 47 
1.2.3.2 Anti-inflammatory mediators 48 
1.2.3 Cell migration during inflammation 49 
1.2.5 Dysregulation of inflammatory responses: sepsis 50 
1.3 Development of immune responses during intracellular infection 52 
1.3.1 Interferon-y 54 
1.3.2 Type 1 inducing cytokines 56 
1.3.2.1 IL-12 and IL-23 56 
1.3.2.2 IL-18 57 
35 
35 
36 
37 
38 
38 
42 
4 
1.3.2.3 IL-27 57 
1.4 Aims of this research 59 
CHAPTER 2: MATERIALS & METHODS 60 
2.1 Materials 61 
2.1.1 General Reagents 61 
2.1.2 Flow cytometry reagents 61 
2.1.3 RNA extraction and removal of DNA contamination 61 
2.1.4. Gene Amp PCR system 9700 62 
2.1.5 Taqman 7000 PCR system 62 
2.1.6 Agarose Gel Electrophoresis 62 
2.1.7 Depleting Antibodies and cytokines 63 
2.1.8 Mice 63 
2.2 Methods 65 
2.2.1 Summary of experiments to characterise host immune responses during 
intraperitoneal B. mallei infection 65 
2.2.2 In vivo procedures 67 
2.2.2.1 Animal welfare 67 
2.2.2.2 Intraperitoneal injection 67 
2.2.2.3 Temperature monitoring and signs of disease 
2.2.3 Bacterial culture, sample extraction and storage 
68 
68 
2.2.3.1 Burkholderia mallei 68 
2.2.3.2 Heat inactivation of B. mallei 68 
5 
2.2.3.3 Removal of blood samples 69 
2.2.3.4 Preparation of spleens for bacteriological analysis, flow cytometry and RT-PCR70 
2.2.4 Flow cytometric analysis 70 
2.2.4.1 Flow cytometric staining 70 
2.2.4.2 Flow cytometric analysis : Immune Analysis 1 70 
2.2.4.3 Flow cytometric analysis: Immune Analysis 2 72 
2.2.5 Bacteriological analysis 72 
2.2.5.1 Bacterial counts 72 
2.2.5.2 Sterility Check 74 
2.2.6 Cytometric bead arrays 75 
2.2.7 RNA isolation and preparation of cDNA 76 
2.2.7.1 Preparation of RNA-free tubes 76 
2.2.7.2 RNA extraction of experimental samples 76 
2.2.7.3 Removal of DNA contamination from RNA samples 78 
2.2.7.4 Detection of RNA and DNA integrity and contamination 78 
2.2.7.5 Reverse Transcription 
2.2.8 Real Time Polymerase Chain Reaction (RT-PCR) 
80 
83 
2.2.8.1 RT-PCR 83 
2.2.8.2 Data analysis of Real time RT-PCR results 83 
2.2.9 Constant expression of endogenous control (18sRNA) following S. typhimurium 
LPS challenge 86 
2.2.10 Antibody depletion experiments 88 
6 
2.2.10.1 Neutrophil depletion 88 
2.2.10.2 TNFa neutralisation 88 
2.2.10.3 T cell depletion 92 
2.2.11 In vitro stimulation of spleen cells 94 
2.2.11.1 Preparation and stimulation of spleen cell suspensions 94 
2.2.11.2 Intracellular IFN-y staining for flow cytometry 94 
2.2.12 Statistical Analysis 95 
2.2.12.1 Analysis of temperature data 95 
2.2.12.2 Analysis of in vivo infection data 95 
2.2.12.3 Analysis of in vitro stimulation data 96 
CHAPTER 3: CHARACTERISATION OF AN INTRAPERITONEAL MODEL 
OF B. MALLEI INFECTION. 97 
3.1 Introduction 98 
3.2 Methods 99 
3.3 Results 100 
3.3.1 Signs of disease and temperature changes 100 
3.3.2 Bacteriological analysis and abscess formation 104 
3.4 Discussion 107 
CHAPTER 4: CHARACTERISATION OF NEUTROPHIL AND MACROPHAGE 
RESPONSES DURING B. MALLEI INFECTION 111 
4.1 Introduction 112 
4.2 Methods 113 
4.3 Results 114 
7 
4.3.1 Neutrophil responses during B. mallei infection 114 
4.3.1.1 Splenic Neutrophil infiltration 114 
4.3.1.2 Splenic Neutrophil activation 119 
4.3.1.3 Characterisation of splenic Gr-1+ populations 122 
4.3.1.3 Depletion of Gr-1+ populations during B. mallei infection 125 
4.3.2 Macrophage responses 125 
4.3.2.1 Splenic Macrophage infiltration 125 
4.3.2.2 Splenic Macrophage activation 129 
4.4 Discussion 132 
CHAPTER 5: CHARACTERISATION OF LYMPHOCYTE RESPONSES 
DURING B. MALLEI INFECTION 137 
5.1 Introduction 138 
5.2 Methods 139 
5.3 Results 140 
5.3.1 Lymphocyte responses 140 
5.3.1.2 T cell and B cell infiltration 140 
5.3.1.3 T cell activation 144 
5.3.2 The role of T cells during B. mallei infection 150 
5.3.2.1 Specificity of anti-CD4 and CD8 antibodies 150 
5.3.2.2 T cell depletion during B. mallei infection 150 
5.4 Discussion 154 
8 
CHAPTER 6: CHARACTERISATION OF CYTOKINE RESPONSES DURING 
B. MALLEIINFECTION. 158 
6.1 Introduction 
6.2 Methods 
6.3 Results 
6.3.1 Validation of endogenous control (18sRNA) 
6.3.2 Splenic cytokine mRNA responses 
6.3.3 Splenic cytokine expression during B. mallei infection 
6.3.4 Systemic cytokine responses 
6.3.5 The role of IFN-y during B. mallei infection. 
6.3.5.1 Infection of IFN-y knockout mice with B. mallei 
6.3.6 The role of TNFa during B. mallei infection 
6.3.6.1 Specificity of TNFa antibodies 
6.3.6.2 Depletion of TNFa during B. mallei infection 
159 
160 
161 
161 
161 
164 
173 
176 
176 
176 
178 
178 
6.4 Discussion 183 
CHAPTER 7: INDUCTION AND PRODUCTION OF IFN-y IN RESPONSE TO 
HEAT-KILLED B. MALLEIIN VITRO 190 
7.1 Introduction 191 
7.2 Methods 192 
7.3 Results 194 
7.3.1 Induction of IFN-y in response to B. mallei in vitro 194 
7.3.1.1 IL12p35 and IL12p40 194 
9 
7.3.1.2 IL-18 194 
7.3.1.3 IL-27 196 
7.3.1.4 IL-6 196 
7.3.2 Cellular sources of B. mallei-induced IFN-y in vitro _ 
7.3.2.1 Effects of Gr-1 depletion on B. mallei induced IFN-y 
7.4 Discussion 
CHAPTER 8: GENERAL DISCUSSION 
8.1 Introduction 
201 
208 
210 
214 
215 
8.2 The early, innate response to B. mallei infection: 5-24 h p. i. 215 
8.3 Downregulation of immune responses: Day 3 p. i. 220 
8.4 The intermediate phase of infection: Days 5-14 p. i. 222 
8.5 The chronic phase of infection: Days 14-36 223 
8.6 Conclusions 226 
Bibliography 229 
10 
Figures 
Figure 1.1: Immunogold electron microscopy of a B. mallei bacterium 
Figure 1.2: Diagram showing a common pathway of activation of inflammatory mediators 
via Toll-like receptors (TLR) 4 and TLR9 and the nuclear transcription factor NFKB. 
Figure 1.3: Representation of the inflammatory response following bacterial infection of 
the spleen. 
Figure 1.4: Representation of the interactions occurring between cytokines in type 1 
immune responses during intracellular infection. 
Figure 2.1: Summary of the experimental process from the removal of a spleen from a 
BALB/c mouse to the final PCR product. 
Figure 2.2: Hotstart 36 PCR programme. 
Figure 2.3: Reverse transcription reaction programme. 
Figure 2.4: Taqman programme. 
Figure 3.1: Number of BALB/c mice surviving following intraperitoneal infection with 1 
x 106 cfu B. mallei. 
Figure 3.2: Temperature and symptoms measured in animals from cage A in the morning 
and the afternoon. 
Figure 3.3: Temperature and symptoms measured in animals from cage B in the morning 
and the afternoon. 
Figure 3.4: The number of colonies detected in the spleens of BALB/c mice infected with 
Ix 106 cfu B. mallei over the first 7 days of infection. 
Figure 3.5: The number of colonies detected in the spleens of BALB/c mice infected with 
Ix 106 cfu B. mallet over 36 days of infection. 
Figure 4.1: Splenic cell populations in a naive and an infected mouse. 
Figure 4.2: Representative flow cytometry histograms to indicate positive staining profiles 
of neutrophils during B. mallei infection. 
11 
Figure 4.3: Splenic Gr-1+ neutrophil populations during B. mallei infection. 
Figure 4.4: Comparison of splenic neutrophil populations during B. mallei infection in 
Immune Analysis 1 and 2. 
Figure 4.5: Activation status of splenic Gr-l+ neutrophils during the first 7 days of B. 
mallei infection. 
Figure 4.6: Activation status of splenic Gr-1+ neutrophils during B. mallei infection. 
Figure 4.7: CD54+ neutrophils are associated with abscessed spleens. 
Figure 4.8: Gr-1+ neutrophil and macrophages identified in the spleens of naive BALB/c 
mice. 
Figure 4.9: Splenic Gr-1+ cell populations depleted by RB6-8C5 antibodies. 
Figure 4.10: Survival of BALB/c mice following depletion of Gr-1+ cells during B. mallei 
infection. 
Figure 4.11: Splenic F4/80+ macrophage populations during B. mallei infection. 
Figure 4.12: F4/80 macrophage populations expressing different levels of CD54 and 
MHCII. 
Figure 4.13: Activation status of splenic F4/80+ macrophages during the first 7 days of B. 
mallei infection. 
Figure 5.1: Representative flow cytometry histograms to indicate positive staining profiles 
of CD3+ T and CD 19+ B cells during B. mallei infection. 
Figure 5.2: Splenic CD3+ T cell and CD19+ B cell populations during B. mallei infection. 
Figure 5.3: A comparison of the splenic CD3+ T cell population in BALB/c mice during 
B. mallei infection in Immune Analysis (1) and (2). 
Figure 5.4: Representative flow cytometry histograms indicating positive staining profiles 
of T cell activation markers during B. mallei infection. 
Figure 5.5: CD25 expression on splenic CD3+ T cells during the first 7 days of B. mallei 
infection in Immune Analysis (1) and (2). 
12 
Figure 5.6: CD54 expression on splenic T cells during the first 7 days of B. mallei 
infection in Immune Analysis (1) and (2). 
Figure 5.7: CD54 expression on splenic T cells from 21-36 days post-infection with B. 
mallei during Immune Analysis (1). 
Figure 5.8: High intensity expression of CD44 on T helper and cytotoxic T cell subsets 
during the first 7 days of B. mallei infection. 
Figure 5.9: Splenic T cell populations in BALG/c mice identified by flow cytometry 
following administration of CD4 and/or CD8 antibodies to BALB/c mice. 
Figure 5.10: Survival of BALB/c mice following depletion of T cell populations during B. 
mallei infection. 
Figure 6.1: Mean threshold cycle values for 18sRNA, TNFa and IL-10 in the spleens of 
BALB/c mice following LPS challenge. 
Figure 6.2: Comparison of the relative fold increase in splenic mRNA expression between 
infected and control BALB/c mice of cytokines investigated from 24 hours to 7 days post- 
infection with B. mallei. 
Figure 6.3: Splenic expression of IL-18 and IL-1ß during B. mallei infection of BALB/c 
mice. 
Figure 6.4: Splenic expression of TNFa, GM-CSF and IL-10 during B. mallet infection of 
BALB/c mice. 
Figure 6.5: Splenic expression of IFN-y, IL-6 and IL-27 during B. mallei infection of 
BALB/c mice. 
Figure 6.6: Splenic expression of IL12p35 and IL12p40 during B. mallei infection of 
BALB/c mice. 
Figure 6.7: Comparison of bacterial colonisation and cytokine expression in the spleen for 
IFN-y, IL-6, IL-27, TNFq IL12p35, GM-CSF and IL-10. 
Figure 6.8: Comparison of bacterial colonisation and cytokine expression in the spleen for 
IL12p40, IL-18 and IL-1 ß. 
13 
Figure 6.9: Splenic cytokine expression is related to abscess formation during B. mallei 
infection. 
Figure 6.10: Systemic cytokine responses during B. mallei infection. 
Figure 6.11: Systemic cytokine responses during 36 days of B. mallei infection (Immune 
Analysis 1). 
Figure 6.12: IFN-y is essential for protection against B. mallei infection. 
Figure 6.13: TNFa antibodies reduce TNFa-mediated macrophage activation. 
Figure 6.14: Bacterial counts detected in the spleens of BALB/c mice 7 days following 
infection with B. mallei treated with TNFa antibodies. 
Figure 6.15: Survival of BALB/c mice treated with TNFa antibodies 6 weeks following 
infection with B. mallei. 
Figure 7.1: Mean cytokine production in cell culture supernatants following in vitro 
stimulation of spleens from IL12p35KO and IL12p4OKO with heat-killed B. mallei. 
Figure 7.2: Mean cytokine production in the supernatant following in vitro culture of 
C57BL/6 spleens with IL-18R antibody and heat-killed B. mallei. 
Figure 7.3: Mean cytokine production in the supernatant following in vitro culture of 
spleens from WSX-IKO (IL-27 receptor) mice stimulated with heat-killed B. mallet. 
Figure 7.4: Mean cytokine production in the supernatant following in vitro culture of 
spleens from IL-6KO mice stimulated with heat-killed B. mallei. 
Figure 7.5: Mean IFN-y production in the supernatant following in vitro stimulation of 
splenic cell cultures from C57BL/6 and BALB/c mice with IL-6. 
Figure 7.6: Intracellular IFN-'y production in T cells and NK cells in response to heat- 
killed B. mallei in vitro. 
Figure 7.7: Mean percentage of IFN-y+ T cells and NK cells produced in response to heat- 
killed B. mallei in vitro. 
Figure 7.8: Intracellular IFN-y production in T cells and NK cells in response to heat- 
killed B. mallei in vitro. 
14 
Figure 7.9: Intracellular IFN-y production in NK cells in response to a combination of IL- 
12 and IL-18 in vitro. 
Figure 7.10: Percentage of IFN-y+ NK cells detected in response to heat-killed B. mallei 
following IL-18R neutralisation in vitro. 
Figure 7.11: Intracellular IFN-y production in T cells and NK cells in response to heat- 
killed B. mallei in vitro. 
Figure 7.12: The role of Gr-1+ cells in cytokine production in response to heat-killed B. 
mallei in vitro. 
Figure 8.1: Summary of host immune responses occurring in the spleen during the first 24 
hours of B. mallei infection in BALB/c mice. 
Figure 8.2: Proposed mechanism of protective immunity to B. mallei infection. 
Tables 
Table 2.1: Antibody clone, target and isotype for monoclonal antibodies used during 
depletion experiments. 
Table 2.2: Summary of experiments performed to characterise the disease and host 
immune responses following intraperitoneal infection with B. mallei 
Table 2.3: Stains used for flow cytometric analysis of samples during Immune Analysis 1. 
Table 2.4: Stains used for flow cytometric analysis of samples obtained during Immune 
Analysis 2. 
Table 2.5: PCR reaction mixture using the HotstartTM kit. 
Table 2.6: Reaction mixture for reverse transcription using OmniscriptTM kit. 
Table 2.7: Cytokine and endogenous control gene cDNA targets for primers and probes in 
PDAR and AoD products. 
Table 2.8: Reaction mixture for Taqman PCR reactions using PDAR and AoD products. 
Table 2.9: Stains used for flow cytometric analysis of spleen samples. 
15 
Table 2.10: Description of TNFa neutralisation groups and the antibody dosing regimen 
for each group post-infection. 
Table 2.11: Description of T cell depletion groups. 
Table 7.1: Summary of the mouse strains and antibodies used to determine the role of IL- 
6, IL-27, IL12p35, IL12p4O, IL-18 and Gr-1+ cells on IFN-y production in vitro. 
16 
Declaration 
I hereby declare that the material contained within this report has not previously been 
submitted for any other qualification. The work contained within this report was performed 
by myself, unless otherwise stated and all sources of reference and information have been 
appropriately acknowledged. 
17 
Acknowledgements 
I would like to give a big thanks to my supervisor Roman Lukaszewski for all his advice, 
technical assistance, patience and support throughout the entirety of my PhD studies. I 
would also like to acknowledge my PhD advisor Greg Bancroft at the London School of 
Hygiene and Tropical Medicine (LSHTM) who provided me with expert immunological 
advice and the opportunity to work in his lab. I would also like to thank my Director of 
Studies, Diane Williamson, especially for her advice in the later stages of in writing this 
thesis, and to Rob for bypassing sleep to finish reading the final version of this work. 
Thank you to Michelle, Morwenna and Peter and everyone else who has supported me 
throughout this work. I would like to thank Roman, Steve Lever and Kate Griffin for their 
technical support and advice during all ACDP Category III animal experiments and to 
thank all the staff responsible for animal husbandry and animal checking who spent their 
valuable time taking temperatures and recording signs and symptoms at weekends. I would 
like to thank Matt Jackson for providing technical assistance during PCR analysis of 
samples and providing me with welcome scientific distractions from my PhD. I would like 
to give a big thanks to Bob Gwyther for providing me with statistical advice on numerous 
occasions. I would also like to thank Ashraful Haque and Helena Helmby at the LSHTM 
for their constant supply of spleens from IL-12KO mice and Alison Bancroft at 
Manchester University for processing and sending supernatants from IL-6 and IL-27R-KO 
mice for further analysis. 
I would like to acknowledge Dstl for providing the required facilities and for funding me 
throughout the work presented in this thesis. I would also like to thank Dstl for its generous 
maternity leave and flexible working during this project. 
18 
Dedication 
This thesis is dedicated to my family. 
To my little flower Florence for her love, and providing me with many happy distractions 
from writing. To Rob, without whose love, support and endless visits to the `animals' I 
wouldn't have been able to complete this thesis - Thank you. To my precious bump, who 
has been my constant companion throughout the final writing of this thesis, becoming my 
little cherub Charlotte before final completion of this thesis. 
To my Mum and Dad whose love, support and encouragement throughout my whole life, 
and in the last couple of years as grandparents, has given me the opportunity to begin and 
complete this PhD. Thankyou for everything. To David, and especially my little sis Jenny, 
for their constant unconditional love, help and friendship. To my grandparents who have 
continually provided me with love and support throughout my life. 
19 
Publications 
Open literature 
The critical role of Type 1 cytokines in controlling initial infection with Burkholderia 
mallei. Caroline A. Rowland, Ganjana Lertmemongkolchai, Alison Bancroft, Ashraful 
Haque, M. Stephen Lever, Kate F. Griffin, Matthew C. Jackson, Michelle Nelson, Anne 
O'Garra, Richard Grencis, Gregory J. Bancroft, Roman A. Lukaszewski. Infection and 
Immunity 74 (9): 5333-40; September 2006. 
Conference presentations 
The Inflammatory response in mice following Burkholderia mallei infection. Caroline 
A. Rowland, K. F. Griffin, M. S. Lever & Roman A. Lukaszewski. BSI Annual congress, 
Harrogate, December 2002. 
Early IFN-y-mediated control of Burkholderia mallei infection coincides with 
increased expression of IL-6 and IL-27. Caroline A. Rowland, K. F. Griffin, M. S. Lever 
& Roman A. Lukaszewski. BSI Annual congress, Harrogate, December 2003. 
The Role of Ly6G+ neutrophils during Burkholderia mallei infection. Caroline A. 
Rowland & Roman A. Lukaszewski. BSI Annual congress, Harrogate, December 2004. 
20 
Abbreviations 
Ab - Antibody 
ACDP - Advisory Committee on Dangerous Pathogens 
ANOVA - Analysis Of Variance 
AoD - Assay on Demand 
ATCC - American Tissue Culture Collection 
B. m. - Heat killed Burkholderia mallei 
CARS - Compensatory Anti-inflammatory Response Syndrome 
CBA - Cytometric Bead Array 
CD - Complimentary Determining 
cDNA - complementary DNA 
cfu - Colony forming unit 
CpG - Cytosine linked to a Guanine by a Phosphate bond 
CR3 - Receptor for Complement component 3 
Ct - Threshold cycle 
DC - Dendritic cell 
DEPC - Diethyl-pyruvate carbonate 
DNA - Deoxyribosenucleic acid 
FCS - Foetal calf serum 
FITC - Fluorescein isothyiocyanate 
FS - Forward Scatter 
GM-CSF - Granulocyte Macrophage Colony Stimulating Factor 
ICAM - Intercellular Adhesion Molecule 
IFN - Interferon 
Ig - Immunoglobulin 
IKK - IkB kinase 
21 
IL - Interleukin 
IL-18 R- IL-18 Receptor 
i. p. - Intraperitoneal 
IRAK - Interleukin-1 receptor associated kinase 
KO - Knockout 
LBP - Lipopolysaccahride Binding Protein 
LPS - Lipopolysaccharide 
MCP-1 - Macrophage Chemoattractant Protein-1 
MHC - Major Histocompatability Complex 
MOPS - Morpholinopropane Sulphonic acid 
mRNA - messenger RNA 
NADPH - Nicotinamde Adenine Dinucleotide Phosphate Hydrogen 
NK - Natural Killer 
NOD - Nucleotide-binding Oligomerisation Domain 
NOS - Nitric Oxide Synthetase 
NO - Nitric Oxide 
PAMPs - Pathogen-associated Molecular Patterns 
PBS - Phosphate Buffered Saline 
PDAR - Predetermined Assay Reagents 
PE-Cy5 - Phycoerythrin-cyanin 5 
PCR - Polymerase Chain Reaction 
pDC - Plasmacytoid Dendritic Cell 
PE - Phycoerythrin 
p. i. - Post-infection 
PMN - Polymorphnuclear 
PRRs - Pattern Recognition Receptors 
ROI - Reactive Oxygen Intermediate 
22 
ROS - Reactive Oxygen Species 
RNA - Ribose Nucleic Acid 
RNS - Reactive Nitrogen Species 
RT - Room Temperature 
RT-PCR - Reverse Transcriptase Polymerase Chain Reaction 
SIRS - Systemic Inflammatory Response Syndrome 
SOCS - Suppressor of Cytokine Signalling 
SS - Side Scatter 
STAT - Signal Transducing Activator of Transcription 
Th cell -T helper cell 
Tc cell - Cytotoxic T cell 
TGF - Tumour Growth Factor 
TIR - Toll-IL-1-Receptor 
TLR - Toll-like receptor 
TNF - Tumour Necrosis Factor 
23 
Chapter 1 Introduction 
24 
1.1 Burkholderia mallei 
1.1.1 Introduction 
Burkholderia mallei is a Gram-negative, non-motile, aerobic, non-spore forming bacillus 
and an obligate animal parasite (Figure 1.1). In humans, the nasal and pulmonary form of 
the disease caused by B. mallei is known as glanders whereas a cutaneous form of the 
disease affecting the lymphatic system is known as Farcy (McGilvray, 1944a). Glanders is 
principally a disease of solipeds (horses, donkeys and mules) but can infect humans 
(Bernstein & Carling, 1909; Bristow & White, 1910; Howe & Miller, 1947; Srinivasan et 
at, 2001) and other animal species such as cats and dogs (Blancou, 1994). Experimental 
animal models exist including monkeys (Kalachev et at, 1997; Khomyakov et at, 1998) 
guinea pigs and ferrets (Miller et at, 1948a), hamsters (Fritz et at, 1999), mice (Fritz et at, 
2000) and the invertebrate species Caenorhabditis elegans (0' Quinn et at, 2001). Other 
animals, including cattle, sheep, swine (McGilvray, 1944a), rabbits and white rats (Miller 
et at, 1948a) are not susceptible to B. mallei infection. Limited studies have been 
undertaken to study B. mallei infection, possibly due to the few natural cases now observed 
in the Western world and the dangerous nature of working with this pathogen. 
The Burkholderia genus contains a number of bacteria including the human pathogens B. 
mallei, B. pseudomallei, B. cepacia, B. gladioli and B. pickettii. Burkholderia mallei and B. 
pseudomallei are close phylogenetic relatives and some strains of B. mallei are 
antigenically related to B. pseudomallei (Anuntagool & Sirisinha, 2002). Examination of 
population genetics suggests that B. mallei and B. pseudomallei share a large proportion of 
25 
7 ; 
'. 
'. 
- 
. 'I 
. +.; ý 
.. . 4.. -e, 
ý. Capsule 
"y, 'ý 
ý" 
1".. 
f 
.. s .. .44S 
V 
yý__w 
4 'r 
ýý 
I 
Figure l. l: Immunogold electron microscopy of a B. mallei bacterium (strain 
ATCC23344). The capsule of the bacterium is visible and surrounds the cell. The bar 
represents 500nm. Reproduced from l)eShazer el al, 2001. 
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-w.. 
allelic loci and that on this basis, both bacteria belong to the same species despite their 
differing disease profiles (Godoy et al, 2003). 
1.1.2 Epidemiology 
Glanders has been eradicated from most of the Western World due to a policy to slaughter 
all infected animals or potentially exposed ones and strict quarantine controls. Glanders 
was eradicated from Canada by 1915 (McGilvray, 1944a) and the USA by 1934 (Sharrer, 
1995). It is a notifiable disease in most countries (including the UK) due to its 
pathogenicity in humans and animals (Muhammad et al, 1998). During the 1990s glanders 
was reported to be endemic in Asia and Africa (Dance, 1990) and prevalent in developing 
countries such as India (Verma, 1981), Turkey (Arun et al, 1999) and Pakistan 
(Muhammad et al, 1998) where it is mainly associated with disease in horses although 
human cases are occasionally reported (Arun et al, 1999). The latest report showing B. 
mallei cases was produced in 1999 and countries reporting the disease were Brazil, 
Pakistan and Mongolia (Derbyshire, 2002). 
1.1.3 B. mallei and Biological Warfare 
Horses were the main form of civilian and military transport in the 19th and early 20th 
centuries and infection of horses with B. mallei caused serious tactical and strategic 
problems during the American Civil war (Sharrer, 1995). It has also been suggested that 
during the 1s` and 2"d World Wars glanders was used as a form of biological warfare to 
infect military horses thus depleting military capability (Christopher et al, 1997; Wheelis, 
1998 [communication]). Samples obtained from the German Legation in 1916 contained B. 
mallei cultures and Romanian sheep to be transported to Russia during World War I were 
infected with B. mallei (Christopher et al, 1997). Burkholderia mallei is currently 
considered to be a potential biological warfare agent (Rosenbloom et al, 2002). 
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1.1.4 Route of infection 
Burkholderia mallei may be transmitted via a number of routes to cause disease. 
Accidental inhalation of aerosolised B. mallei produced during laboratory procedures was 
the most likely source of infection in 6 human cases of laboratory acquired glanders (Howe 
& Miller, 1947). Transmission via the inhalation route has also been demonstrated 
experimentally in hamsters (Miller et al, 1948a) and in BALB/c mice (Lever et al, 2003) 
following aerosolisation of B. mallei. Direct contamination of broken skin or wounds with 
the bacterium has been demonstrated in laboratory infection (Bernstein & Carling, 1909) 
and was thought to be the most likely mode of infection in a recent laboratory acquired 
case of glanders (Srinivasan et al, 2001). Inoculation of pus from infected animals or 
humans into another animal experimentally also allows transfer of the disease (Blancou, 
1994). A mortality rate of 56% was reported in acute human cases of the disease following 
wound inoculation with further deaths occurring within 5 years in chronic forms of the 
disease (Bristow & White, 1910). 
Natural transmission of glanders in horses may occur via ingestion from shared feeding 
troughs and water supplies (Verma, 1981; Shaffer, 1995). Transmission of the disease via 
nasal discharge from infected horses rubbing noses with each other has also been reported 
(Blancou, 1994; Sharrer, 1995). Burkholderia mallei infection is also naturally acquired by 
humans via transmission from horses (Bernstein & Carling, 1909; Gaiger, 1913; 
McGilvray, 1944a; McGilvray, 1944b; Arun et al, 1999) and cases of Glanders have been 
reported in people who worked closely with horses including grooms, stable workers and 
veterinarians (Bernstein & Carling, 1909; Blancou, 1994). Human to human transmission 
may occur with carers and family members of patients with glanders contracting the 
disease. In some cases the disease was sexually transmitted, with wives of sufferers 
becoming infected per vaginum (Bristow & White, 1910). 
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1.1.5 Incubation period 
Varying incubation periods for the disease exist and months or years may elapse between 
the time of infection and the onset of disease (Bernstein & Carling, 1909). An incubation 
period of about 10-14 days has been recorded in some cases of laboratory acquired 
infection although the exact time of exposure of the infected individuals was not known 
(Howe & Miller, 1947). Following exposure of one individual to an infected horse an 
incubation time of 2 days was recorded (McGilvray, 1944b). The likelihood of infection 
with B. mallei is increased by factors such as overcrowding and poor housing of horses and 
immunosuppression due to other infections (Verma, 1981; Sharrer, 1995). Climatic 
conditions also affect the spread of glanders. B. mallei is easily destroyed by heat and 
dessication (Verma, 1981) but can remain viable in tap water for at least 4 weeks (Miller et 
al, 1948b). Therefore, rainy seasons in countries like India enhance the spread of disease 
with warmth and moisture allowing bacterial survival (Verma, 1981). Diabetes has also 
been implicated in increasing susceptibility to infection with Burkholderia spp. (Simpson, 
2000) and the most recent case of human glanders occurred in an individual with Diabetes 
mellitus (Srinivasan et al, 2001). 
Latency of infection has been recognised in human cases. Chronic cases may develop into 
the acute form of the disease from weeks, months or up to 10 years following infection 
(Berstein & Carling, 1909). Pathological signs of the disease have also been discovered 
during autopsies of people who worked with infected horses but did not die as a result of 
glanders (Bernstein & Carling, 1909) suggesting a much higher prevalence of human 
infection than previously recorded. This latency may result from B. mallei acting as an 
intracellular pathogen (Arun et al, 1999). 
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1.1.6 Glanders: characteristics of the disease 
1.1.6.1 Natural infection 
1.1.6.1.1 Human cases 
Glanders is a rare disease in humans and most reported cases have been due to working 
with infected animals, particularly horses, or from laboratory acquired infections. 
However, the number of cases reported is likely to be only a small proportion of the 
number of infected people due to difficulties in diagnosing the disease. Cases of human 
glanders have been misdiagnosed and patients treated for other diseases including syphilis, 
typhus, tuberculosis and typhoid before correct diagnosis (Bristow & White, 1910). In the 
acute form of the disease general symptoms include high fever, mucopurulent nasal 
discharge, overwhelming exhaustion (Bernstein & Carling, 1909) and respiratory distress 
(Srinivasan et al, 2001) leading to pneumonia and/or septicaemia and death in up to 100% 
of cases if left untreated (Howe & Miller, 1947). Other symptoms observed include 
subcutaneous and intra-muscular abscesses, nodules and abscesses on the limbs, pus-filled 
abscesses and nodules in the lungs and ulceration of mucosal surfaces (Bernstein & 
Carling, 1909). Swollen lymph nodes, chest pain, cough, fatigue, general malaise and night 
sweats have also been reported (Howe & Miller, 1947; Srivinasan et al, 2001). Severe pain 
can occur following the development of skin ulcers, bone infections and abscesses at 
multiple sites within the body and the continual development of new lesions may occur for 
many months (Gaiger, 1913). Abscesses in the liver and spleen may also be present. In the 
last recorded human case, glanders was diagnosed in a US Defence laboratory worker 
following a systemic febrile illness (Srinivasan, 2001; Anon, 2001). In this case, a chest 
radiograph revealed diffuse airspace infiltrates in the lung. In the liver and spleen cystic 
lesions were revealed using a computer topography (CT) scan suggesting the presence of 
abscesses that were more pronounced in the spleen (Georgiades & Fishman, 2001). 
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1.1.6.1.2 Equine cases 
Glanders in equine species occurs in an acute or chronic form. In mules and asses the 
disease is principally acute whereas in horses the disease is often chronic (Verma, 1981), 
although an acute phase may develop following chronic disease. Symptoms commonly 
found in glanderous horses with the acute form of the disease include a high fever, and 
thick nasal discharge followed by death after a few days (Sharrer, 1995). In the chronic 
form of the disease nasal, pulmonary and cutaneous forms exist (Sharrer, 1995). Other 
symptoms include bloody, mucopurulent nasal discharge, nodules and ulceration of nasal 
tissue, sinuses and lungs (Arun et al, 1999). Enlargement of the lymph nodes, cough, 
debilitation and loss of stamina in horses whilst working are also features of the disease 
(Muhammad et al, 1998). An intratracheal experimental model of acute equine glanders 
exists to study pathogenesis of disease and to assess the efficacy of potential vaccine 
candidates for B. mallei infection. Similar disease characteristics to natural equine 
infection occur in this model of infection and neurological degeneration was observed 
suggesting that B. mallei may invade the brainstem or spinal cord (Lopez et al, 2003). 
1.1.6.2 Experimental infection 
Experimental animal models of infection allow in-depth characterisation of the disease 
where parameters such as dose, route of infection and time course of infection can be 
controlled. This information can be used to allow development of therapies against B. 
mallei, diagnosis of disease and predicting the outcome of infection. 
1.1.6.2.1 Non-human primate 
In experimental non-human primate models of glanders, variation in individual 
susceptibility to the disease is evidently similar to human forms of the disease (Manzeniuk 
et al, 1997). Several outcomes to the infection are observed, with some animals having no 
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external signs of disease, others having obvious signs of disease associated with pyrexia 
(>39.5°C) and in other individuals the infection is fatal. 
Following subcutaneous and intravenous infection (2.5 x 108 cfu) of non-human primates 
(baboon-hamadryads), severe glanders develops within 1-2 days. This was characterised by 
fever, apathy, anorexia, multiple abscesses and cutaneous ulcers on the head and 
extremities followed by death 5 days post-infection (p. i. ) (Khomyakov et al, 1998). Post- 
mortem investigation of monkeys with lethal outcome of disease showed suppurative 
inflammation of local lymph nodes, oedema and haemorrhage in remote lymph nodes, 
enlarged liver and kidneys and oedema in the lungs, pleural space and spleen. Destruction 
of lymphoid tissues prevented control of the infection leading to bacteraemia and septic 
shock. In the chronic form of the disease, extensive abscesses were infiltrated by 
lymphocytes which developed in the soft tissues of upper and lower extremities. 
Progressive damage to kidneys, liver, spleen and lungs occurred, characterised by 
substitution of functional structures with connective tissue (Manzeniuk et al, 1997). 
1.1.6.2.2 Experimental Rodent Models 
Both outbred (Porton) and inbred (BALB/c and C57BL/6) mouse strains (Fritz et al, 2000; 
Amemiya et al, 2002) have been used to study glanders following intraperitoneal challenge 
and more recently an aerosol model of infection in BALB/c mice has been developed 
(Lever et al, 2003). 
Intraperitoneal infection of BALB/c mice with 106 B. mallei organisms induces a systemic 
infection characterised by histopathological changes in the lymph nodes, bone marrow, 
liver and spleen (Fritz et al, 2000). Livers and spleens of mice contain high numbers of 
bacteria and mild splenomegaly (increasing over the time course of infection) and thymic 
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atrophy are observed from day 2 p. i.. Varying numbers of bacteria are detected in the blood 
and lungs in different mice but by day 3 post-infection, bacteria are not found in the blood. 
During the first 4 days of infection mice are overtly ill but begin to recover after 5 days and 
appear normal at day 7 even though bacterial numbers remain high in the liver and spleen. 
Intraperitoneal challenge with 107 B. mallei organisms causes an acute disease and 75% of 
mice die by day 3 post-infection. Splenomegaly, pathological changes to the liver and 
bacterial colonisation of the blood, lung, liver and spleen occurs in most animals (Fritz et 
al, 2000). Aerosol infection of BALB/c mice with B. mallei causes a disease similar to 
acute human glanders with highest bacterial numbers detected in the lungs. Mice are more 
susceptible to the disease following challenge via the aerosol route with a 1000-fold lower 
median lethal dose in comparison to intraperitoneal challenge (Lever et al, 2003). 
Following aerosol infection of mice, hamsters and guinea pigs the pathogen is localised in 
the respiratory organs leading to haemorrhage 3-12 hours post-infection. Inflammation and 
bronchopneumonia develop in the lungs within 24 hours. Rapid dissemination of the 
infection follows, possibly via alveolar macrophages spreading bacteria to local lymph 
nodes. This leads to bacteraemia, bacteriuria and colonisation of the liver and spleen 24 
hours p. i. where metastatic inflammation develops. In the terminal stages of the disease, 
colonisation and necrosis of the internal organs occurs followed by septicaemia and death 
within 3-14 days, depending on species (Alekseev et al, 2000). 
1.1.7 Diagnosis 
The wide range of symptoms and variability in outcome between individuals leads to 
difficulties in diagnosing glanders definitively (Bernstein & Carling, 1909; McGilvray, 
1944; Howe & Miller, 1947; Srinivasan et al, 2001). Granulomatous lesions which develop 
in chronic glanders are hard to distinguish from those produced during infection with M. 
tuberculosis or syphilis (Bernstein & Carling, 1909). The Mallein test is used for the 
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diagnosis of glanders in horses and has been used in the diagnosis of human glanders 
(Bernstein & Carling, 1909; Howe & Miller, 1947). It involves giving autoclaved B. mallei 
sub-cutaneously to an animal or human suspected of carrying the bacillus either 
chronically or in a latent form. A positive reaction in both humans and horses may cause 
local swelling and/or pain at the site of injection, rigors and increases in temperature 
(Bernstein & Carling, 1909; McGilvray, 1944a). Modern methods in molecular biology 
allow more definitive identification of bacterial species. Gas-liquid chromatography of 
cellular fatty acids and 16S ribosomal RNA gene-sequence analysis on bacteria isolated 
from an infected individual allowed clinical identification of B. mallei (Srinivasan et al, 
2001). However, these methods rely on the isolation of bacteria. This may delay 
identification as bacterial blood cultures often prove negative even when acute abscesses 
are present (Bernstein & Carling, 1909; Howe & Miller, 1947) and bacteria may not enter 
the bloodstream until the final stages of the disease. 
Detection of B. mallei antigen in experimental models of infection is possible by 
chemiluminescent immunoanalysis and solid phase immunoenzyme analysis. Identification 
of B. mallei antigen in the nasopharynx, blood and urine of mice, guinea pigs and hamsters 
3-12 hours post-infection allows the isolation of sick animals. Further identification of 
antigen in the blood is predictive of bacteraemia with levels decreasing 1-2 days before the 
death of the animal (Alekseev et al, 2000). 
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1.1.8 Current treatments and prophylaxis 
1.1.8.1 Pre-antibiotic treatments 
Early suggestions for the treatment of glanders in horses in eighteenth century Europe 
included administering an extract made from "boiling two new-born puppies in eight pints 
of white wine with an ounce of ginger and pepper and four ounces of sugar... " (Sharrer, 
1995). Human cases of glanders during the late 19th century and early 20th century were 
treated using severe forms of medicine including continual operations or placing phenol 
into infected cavities following drainage of pus from abscesses. This was often 
supplemented with doses of morphine and heroin to suppress the severe pain caused by the 
disease (and the treatment) (Gaiger, 1913). Currently no vaccine is available for the 
treatment of glanders although an autogenous vaccine was trialled using B. mallei bacilli 
isolated from the patient's own infection. This involved a treatment regimen of 15 
injections over 4 months with doses rising from 1x107 to 3x108 heat-killed B. mallei bacilli 
leading to relief of symptoms for several months, although the disease was not shown to 
have been cured (Bristow & White, 1910). 
1.1.8.2 Antibiotic therapy 
Little information exists regarding the antibiotic treatment of human glanders which is 
partly due to the small number of cases definitively diagnosed and recorded since the 
development and widespread availability of antibiotics - only one case of human glanders 
has been reported in the English language medical literature since 1949 (Srinivasan et at, 
2001). Several antibiotic treatments have been trialled in vitro and, in the case of 
laboratory-acquired infection, clinically. Sulfadiazine, a bacteriostatic sulphonamide, was 
used to treat patients with B. mallei infection due to its previous proven efficacy in treating 
animal models with B. mallei infection (Miller et at, 1948c). This antibiotic was clinically 
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effective in some of the 6 patients treated but this depended on the stage of the 
disease in 
which the antibiotics were delivered and the time course of treatment (Howe & Miller, 
1947). Penicillin B is ineffective on the outcome of experimental glanders (Miller et al, 
1948c) and penicillin G resistance in B. mallei occurs naturally (Al-Izzi & Al-Bassam, 
1989; Muhammad et al, 1999). Natural resistance of B. mallei isolated from infected 
horses to other antibiotics including ampicillin, colistin (Al-Izzi & Al-Bassam, 1989) and 
metronizadole (Muhammad et al, 1998) also occurs. Tetracycline-resistant strains have 
also been reported (Manzenyuk et al, 1995). However, B. mallei is sensitive in vitro to 
chloramphenicol, danofloxacin, norfloxacin, co-trizamole (Muhammad et al, 1998) and 
streptomycin (Miller et al, 1948c; Al-Izzi & Al-Bassam, 1989). Antibiotic susceptibilities 
of B. mallei in a mouse model showed that doxycycline had some bactericidal action 
against B. mallei (Russell et al, 2000). Doxycycline in combination with imipenem, 
followed by azithromycin and doxycycline treatment, was successful in keeping the most 
recent recorded human case of glanders under control following initial ineffective 
treatment with a first generation cephalosporin and later clarithromycin (Srinivasan et al, 
2001). Treatment normally has to be continued for several months even after apparent 
recovery from the disease as B. mallei may remain latent for many years (Bernstein & 
Carling, 1909; Russell et al, 2000). 
1.1.8.3 Alternative Treatments 
Treatment of glanders without the use of antibiotics has been reported in a non-human 
primate model of infection: circulating blood from animals with severe forms of glanders 
was detoxified by dialysis and haemosorption on carbon columns. This improved the 
outcome of the disease, reduced the number of B. mallei organisms in the circulation and 
improved the outcome of septic shock (Khomyakov et al, 1998). 
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1.1.9 Host responses to B. mallei infection 
B. mallei interacts with the host immune system leading to activation of general 
inflammatory responses. A range of non-specific immune factors such as ß2-microglobulin 
(part of the major histocompatiblity complex (MHC) on antigen presenting cells), 
prostaglandin-E2 (PGE2) - an inflammatory mediator involved in production of acute phase 
proteins, proliferation of lymphoid tissue and migration of cells - and complement factor 
C3a, are raised during infection in non-human primates demonstrating the presence of an 
inflammatory response (Manzeniuk et al, 1997). B. mallei causes disruption of homeostatic 
mechanisms and hormonal balance affecting the hosts' innate protection against infection 
(Manzeniuk et al, 1997). Although the host is able to mount an inflammatory response, B. 
mallei may be able to evade this response using its extracellular capsule which has 
immunosuppressive actions and is important for the virulence of this pathogen (DeShazer 
et al, 2001; Popov et al, 2002). The type III secretion system of B. mallei is also important 
in its virulence and allows it to replicate within macrophages (Ulrich & DeShazer, 2004). 
Macrophages normally engulf and kill bacteria following infection. However, following 
aerosol challenge in the guinea pig and hamster, B. mallei interacts with alveolar 
macrophages to downregulate their bactericidal mechanisms and transfer the infection to 
regional lymph nodes (Alekseev et al, 2000). Nitric oxide, a bactericidal product of 
macrophages, is not essential for protection against infection as the absence of iNOS2 
(inducible Nitric Oxide Synthetase-2) in knockout mouse studies did not change the 
outcome of infection (Lukaszewski, 2004). Specific antibodies formed during infection do 
not appear to be essential for immunity to B. mallei infection. Humoral immunity was not 
found to be protective in monkeys developing high titres of antibody during infection and 
then reinfected with B. mallei (Manzeniuk et al, 1997). Genetic knockout mice lacking B 
cells or CD28 (a T cell co-stimulatory molecule) survive infection demonstrating that 
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antibody mediated immunity is not essential during B. mallei infection (Lukaszewski, 
2004). 
Although little is known about the immune response to B. mallei infection, immune 
responses to other intracellular pathogens have been well characterised. Innate and type 1 
immune responses commonly observed during infection with intracellular bacteria are 
described below to illustrate the immune interactions which may be important in immunity 
to B. mallei infection. 
1.2 Innate immune responses and inflammation 
1.2.1 Bacterial initiation of innate responses 
Innate inflammatory responses are triggered in response to pathogen invasion and aim to 
protect the host against infection. Innate immune activity is stimulated directly by the 
pathogen to create an immediate non-specific response to infection. This is in contrast to 
adaptive immune responses where specific, long-lived responses are initiated and become 
effective several days after infection. Innate responses are instigated during bacterial 
infection by bacterial components that may either be membrane bound, secreted or 
released following pathogen destruction. Some bacterial components are known initiators 
of inflammation including lipopolysaccharide (LPS), bacterial lipoprotein (BLP), 
peptidoglycan, porins, lipoproteins, lipopeptides, lipid-A associated proteins and pili 
(Heumann et al, 1998a). Other immuno-stimulatory molecules are specific to particular 
bacterial species. For example, flagellin is present only in motile bacteria such as B. 
pseudomallei (Hersh et al, 1998). 
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Neutrophils, monocytes, macrophages and dendritic cells (DCs) express specific receptors 
known as pattern recognition receptors (PRRs) which recognise the conserved structures of 
these bacterial components known as pathogen associated molecular patterns (PAMPs) 
(Medzhitov & Janeway, 2000). Toll-like receptors (TLRs) are PRRs that recognise 
conserved fragments from pathogens including bacteria, viruses and fungi (Akira & 
Takeda, 2004). TLRs (1-10) are expressed on the surface or within the cytoplasm of innate 
immune effector cells including macrophages, neutrophils and DCs. Several TLRs exist 
which recognise specific bacterial components. TLR2 recognises the cell wall 
polysaccharide peptidoglycan from gram-positive bacteria eg. S. aureus (Yoshimura et al, 
1999). TLR5 recognises flagellin from motile bacteria eg. S. typhimurium (Hayashi et al, 
2001). TLR4, in combination with an adaptor molecule MD2, recognises 
lipopolysaccharide (LPS), a component of the gram-negative bacterial cell wall. LPS is 
initially bound by CD 14 on the surface of monocytes, macrophages and neutrophils. This 
complex associates with TLR4 following LPS binding to enable signal transduction via the 
intracellular portion of TLR4 (Heumann et al, 1998a). TLR9 recognises and associates 
with conserved bacterial (and viral) DNA sequences, which contain unmethylated 
dinucleotide motifs containing cytosine and guanine residues (CpGs), within the 
endosomal compartment (Hemmi et al, 2000). TLR9 is present in macrophages, DCs and 
B cells in mice and plasmacytoid DCs (pDCs), B cells, monocytes (Takeshita et al, 2001) 
and NK cells (Roda et al, 2005) in humans. TLR9 is not expressed on the cell surface but 
resides within the endoplasmic reticulum and moves into the endosomal membrane and 
lysosomal systems following internalisation of DNA. Direct association between TLR9 
and DNA from intracellular bacteria may occur in the endosomal compartment as bacteria 
are phagocytosed into the endosome and destroyed releasing DNA fragments in close 
proximity to TLR9 (Latz et al, 2004). 
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Interaction of TLRs with their specific ligand leads to induction of common signal 
transduction cascades via the cytoplasmic tail of the receptor - the Toll-IL-1-Receptor 
(TIR) domain. This interacts with the intracellular signal transducing molecule MyD88 and 
interleukin-1 receptor associated kinase (IRAK) initiating phosphorylation cascades and 
leading ultimately to the transcription of immune response genes and the production of 
inflammatory mediators via the nuclear transcription factor NFKB (Figure1.2) (Hawiger, 
2001). In addition to common pathways of activation by TLRs, alternative signal 
transduction pathways may be utilised by a specific TLR and its ligand. Alternative 
adaptor molecules and transcription factors are utilised to allow the transcription of genes 
specific for the TLR. This leads to expression of specific gene profiles and the production 
of inflammatory mediators which allow fine-tuned immune responses to develop which are 
appropriate for the infective pathogen (Boldrick et al, 2002; Feezor et al, 2003). 
Intracellular pathogens are also recognised within the cytoplasm by a set of recently 
recognised receptors known as nucleotide-binding oligomerisation domain (NOD) 
proteins. These recognise components of peptidoglycan presented to the receptors directly 
within the cytoplasm. Gram-positive and gram-negative bacteria contain different types of 
peptidoglycan and these differences are recognised by NOD I and NOD2 respectively 
leading to responses tuned to the pathogen (Girardin et al, 2003). Although these receptors 
appear to recognise intracellular pathogens, their role in infection has yet to be elucidated 
(Murray, 2005). 
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Figure 1.2: Diagram showing a common pathway of activation of inflammatory 
mediators via 'l'oll-like receptors (TLR)4 and TLR9 and the nuclear transcription 
factor NHKB. "II. Rs activated following ligand binding (I, PS/Ct)14: 'I'LR4; I)NA: 'l'LR9) 
recruit the adaptor protein Myl)88 which interacts with the serine-threonine protein kinase 
IRAK. Following a series of intermediate steps IKB kinase (IKK) phosphorylates the 
NFxl3 inhibitor IKII releasing NFKB and allowing it to translocate into the nucleus where it 
interacts with the NI"KII binding motif leading to transcription of immune response genes 
and inflammatory cytokines. Alternative adaptor molecules are used by TLR4 in MyD88- 
independent pathways and alternative transcriptions factors eg. IRIF3 may be used to 
induce different patterns of gene expression including IFN-inducible genes. 
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1.2.2 The Inflammatory response: Cells 
The inflammatory responses instigated in response to bacterial infection in the spleen are 
summarised in Figure 1.3. The main cellular components of the innate immune system are 
neutrophils, macrophages, natural killer (NK) cells and DCs. These cells enable innate, 
non-specific killing of pathogens and are able to respond rapidly to infection due to the 
pathogen-recognition systems that they express. In addition to their role in innate 
immunity, the responses elicited by these cells during the early phase of infection may 
influence and determine the development of adaptive responses. 
1.2.2.1 Neutrophils 
Neutrophils are blood-borne phagocytic, granulocytic, polymorphonuclear (PMN) cells 
and are important in the innate response to infection. They are a major component of the 
innate immune system and are the most numerous white blood cell. Neutrophils migrate 
into infected tissues in response to chemotactic factors particularly beta-chemokines and 
peptides eg. fMLP (Burg & Pillinger, 2001). Neutrophils are activated following 
recognition of pathogen components (PAMPs) via PRRs and also by pro-inflammatory 
mediators, such as TNFa and IL-6. Neutrophils ingest pathogens by phagocytosis which is 
enhanced by neutrophil receptors that recognise bacteria coated with antibody (Fc 
receptors) or complement components (eg. iC3R; CDIIb) allowing opsonisation to occur 
(Hellwig et al, 2001). Neutrophils effect pathogen killing using anti-bacterial and pro- 
phagocytic molecules including proteinases and reactive oxygen species produced 
following activation of NADPH oxidases and myeloperoxidases (Hersh et al, 1998; 
Gregory & Wing, 2002). Neutrophils also secrete a range of pro-inflammatory mediators 
such as TNF-a (Bliss et al, 1999) and IL-6 to propagate inflammatory processes and also 
secrete cytokines involved in the development of Type 1 immune responses including IL- 
12 (Bliss et al, 2000). 
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Figure 1.3: Representation of the inflammatory response following bacterial infection 
of the spleen. Macrophages and neutrophils are activated by bacteria and their components 
and release a range of cytokines in response. Release of pro-inflammatory cytokines such 
as i'Nki, IL-Ili, [[, -6 and IFN-y causes local induction of anti-bacterial mechanisms by 
innate immune cells. Systemic effects on the hypothalamus leads to the development of 
symptoms associated with infection and effects on the liver increase protein synthesis to 
stimulate host defences. Release of chemokines (IL-8, MCP-l) recruit neutrophils and 
macrophages into the site of infection aided by increased blood flow and vascular 
permeability to allow cellular influx. 
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1.2.2.2 Macrophages 
Macrophages are phagocytic cells which reside in the tissues and mature from blood-borne 
monocytes which continually migrate into the tissues. During infection, monocyte 
migration and macrophage maturation occurs to enable further bacterial killing (Gonzalez- 
Juarrero et al, 2003). Resting macrophages express a range of TLRs enabling them to 
respond rapidly to infection and are further activated by interferon-y (IFNy) released by T 
cell subsets and NK cells during infection (Berg et al, 2005). Macrophages engulf 
pathogens by phagocytosis using cell surface scavenger receptors eg. MARCO or receptors 
for complement components including C3 which, when bound to bacteria eg. F. tularensis, 
enhance uptake (Clemens et al, 2005). Macrophages kill bacteria by a number of 
intracellular mechanisms including degradation by lysosomal enzymes, release of toxic 
reactive oxygen and nitrogen species (Farrar & Schreiber, 1993) and apoptosis of infected 
macrophages (Sousa-Franco et al, 2005; Ulett et al, 2005). Prior to their activation during 
infection, resting macrophages may be infected by bacteria including M tuberculosis 
(Leeman et al, 2005) and B. pseudomallei (Utaisincharoen et al, 2001). These bacteria are 
able to survive, multiply and propagate the infection leading to a complex interplay 
between host cells and the infective pathogen. 
1.2.2.3 Dendritic cells 
Dendritic cells are important in initiation of innate and adaptive responses due to their 
efficient recognition of pathogens and constitutive expression of markers involved in 
antigen presentation. DCs are a heterogeneous family of cell populations distinguished by 
their differential expression of cell surface markers. These include the differential 
expression of TLRs on different subsets of DCs allowing them to respond appropriately to 
PAMPs (Sousa et al, 2004). Tissue-resident DCs sample their environment continually 
until they recognise PAMPs via PRRs (Foti et al, 2004). DCs then migrate to the lymph 
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nodes where they are able to present processed antigen to T cells leading to the 
development of adaptive immune responses. MHCII and co-stimulatory molecules, 
including CD80 and CD86, are expressed on the cell surface to allow efficient antigen 
presentation to T cells (Warncke et al, 2005). Activated DCs secrete pro-inflammatory 
cytokines involved in the induction of Type 1 responses including IL-12, IFN-y and IFN-a, 
depending on the DC subset involved (Hochrein et al, 2001). DCs can also stimulate the 
development of type 2 responses important for fighting extracellular pathogens (Boonstra 
et al, 2003). In addition to their role in instigating adaptive immune responses, DCs also 
play an integral role in controlling innate immune responses in a reciprocal relationship 
with NK cells. 
1.2.2.4 Natural Killer (NK) cells 
NK cells are lymphocytes traditionally known for cytolytic killing of infected host cells or 
tumour cells. NK cells play an important role directly in innate responses to infection and 
by influencing the development of appropriate adaptive immune responses. The cytolytic 
activity of NK cells is enhanced by IFN-a production by DCs (Gerosa et al, 2005) and DCs 
also stimulate NK cells through secretion of IL-2. In turn, NK cells induce the maturation 
of DCs thus stimulating the development of type 1 immunity to intracellular pathogens 
(Mailliard et al, 2003). Human NK cells express a range of TLRs involved in recognition 
of pathogens early in the innate immune response leading to their activation (Hart et al, 
2005). Following their activation, NK cells secrete cytokines, e. g. IFN-y and TNF-a, in a 
non-antigen-specific manner (Zingoni et al, 2005). NK cells are a major source of innate 
IFN-y during infection with pathogens such as B. pseudomallei (Lertmemongkolchai et al, 
2001; Haque et al, 2005) and F. tularensis (Lopez et al, 2004). NK cells also secrete IFN-y 
in response to IL-12 and IL-18 (Baratin et al, 2005). This allows promotion of Type I cell- 
mediated immune responses and IFN-'y dependent activation of macrophages. 
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1.2.2.5 T cells 
T cells are lymphocytes predominantly associated with the development of adaptive 
immunity although certain T cell subsets have important roles during innate responses to 
infection. CD8+ T cells, expressing markers characteristic of memory T cells, can secrete 
IFN-? non-specifically in response to cytokines early in infection (eg. IL-12 and IL-18) 
and are involved in protection against infection with L. monocytogenes (Berg et al, 2005) 
and B. pseudomallei (Haque et al, 2005). Other T cell populations involved in innate 
immune responses include y8 T cells and NKT cells which appear to have pathogen- 
specific roles in immunity to infection (Kawakami, 2004). 
Specific effector and memory T cell subsets are generated following presentation of 
antigen to naive T cells with the aid of co-stimulatory molecules on the cell surface. CD4+ 
T cells recognise peptide associated with MHCII molecules on the surface of antigen 
presenting cells (Neild et al, 2005). Appropriate polarising conditions allow the 
differentiation of naive T cells into Thl (IFN-, y; IL-12) or Th2 (IL-4; IL-5) subsets with 
specific effector functions (Abbas et al, 1996). CD4+ Thl cells activate macrophage 
responses through IFN-y secretion (Murray, 1990) and also induce production of 
opsonising antibody by B cells enabling targeted uptake of pathogens (e. g. Candida 
albicans) into phagocytic cells (Kozel et al, 2004). CD4+ Th2 cells stimulate B cells to 
generate antigen-specific antibody responses important in protective immunity to 
extracellular pathogens (Coffman et al, 1988). Effector CD8+ T cells can also differentiate 
into Tcl and Tc2 subsets that secrete cytokines and are cytotoxic for infected host cells 
that are presenting peptide associated with MHC I molecules (Li et al, 1997). 
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1.2.3 The Inflammatory response: Inflammatory mediators 
Binding of bacterial components to cellular receptors triggers the expression of immune 
response genes leading to the production of inflammatory mediators which are released in 
order to propagate and control host defences. 
1.2.3.1 Pro-inflammatory mediators 
A range of mediators which stimulate inflammatory responses are released during 
infection. Pro-inflammatory cytokines are released by activated neutrophils, monocytes, 
DCs and macrophages (Zhan & Cheers, 1995) in response to recognition of bacterial 
components early in infection. Cytokines, including Tumour Necrosis Factor (TNF)a, 
Interleukin (IL)-lß and IL-6, act locally by activating cellular responses and have diverse 
roles in protection against infection with pathogens including M tuberculosis (Mohan et 
al, 2001) and B. pseudomallei (Santanirand et al, 1999). 
Systemic release of TNFa, IL-lß and IL-6 leads to the transcription of immune response 
genes in the liver causing an acute phase response (Deutschman, 1998). This involves the 
production of proteins such as LPS-binding protein (LBP), fibrinogen, C3, serum amyloid 
P (van der Poll et al, 1996) and affects blood coagulation cascades (Esmon et al, 1999). 
These acute phase proteins can bind to bacterial molecules and activate complement or 
phagocytosis (Oberholzer et al, 2001). For example, LBP enhances the binding of LPS or 
whole bacteria to CD 14 on monocytes or macrophages propagating inflammatory 
responses (Stelter, 1998) and thus plays an important role in host inflammation (Heinrich 
et al, 2001). These cytokines also act on the hypothalamus and cause the release of 
prostaglandins leading to fever, pyrexia and behavioural changes known as "sickness 
syndrome" (Oberholzer et al, 2001). 
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Chemokines, including IL-8 and CCL-2 alternatively known as macrophage 
chemoattractant protein (MCP)-1, also propagate inflammatory responses by recruiting 
neutrophils, monocytes and macrophages to the site of inflammation. This allows bacterial 
killing and repair at the site of infection. Colony stimulating factors, including 
macrophage-colony stimulating factor (M-CSF), granulocyte-CSF (G-CSF) and 
granulocyte/macrophage-CSF (GM-CSF), stimulate the development and proliferation of 
phagocytic cells eg. macrophages and neutrophils (Rollins, 1997; Beishuizen et al, 1999). 
1.2.3.2 Anti-inflammatory mediators 
Anti-inflammatory cytokines, including IL-10, IL-4 and TGF-ß, are also secreted during 
the inflammatory process and act antagonistically to control pro-inflammatory processes, 
preventing tissue damage by mediators released during inflammation (van der Poll, 1999). 
Interleukin-10 (IL-10) is an anti-inflammatory cytokine released by T cells, B cells, 
monocytes and macrophages following activation with bacterial products that 
downregulates inflammatory immune responses by inhibiting macrophage functions 
(Beishuizen et al, 1999). It causes the upregulation of anti-inflammatory molecules by 
increasing Suppresser Of Cytokine Signalling (SOCS)-3 expression. SOCS-3 is a 
cytoplasmic protein that negatively regulates responses to proinflammatory cytokines and 
bacterial products (Hanada & Yoshimura, 2002). Other natural anti-inflammatory 
molecules exist in the serum and act by mopping up specific inflammatory mediators, 
preventing their action on target cells. Soluble CD14 binds to LPS in the circulation 
preventing it from activating cells expressing the CD14/TLR4 complex (Stelter, 1998) and 
soluble TNFa Receptors bind excess TNFa to prevent further propagation of 
inflammatory responses (Goetz et al, 2002). Release of soluble IL-10 binding protein, 
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inhibits the binding of IL-10 to its receptor and is modulated by IL-10, thus negatively 
regulating inflammatory responses (Crepaldi et al, 2002). 
1.2.3 Cell migration during inflammation 
The inflammatory response is dependent on cell trafficking from the blood into the tissues 
in order to overcome the infection. This requires a complex series of events involving cell 
recruitment by chemokines and changes to the local vascular system and cell surface 
receptors. Nitric Oxide synthetase (iNOS) is induced on endothelial blood vessels by 
proinflammatory cytokines and bacterial components (eg. LPS) (Ciornei et al, 2002) 
leading to synthesis of NO. This results in vasodilation of blood vessels, increasing blood 
flow and cellular infiltration into infected areas. The vascular permeability of blood vessels 
also increases in response to proinflammatory cytokines allowing cells to move from the 
blood into the tissues (Panas et al, 1998). Adhesion molecules on the surface of cells are 
upregulated to allow neutrophil, monocyte and T cell infiltration into tissues. Intercellular 
Adhesion Molecules (ICAMs) in particular ICAM-1 (CD54) are upregulated on 
macrophages, neutrophils (Wang et al, 1998) and endothelial cells during inflammation in 
response to TNF-a (Krakauer, 2000). CD54 is important in neutrophil infiltration and 
when expressed on endothelial cells interacts with Mac-1 (CD11b) on the surface of 
neutrophils and macrophages (Kishimoto et al, 1989). CD11b, a receptor for the C3a 
component of the complement system (CR3), is upregulated following neutrophil 
activation with bacterial lipoprotein (Power et al, 2001). Both CD54 and CD11b are 
important in neutrophil recruitment and accumulation at sites of inflammation (Goncalves 
& Appelberg, 2000). L-selectin (CD62L) is also involved in neutrophil and mononuclear 
leukocyte infiltration into areas of inflammation through the vascular endothelium 
(Pizcueta & Luscinskas, 1994). However, CD62L is shed once neutrophils and other 
leukocytes have entered into tissues possibly to prevent them from escaping from areas of 
inflammation (Kishimoto et a1,1989). 
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1.2.5 Dysregulation of inflammatory responses: sepsis 
Regulation of immune responses is crucial to provide a balance between pathogen killing 
and damage to the host. Inflammatory responses provide an environment suitable for the 
destruction of bacteria that is beneficial to the host. However, in the presence of severe 
infection or in immunocompromised individuals a massive, unregulated systemic 
inflammatory response can occur with the overproduction and release of potentially 
damaging inflammatory mediators. This systemic inflammatory response syndrome (SIRS) 
is known as sepsis following bacterial infection (Bone, 1993). During sepsis, dysregulation 
of both pro- and anti-inflammatory processes occurs leading to serious tissue damage and 
is of clinical relevance in intensive care units (ICU) as a major cause of death and 
morbidity each year (Bone, 1993). 
Dysregulation of the pro-inflammatory response leads to massive overproduction of 
inflammatory mediators eg. TNFa, IL1ß and IL-6. High levels of TNFa 
(Supputtamongkol et al, 1992; Terregino et al, 2000; Gogos et al, 2000), IL-1 0 (Berner et 
al, 1998) and IL-6 (Gallagher et al, 2001; Terregino et al, 2000; Groeneveld et al, 2001) 
are implicated in poor outcome and severity of sepsis in man. Overproduction of these 
inflammatory mediators can cause symptoms which contribute to the development of 
sepsis. Hypovolaemia, low blood volume, commonly occurs during sepsis and develops as 
a result of systemic vasodilation of blood vessels. The continual production of nitric oxide 
by endothelial cells following unregulated TNFa production also contributes by increasing 
vascular permeability (Fujii et al, 2000). This overproduction of nitric oxide, TNF-a and 
IL-lß may also decrease myocardial contraction (Panas et al, 1998; Kumar et al, 1996) 
leading to hypotension. Increased expression of adhesion molecules (eg. CD54) on 
vascular endothelium (mediated by TNFa) leads to an increase in adherence of leukocytes 
to endothelial cells (Zeng et al, 2002). Coagulation cascades, also induced by TNFa, cause 
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the release of pro-coagulant factors such as thromboxane and inhibition of anti-coagulant 
mechanisms (Esmon et al, 1999). This can lead to micro-vascular thrombi restricting organ 
blood perfusion and contributing to organ failure. Neutrophils are also implicated in organ 
pathogenesis and damage by the uncontrolled release of large amounts of necrotic 
inflammatory products including proteinases and free radicals causing widespread cell 
death and tissue necrosis. Increased production of prostaglandins mediated by TNFa, IL- 
1ß and IL-6 production leads to fever, rigors, anorexia, hyper metabolism and altered 
metabolism of fat and glucose (Davies & Hagen, 1997). 
Unregulated production of pro-inflammatory molecules can be accompanied by 
overproduction of anti-inflammatory compounds to downregulate the pro-inflammatory 
response known as compensatory anti-inflammatory response syndrome (CARS). This can 
lead to macrophage and monocyte deactivation by increasing serum levels of soluble CD 14 
(Gluck et al, 2001), reduction of monocyte membrane-bound CD14 and decreased TNFcc 
production (de Werra et al, 2001). High serum levels of IL-10 and a high IL-10: TNFa 
ratio are indicators of severe sepsis and poor outcome (Gogos et al, 2000). Abnormalities 
and reductions in neutrophil function (Rothe et al, 1990; Terregino et al, 1997) may also 
be present, leading to immunosuppression, and allowing secondary infections to develop 
(Steinhauser et al, 1999a). 
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1.3 Development of immune responses during intracellular 
infection 
Intracellular bacteria are pathogens that grow and replicate within host cells enabling them 
to survive and colonise the host organism. In addition to causing acute infections, chronic 
or latent infection may develop which can reactivate after several years following initial 
infection with pathogens such as M tuberculosis and B. pseudomallei. 
Immune responses targeting intracellular pathogens are generally characterised as type I 
immunity. Polarisation of the immune response towards type 1 immunity during these 
early innate responses ensures the development of appropriate, antigen-specific, memory 
responses. In general, type 1 responses are characterised by the induction, production, and 
interaction of IFN-y and other cytokines including IL-12, IL-18 and IL-27, with 
macrophages, NK cells and T cells allowing the destruction of sequestered intracellular 
bacteria (Figure 1.4). This is in contrast to type 2 responses which target the extracellular 
stages of infection by production of antibody to neutralise or opsonise extracellular 
pathogens and toxins. Type 2 responses are generally mediated by IL-4 and other cytokines 
including IL-5, IL-6 and IL-l0 are involved in propagation of these responses (Mosmann 
& Coffman, 1989). 
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Figure 1.4: Representation of the interactions occurring between cytokines in type I 
immune responses during intracellular infection. Following infection, macrophages and 
other innate cells arc activated to produce type I cytokines IL-12 and lI, -18 by bacterial 
components e. g. lipopolysaccharide (LPS) or pro-inflammatory cytokines eg. TNF-a. IL- 
12 acts on activated 'l' cells expressing II, -12R[32, whose expression is controlled by IL-27 
and 'I'-bet (type 1 transcription factor), leading to IFN-y production via signal transducing 
activator of transcription (S'CA"f)-I signalling. IIFN-y further activates macrophages to 
express II'N-y inducible genes leading to nitric oxide production, anti-bacterial 
mechanisms and upregulation of MI ICII leading to presentation of antigen to I cells and 
the development of adaptive type 1 immunity. 
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1.3.1 Interferon-y 
IFN-y is essential in protection against a number of intracellular pathogens including B. 
pseudomallei (Santanirand et al, 1999), Leishmania major (Wang et al, 1994), 
Mycobacterium tuberculosis (Shams et al, 2001) and Listeria monocytogenes (Portnoy et 
al, 1989). The importance of host resistance to B. pseudomallei was demonstrated 
following neutralisation of IFNy with anti-IFN-y antibodies during infection in BALB/c 
mice which caused acute sepsis and death (Santanirand et al, 1999). Studies with IFN-y 
gene knockout mice have also demonstrated the importance of IFN-y in protection against 
infection with Bacille Calmette Guerin (BCG) (Dalton et al, 1993), L. major (Wang et al, 
1994) and M. tuberculosis (Cooper et al, 1993). 
IFN-y is secreted by activated type 1T cells and NK cells in response to infection. During 
the early stages of infection with B. pseudomallei, NK cells and memory CD8+ CD44' T 
cells are stimulated to produce IFN-y by cytokines in a non-specific manner in a `bystander 
effect' (Lertmemongkolchai et al, 2001). This propagates the development of an IFN-y- 
dependent immune response. IFN-y acts on T cells and other cells expressing a functional 
IFN-y-receptor (IFN-y-R) (Thl cells releasing IFN-y do not express a functional receptor) 
and induces signal transducer and activator of transcription (STAT)-1 and IFN-y 
dependent gene expression in Th2 cell subsets (Tau et al, 2000). This appears to have anti- 
proliferative and anti-metabolic effects on these subsets and downregulates inappropriate 
IL-4-mediated responses. This allows the proliferation of IFN-y-secreting T cell subsets to 
develop a protective type I immune response to intracellular pathogens (Wang et al, 1994; 
Tau et al, 2000). 
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IFN-y induces a range of IFN-y-inducible genes following engagement with its receptor on 
macrophages and neutrophils which in turn stimulates anti-bacterial mechanisms and 
enhances non-specific bacterial killing of intracellular pathogens. These genes include 
inducible nitric oxide synthase (iNOS) leading to production of nitric oxide, P47 GTPases 
implicated in host defence against intracellular bacteria (Taylor et al, 2004) and the Thl 
differentiation transcription factor T-bet, (Szabo et al, 2000). Cellular receptors including 
MHC II involved in antigen presentation (Dalton et al, 1993) and Fc Receptors involved in 
phagocytosis are also upregulated in response to IFN-y. 
IFN-y is essential in inducing macrophage bactericidal mechanisms during infection with 
M. tuberculosis (Cooper et al, 1993), B. pseudomallei (Utaisincharoen et al, 2001) and L. 
monocytogenes (Portnoy et al, 1989). Macrophages engulf bacteria and cause death by a 
number of anti-microbial mechanisms including the production of reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) (Miyagi et al, 1997). Nitric oxide (NO)- 
mediated killing of BCG infection in mice by macrophages is IFN-y-dependent although 
production of reactive oxygen intermediates (ROIs) is only partially dependent on IFN-y 
(Dalton et al, 1993). Macrophage-mediated killing of B. pseudomallei is also IFNy- 
dependent. In the absence of IFN-y,. B. pseudomallei is able to multiply within 
macrophages without increased expression of inducible nitric oxide synthetase (iNOS) 
(Utaisincharoen et al, 2001) and survives the respiratory burst in human phagocytes in 
vitro (Pruksachartvuthi et a1,1990). In the presence of IFN-y, macrophages kill internalised 
B. pseudomallei in vitro using an iNOS-dependent pathway (Utaisincharoen et al, 2001), 
utilising both ROS and RNS, although RNS plays a greater role in bacterial death (Miyagi 
et al, 1997). IFN-y also aids bacterial killing by preventing movement of intracellular 
bacteria eg. L. monocylogenes from the phagolysosome into the cytoplasm thus preventing 
cell-to-cell spread of the bacteria via the cytoplasm of adjacent cells (Portnoy et al, 1989). 
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IFN-y also acts on NK cells to increase the cytolytic capability of these cells (Dalton et al, 
1993). Control of IFN-y production is crucial in regulating cell-mediated responses to 
intracellular infection and may be mediated by a number of cytokines during infection 
including IL-12, IL-18 and IL-27 (Robinson & O'Garra, 2002). 
1.3.2 Type 1 inducing cytokines 
Cytokines which induce type 1 responses directly or via inducing IFN-y production include 
IL-12, IL-18 and the IL-12 related cytokines IL-23 and IL-27 (Figurel. 4). 
1.3.2.1 IL-12 and IL-23 
Interleukin-12 (IL-12), a pro-inflammatory cytokine, is a heterodimer composed of IL- 
12p35 and IL-12p40 subunits. It is released by monocytes, macrophages and B cells during 
early infection following recognition of bacterial components via TLRs. IL-12 is also 
released by macrophages following activation by inflammatory cytokines eg. TNF-a 
which activates macrophages during early infection with M avium to produce IL-12 and 
IL-18 (Danelishvilli & Bernudez, 2003). IL-12 is pivotal in polarising type 1 immune 
responses and ensuring Thl cell differentiation. Engagement of IL-12 with the IL-12R 
causes activation of signalling pathways including STAT-I which ensures the expression 
of T-bet and development of type I responses. IL-12 interacts with the IL-12R on NK cells 
and activated T cells inducing production of IFN-y thus propagating macrophage activation 
and type 1 responses (Gazzinelli et al, 1994; Flesch et al, 1995). IL-12 is important in 
protection against infection with the intracellular pathogens L. major (Heinzel & Rerko, 
1999) and B. pseudomallei (Lertmemongkolchai et al, 2001) by augmenting type 1 
responses and IFN-y production thus stimulating the development of Thl-mediated 
immune responses (Heinzel & Rerko, 1999). 
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The IL-12p40 subunit of IL-12 is shared with IL-23, another closely related cytokine. 
IL12p4O combines with an IL-12p35 related subunit p19 to form IL-23, a heterodimer 
similar to IL-12. Although IL-12 and IL-23 have similar structures, IL-23 has distinct roles 
in maintenance of Type 1 responses and acts on CD4+ memory T cells to induce IFN-y 
production whereas IL-12 exerts its effects on naive T cells (Lankford & Frucht, 2003). IL- 
23 is important in immunity to intracellular infection which has been shown indirectly by 
comparing the susceptibility of IL12p35-/- and IL12p4O-/- knockout mice to Francisella 
tularensis (Elkins et al, 2002). 
1.3.2.2 IL-18 
In addition to its independent role in Type 1 responses, IL-12 works in synergy with 
another cytokine, IL-18 which is produced by macrophages and DCs and acts on NK cells 
and T cells. An IL-12/IL-18 synergy is involved in the induction of IFN-y during infection 
with a number of pathogens including B. pseudomallei (Lertmemongkolchai et al, 2001), 
L. monocytogenes (Neighbors et al, 2001) and Mycobacterium leprae (Garcia et al, 1999). 
IL-18 also has an essential role in host defence during L. monocytogenes infection in the 
absence of IL-12, through IFN-y-independent induction of NO and TNF-a from 
macrophages (Neighbors et al, 2001). IL-18 plays an IL-12-independent regulatory role 
early in host defences during Streptococcus pneumoniae infection (Lauw et al, 2002) and 
is critical in host resistance to L. major infection playing a role in regulation of Thl/Th2 
balance not mediated by IL-12 (Wei et al, 1999). 
1.3.2.3 IL-27 
Although IL-12 is important in polarisation of Type 1 responses, other cytokines are also 
involved as Thl polarisation occurs in the absence of both IL-12 subunits and IL-12 
receptor subunits during mouse knockout studies (Lankford & Frucht, 2003). IL-27 is a 
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cytokine structurally related to the IL-12 family of cytokines. IL-27 is independently 
involved in the early development of Thl cells by inducing expression of T-bet. It is also 
involved in commitment to type 1 immunity by upregulating the IL-12Rß2 on T cells, thus 
increasing and maintaining the responsiveness of T cells to IL-12 (Lucas et al, 2003; 
Hibbert et al, 2003). Initial studies demonstrated a role for IL-27 in IFN-y production from 
naive CD4+ T cells in vitro (Pflanz et al, 2002). This finding was corroborated in vivo in a 
model of L. major infection where WSX-1 (IL-27 Receptor) knockout mice had impaired 
IFN-y production and consequently increased susceptibility to infection (Yoshida et al, 
2001). However, other in vitro studies (Lucas et al, 2003) and studies with other 
intracellular pathogens eg. Toxoplasma gondii, suggest that IL-27 is not required for the 
development of IFN-y mediated immunity but is important in controlling the kinetics of 
Thl responses later in infection (Villarino et al, 2003). The discrepancy between the 
requirement for IL-27 in development of IFN-y mediated immunity appears to be due to 
the production of IL-4 during infection. High levels of IL-4 are produced early during L. 
major infection and in these circumstances IL-27 appears to be important in IFN-y 
production. However, in infections with low IL-4 involvement (eg. T. gondii, T. cruzii) IL- 
27 is not important during the developmental phases of a Thl response (Artis et al, 2004). 
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1.4 Aims of this research 
The objective of this research is to characterise early host immune responses to 
intraperitoneal infection of BALB/c mice with Burkholderia mallei. This will be achieved 
by: 
" Describing an intraperitoneal model of B. mallei infection by investigating bacterial 
colonisation of the spleen and peripheral effects by monitoring body temperature 
and signs of infection. 
" Investigating the effect of B. mallei, in this intraperitoneal model of infection, on 
host neutrophil, macrophage T and B cell cellular responses by measuring the 
infiltration and activation profiles of these cells during infection. In addition to this, 
splenic and systemic type 1 and proinflammatory cytokine host responses will be 
measured during infection to provide a comparison with cytokine responses 
important during infection with other intracellular pathogens. 
" Investigating the effectiveness of host neutrophil and T cell responses and the 
responses of the type 1 cytokine IFN-y and proinflammatory cytokine TNF-a in 
protecting against B. mallei infection. 
" Investigating the role of type I cytokines, upregulated early during B. mallei 
infection, in induction of IFN-y in vitro in response to heat-killed B. mallei; and to 
investigate the role of T cells, NK cells and neutrophils (and other Gr-1+ cells) in 
IFN-y production in vitro in response to heat-killed B. mallei. This will provide a 
comparison with IFN-y responses induced by other intracellular pathogens and 
determine whether a link exists between IFN-y and Gr-1+ cells, both important in 
protection during the early phases of B. mallei infection. 
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Chapter 2 Materials and Methods 
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2.1 Materials 
2.1.1 General Reagents 
Distilled water and Dulbecco's phosphate buffered saline (D-PBS) were purchased from 
GibcoTM, Invitrogen Corporation, UK. Sterile syringes (2 ml), nylon cell strainers, 15m1 
and 50m1 conical Falcon tubes with caps and 1 ml insulin syringes were purchased from 
Becton Dickinson, UK. Sterile, flat-bottomed 96-well, 24-well and 6-well plates were 
purchased from Coming Incorporated. Foetal calf serum (FCS), RPMI 1640, L-glutamine 
(with penicillin and streptomycin), Trypan blue (0.4%), Red Blood Cell Lysis Buffer and 
Salmonella typhimurium lipopolysaccharide (LPS) were purchased from Sigma, Poole, 
UK. Nutrient broth and Congo Red agar plates for bacteriological analysis were made at, 
and ethanol was supplied by, Dstl, Porton Down. Paraformaldehyde (24%) was purchased 
from Pioneer Research Chemicals Ltd and O-ring sealed tubes were purchased from 
Sarstedt, UK. J774A. 1 macrophage cell line was purchased from the European Cell And 
Culture Collection (ECACC), Health Protection Agency, Salisbury, UK. 
2.1.2 Flow cytometry reagents 
Fluorochrome labelled antibodies and isotype controls were purchased from Becton 
Dickinson, UK, Beckman Coulter, UK and Serotec, UK. OptiLyseTM C and Flow countTM 
beads were purchased from Beckman Coulter, UK. Flow cytometry tubes and Mouse 
Inflammation cytometric bead arrayTM (CBA) kits were purchased from Becton Dickinson, 
UK. For intracelullar staining, LeucopermTM reagents were purchased from Serotec, UK 
and Brefeldin A (Golgi stopTM) was purchased from Becton Dickinson, UK. 
2.1.3 RNA extraction and removal of DNA contamination 
Chloroform, isopropanol (>99%), molecular biology grade absolute ethanol (>99% purity), 
diethyl-pyruvate carbonate (DEPC) and RNA sample loading buffer were purchased from 
Sigma, Poole, UK. RNAseZap®, RNAse-free microfuge (1.5 ml) tubes, mouse spleen total 
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RNA from adult BALB/c mice and RNA milleniumTM size markers were purchased from 
Ambion, UK. Removal of DNA was performed using DNA-freeTM Kit (Ambion, UK). 
Nuclease-free water was purchased from Promega, UK, TrizolTM from Invitrogen, UK and 
micropestles and spectrophotometry cuvettes from Eppendorf, UK. 
2.1.4. Gene Amp PCR system 9700 
The Gene Amp PCR system 9700 machine (Perkin Elmer, UK) was used for reverse 
transcription of RNA using the OmniscriptTM kit (Qiagen, UK). Random hexamers and 
recombinant RNAsin® ribonuclease inhibitor were purchased from Promega, UK. The 
HotstartTM kit (Qiagen, UK) was used to perform PCR reactions to assess the effectiveness 
of DNA-free treatment on extracted RNA samples and to test RNA extraction methods. 
Primers used in this system were synthesised by MWG-biotech, UK. Thin wall-tube strip 
(200µl) PCR reaction tubes and thin wall-cap strips were purchased from BioRad, UK. 
High molecular weight DNA from SALB/c mouse spleen (Sigma, Poole, UK), DNA 
molecular weight markers (0.019-1.11 kbp) (Roche) and DNA loading buffer containing 
bromophenol blue (0.25%) and sucrose (40%) (Dstl, Porton Down) were also used. 
2.1.5 Taqman 7000 PCR system 
The TagMan® 7000 PCR machine (Applied Biosystems, UK) was used to examine gene 
expression in experimental cDNA samples. Pre-Developed TagMan® Assay Reagents 
(PDAR), Assay-on-demand primers and probes, TagMan® Universal PCR master mix and 
optical 96 well reaction plates and optical caps and covers were purchased from Applied 
Biosystems, UK. 
2.1.6 Agarose Gel Electrophoresis 
Agarose powder and MOPS (Morpholinopropane Sulphonic acid) buffer purchased from 
Sigma, Poole, UK were used for making and running 1% agarose gels for RNA analysis. 
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Agarose (1.2% and 2%) E-gelsTM for analysis of DNA and E-gelTM bases were purchased 
from Invitrogen, UK. All gels were run using a Biorad power pack 300 and gel products 
were detected by UV light using a Gel DocTM system. 
2.1.7 Depleting Antibodies and cytokines 
Antibodies used during in vivo depletion studies were supplied by Cymbus Biotechnology, 
UK (Table 2.1). Antibodies were adjusted to the appropriate concentration by dilution with 
D-PBS under sterile conditions. Anti-IL18R antibodies (Clone: TC30-28E3) used during in 
vitro depletion studies were a kind gift from Anne O'Garra, NIMR, London, UK, 
[originally made at DNAX research Institute, Palo Alto, CA, USA (Neighbours et al, 
2001)]. Recombinant murine IL-6, TNF-a, IL-12 and IL-18 were purchased from R&D 
Systems, UK. 
2.1.8 Mice 
Female BALB/c mice purchased from Charles River Ltd, UK aged 6-8 weeks, were used 
for in vivo experiments involving infection or treatment with antibodies. Eight to 14 week- 
old female IFN-y (BALB/c) knockout (KO), C57BL/6 wild type, IFN-y (C57BL/6) KO 
mice, IL12p35 (C57BL/6) KO and IL12p4O (C57BL/6) KO mice were obtained from the 
London School of Hygiene and Tropical Medicine (LSHTM, UK). WSX-1 (IL-27R) 
(C57BL/6) KO mice, C57BL/6 wild type and IL-6 (C57BL/6) KO mice were supplied and 
processed by Alison Bancroft at the University of Manchester, UK for in vitro stimulation 
studies with heat-killed B. mallet. 
63 
Antibody clone I Target Isotype 
RB6-8C5 
MP6-XT22 
YTS 169 
YTS 191 
Macs (control) 
Mac49 (control) 
Murine Gr-1 (Neutrophils) IgG2b 
Murine TNF-a IgGI 
Murine CD8 IgG2b 
Murine CD4 IgG2b 
Chlamydomonas IgG2b 
Avena sativa IgG 1 
Table 2.1: Antibody clone, antibody target and antibody isotype for monoclonal antibodies 
used during depletion experiments. IgG: immunoglobulin G. 
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2.2 Methods 
2.2.1 Summary of experiments to characterise host immune 
responses during intraperitoneal B. mallei infection 
In order to characterise the host immune responses to an intraperitoneal (i. p. ) model of B. 
mallei infection three experiments were performed in BALB/c mice to: 
1) Monitor temperature and signs of disease non-invasively; 
2) Analyse bacterial colonisation and host immune responses to infection by 
investigating cellular and cytokine responses in a 36-day time course experiment (Immune 
Analysis (1)); 
3) Analyse bacterial colonisation and improve and modify analysis of cellular and 
cytokine responses over the first 7 days of infection performed during Immune Analysis 1 
(Immune Analysis (2)). 
Splenic colonisation, cellular responses, splenic cytokine expression and systemic serum 
cytokine production were investigated during both immune analysis experiments. During 
Immune Analysis (2), investigation of cellular and cytokine responses 0-7 days p. i. 
performed in Immune Analysis (1) were repeated. An additional time-point 5 hours p. i. 
was undertaken to describe early immune events and higher animal numbers (n=8) were 
investigated in order to reduce variation in bacterial counts observed during Immune 
Analysis (1). Modifications to flow cytometric methods were also performed to improve 
analysis of cellular responses. Data retrieved over the 7 days of infection from the second 
immune analysis experiment is presented in detail in chapters 4-6. Observations of trends 
in cellular and cytokine responses and their relationship to bacterial colonisation from days 
14 to 36 from Immune Analysis (1) were made to determine the progression of disease 
following abscess formation and are discussed in chapters 4-6. A summary of the 
experiments performed are described in Table 2.2. 
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Experimental Duration 
Aim 
Infection 
(i. p. ) 
Sample Method Sampling time- 
points 
Temperature 70 day 106 cfu n=10 Temperature Diurnally 
& B. mallei (non- probe 
signs invasive) Signs 
Immune 36 day 10 cfu (n=5) Flow Days 
Analysis (1) B. mallei Spleen cytometry 0,1,3,5,7,14,21, 
Colonisation 28,36 
(n=5) 
Spleen RT-PCR 
Serum Systemic 
cytokine 
Immune 7 day 101, cfu (n=8) Flow Days 
Analysis (2) B. mallei Spleen cytometry 0,0.25,1,3,5,7 
RT-PCR 
Colonisation 
Serum Systemic 
cytokine 
Table 2.2: Summary of experiments performed to characterise the disease and host 
immune responses following i. p. infection with B. mallei (ATCC 23344). 
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2.2.2 In vivo procedures 
All experimental procedures on live animals were carried out within the requirements of 
the Animals (Scientific Procedures) Act 1986. A Home Office project license was 
approved and obtained following a stringent Ethical Review process at Dstl, Porton Down. 
2.2.2.1 Animal Welfare 
Mice infected with B. mallei and control uninfected mice were housed in a rigid wall 
isolator within an ACDP animal containment level 3 facility in groups of 5 or 6 and were 
acclimatised for at least 5 days prior to experimental procedure. Mice housed at both 
containment level 2 and 3 were provided with fresh food and water daily and 
environmental enrichment (eg. nesting boxes) were present in each cage. All mice were 
monitored daily for signs of illness. A humane endpoint for B. mallei infection was defined 
when mice developed hind leg paralysis and hunching. Mice were sacrificed by cervical 
dislocation when they reached this humane endpoint, or prior to this, to provide samples 
for experimental analysis at predefined timepoints. 
2.2.2.2 Intraperitoneal injection 
For intraperitoneal infection with B. mallei (Chapters 3-6), mice were scruffed and held 
firmly, but gently, by a trained operator within a containment level 3 isolator. A further 
trained operator injected the mice intraperitoneally using a1 ml insulin needle with 
approximately 106 B. mallei colony forming units (cfu) in 100 µl of nutrient broth. For 
treatment with depleting antibodies at containment level 2 (Chapters 4-6), mice were held 
firmly and injected intraperitoneally using a1 ml insulin needle with less than 2O0µ1 
volume by a trained individual. 
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2.2.2.3 Temperature monitoring and signs of disease 
Mice used during temperature monitoring experiments (Chapter 3) were supplied with 
implanted micro-chips (Datamars, Switzerland) to allow the identification of individual 
mice using a microchip reader. Peripheral body temperature was monitored using a 
temperature probe placed in the fold under the back leg. Mice were gently scruffed and the 
back leg folded and held over the temperature probe. Temperature was recorded once a 
steady measurement was observed on the monitor of the probe. Signs of disease were 
recorded objectively twice daily (morning and afternoon) for each mouse. Control animals 
not challenged with B. mallei were also monitored for temperature and signs of disease in 
the same environmental conditions within the isolator. 
2.2.3 Bacterial culture, sample extraction and storage 
2.2.3.1 Burkholderia mallei 
Work involving live B. mallei was carried out under Advisory Committee on Dangerous 
Pathogens (ACDP) containment level 3. Burkholderia mallei (strain ATCC 23344) was 
used for all challenge experiments. Frozen B. mallei stock cultures were defrosted and 
cultured for 48 h in nutrient broth at 37°C to give a bacterial concentration of 
approximately 108/ml. Cells were harvested by centrifugation and washed three times in 
PBS before resuspending in one tenth the original volume of PBS. 
2.2.3.2 Heat inactivation of B. mallei 
For in vitro stimulation assays, B. mallei (ATCC 23344) was inactivated by heat treatment 
in a water bath at 70°C for 3 h, with occasional gentle shaking. After inactivation each 
suspension was checked for viability by inoculating 10 ml volumes of nutrient broth with 
0.5 ml aliquots of the suspension or 10% volume and incubating at 37°C for seven days. 
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Nutrient agar plates were then inoculated with the total volume of the broth cultures to 
check for bacterial growth, and incubated for a further seven days at 37°C. If no growth 
occurred on agar plates, inactivation of the bacterial suspension was assumed to have 
occurred. 
2.2.3.3 Removal of blood samples 
Mice were terminally anaesthetised by exposure to halothane vapour in a glass bell jar and 
blood was removed by cardiac puncture using 1 ml insulin needles and allowed to clot. 
Mice were then sacrificed by cervical dislocation. Blood was placed into O-ring sealed (1.5 
ml) tubes and centrifuged (13000 rpm, 5 min). Serum supernatant was removed and placed 
into O-ring sealed (1.5 ml) tubes which were stored at -20°C until analysis by cytometric 
bead array. Spleens were removed under sterile conditions and were processed 
immediately following excision. 
2.2.3.4 Preparation of spleens for bacteriological analysis, flow 
cytometry and RT-PCR 
For bacteriological analysis and flow cytometry, spleen sections were transferred into 2 µm 
nylon cell strainers with in the wells of sterile 6 well plates. Spleens were passed through 
sieves into the well below using the pestle from a sterile syringe into 3 ml of D-PBS. For 
bacteriological analysis, 2 ml of splenic cell suspension were removed from each well, 
placed into 15 ml tubes and stored on ice. For flow cytometric staining, 1 ml of D-PBS 
containing 5% FCS was added to the remaining 1 ml of spleen suspension in each well and 
flow cytometric staining was performed immediately. For RT-PCR analysis, TrizolTM (800 
µl) was added to RNAse-free O-ring sealed tubes under sterile conditions. Spleen sections 
were added and broken down in TrizolTM using micropestles. Samples were stored at - 
20'C or -80°C for up to 8 months prior to RNA extraction. 
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2.2.4 Flow cytometric analysis 
2.2.4.1 Flow cytometric staining 
Aliquots of spleen suspension (100 µl) prepared for flow cytometric analysis were added to 
0-ring sealed tubes (Containment level 3) or flow cytometry tubes (Containment level 2) 
containing antibody stain combinations or isotype controls (Tables 2.3 & 2.4). Tubes were 
incubated in the dark for at least 20 min at room temperature (RT). OptiLyse C (400 µl) 
was added to each tube, mixed gently and then incubated for 15 min to allow erythrocyte 
lysis to occur. A 16% paraformaldehyde solution (diluted in PBS) (500 µl) was added to 
infected samples for cellular fixation and bacterial killing to give a final concentration of 
8% paraformaldehyde. Samples were refrigerated for at least 24 h prior to analysis but for 
no more than one week. Samples were transferred into flow cytometry tubes immediately 
prior to acquisition. For non-infected samples, a 1% paraformaldehyde solution was used 
for fixation and samples were analysed immediately or within 48 h. Flow countTM beads 
(100 µl) were added to samples immediately prior to analysis to allow determination of 
absolute counts. Samples were analysed using an EPICS XL® flow cytometer (Beckman 
Coulter, UK). 
2.2.4.2 Flow cytometric analysis : Immune Analysis 1 
During an initial 36 day time course experiment (Immune Analysis 1), 5000 data events 
were collected within the lymphocyte, monocyte or granulocyte populations (Table 2.3). 
Samples were acquired uncompensated. Following acquisition, data was analysed using 
Winlist 4.0TM (Verity Software, Software House, Inc., USA) and compensation was 
performed using compensation controls acquired on the same day as sample acquisition. 
The positive population was determined from isotype controls and unstained samples 
appropriate for each stain (Table 2.3). 
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Cell Type Fluorochrome 
FITC 
Neutrophils Neutrophil (7/4) 
(IgG2a) 
T Cells CD3 (HIgG1x) 
CD3 
PE 
CD54 (HIgG1) 
CD54 
CD25 (RIgG1? ) 
Table 2.3: Stains used for flow cytometric analysis of samples during Immune Analysis 1. 
Cell type lineage markers and cell surface activation markers were identified by specific 
antibodies conjugated to fluorochrome labels: FITC: Fluorescein Isothiocyanate; PE: 
Phycoerythrin; PE-Cy5: phycoerythrin-cychrome-5; CD: complimentarity determining. 
The isotypes of the antibodies are bracketed 0 next to the appropriate marker. H: hamster; 
R: rat; IgG: immunoglobulin G. 
71 
2.2.4.3 Flow cytometric analysis: Immune Analysis 2 
In a further 7 day time course experiment (Immune Analysis 2), several amendments were 
made to the original protocol in order to enhance data capture. Several different markers 
were used in order to improve identification of lymphocyte, monocyte and neutrophil 
populations (Table 2.4). Data from samples investigating lymphocytes was collected for 60 
secs and data from samples which identified monocyte or granulocyte populations was 
collected for 5 min. Samples were compensated during acquisition using compensation 
controls. Following acquisition, data was analysed using Winlist 4. OTM. The positive 
population was determined from isotype controls and unstained samples appropriate for 
each stain (Table 2.4). 
2.2.5 Bacteriological analysis 
2.2.5.1 Bacterial counts 
Spleen suspensions for bacteriological analysis were refrigerated for up to 48 hours prior to 
plating out onto Congo red agar. Nutrient broth media (900 µl) was aliquoted into 24 well 
plates. Neat spleen suspensions (100 µl) were added to nutrient broth for the initial 
dilution. From this dilution, 100 µl was removed and placed into the next well, mixed and 
doubling dilutions of spleen cell suspensions were made until an appropriate dilution series 
was completed. Spleen suspensions (250 µl) from the dilution series were spread onto 
Congo Red plates. Duplicate plates for each dilution sample were made. Plates were 
incubated for 48 h at 37°C and were counted immediately or refrigerated to stop bacterial 
growth and then counted. Colonies of B. mallet were identified and counted manually. 
Average bacterial counts on duplicate plates for each spleen were calculated. This method 
was also used to determine the number of bacterial counts injected into animals during 
challenge with B. mallei. 
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Cell Type 
FITC 
Fluorochrome 
PE PE-Cy5 
Neutrophils Gr-1 (IgG2bk) CD54 (HIgGl) CD69 (HIgG) 
Gr-1 CD62L (rIgG2ax) CDI lb (rIgG2b) 
Macrophages F4/80 (rIgG2b) CD54 CD11b 
F4/80 IA/IE (rIgG2ax) CD11b 
B cells and NK DX5 (CD49b) CD 19 CD69 
cells (rlgMk) 
T Cells CD8a (RIgG2aK) CD3 (HIgGI) CD44 (RIgG2b) 
CD3 (HIgGIz) CD54 CD44 
CD3 CD4 (IgG2ax) CD44 
CD3 CD25 (RIgGI), ) CD44 
Table 2.4: Stains used for flow cytometric analysis of samples obtained during Immune 
Analysis 2. Cell type lineage markers and cell surface activation markers were identified 
by specific antibodies conjugated to fluorochrome labels: FITC: Fluorescein 
Isothiocyanate; PE: Phycoerythrin; PE-Cy5: phycoerythrin-cychrome-5; CD: 
complimentarity determining. The isotypes of the antibodies are bracketed 0 next to the 
appropriate marker. H: hamster; R: rat; IgG: immunoglobulin G. 
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2.2.5.2 Sterility Check 
A sterility check was performed on spleen samples stored in Trizo1TM for RT-PCR analysis 
prior to removal from containment level 3 isolation. From each of the spleen samples, 10% 
was removed and placed into nutrient broth (1 ml), shaken by hand and centrifuged 
(13,000 rpm, 15 min) to remove TrizolTM (which may inhibit bacterial growth). The 
remaining pellet was resuspended in nutrient broth (lml) and added to a further 9 ml of 
nutrient broth. Samples were then incubated at 37°C for seven days. Following this, 250 µl 
were removed from the broth samples and plated onto Congo Red agar plates in duplicate. 
Plates were incubated for a further seven days and were then examined for bacterial 
growth. Plates with no bacterial growth were assumed to be sterile and were removed from 
containment level 3. Samples were then manipulated under ACDP containment level 2 
conditions. 
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2.2.6 Cytometric bead arrays 
Cytokine protein in serum and cell culture supernatants was measured using cytometric 
bead arrayTM (CBA) kits. Cytokine (10x) bulk standards were prepared according to 
manufacturer's instructions by reconstituting each vial of lyophilised standard with assay 
diluent (200 µl) provided in the kit. This was left to equilibrate for at least 15 minutes and 
then mixed thoroughly. The lOx bulk standard (100 µl) was then diluted in assay diluent 
(900 µl). The top standard (300 µl) was then added to assay diluent (300 µl) and mixed 
thoroughly. From this, 300 µd were removed and added to the next tube containing 300 µl 
of assay diluent and so on until a dilution range of 1: 2 to 1: 256 was completed. Assay 
diluent served as a negative control. Capture beads specific for each cytokine were mixed 
and 10 µ1 of each cytokine specific bead was added for each sample. Mixed capture beads 
(50 µl), sample (serum or supernatant) (50 µl) and PE detection reagent (50 µl) were then 
added to O-ring sealed tubes (containment level 3) or flow cytometry tubes (containment 
level 2). Tubes were incubated in the dark at room temperature for 2 h. Samples were 
washed using wash buffer provided in the kit, centrifuged (200 g; 5 min) and the 
supernatant discarded. For infected samples, the pellet was resuspended in 6% 
paraformaldehyde (500 µl) to allow bacterial killing and refrigerated for 24 h prior to 
analysis. For non-infected samples, the pellet was resuspended in wash buffer (300 µl) and 
analysed immediately. Samples were analysed using FACS scan flow cytometer (Becton 
Dickinson, UK) and BD CBA kit software was used for data analysis. 
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2.2.7 RNA isolation and preparation of cDNA 
A diagram summarising the processes involved from RNA extraction to identifying 
changes in gene expression is presented in Figure 2.1. 
2.2.7.1 Preparation of RNA-free tubes 
O-ring sealed Sarstedt tubes were washed with RNAse Zap® and rinsed twice in DEPC- 
treated water and left to dry under sterile conditions. DEPC (1 ml) was added to distilled 
water (1 L) in an ACDP Class I cabinet, mixed thoroughly and incubated at room 
temperature for 2h to prepare nuclease-free DEPC-treated water. DEPC was degraded 
following nuclease-free treatment by autoclaving. 
2.2.7.2 RNA extraction of experimental samples 
The method for RNA extraction was based on a guanidinium thiocyanate-phenol- 
chloroform extraction method (Chomczynski & Sacchi, 1987). Spleens stored in TrizolTM 
were defrosted and 200 µl TrizolTM was added to each sample which were then incubated 
at room temperature for 5 min. Chloroform (200 µl) was added to samples which were 
shaken vigorously by hand twice for 15 sec and incubated at room temperature for 5 min. 
Samples were centrifuged (12,000 g; 15 min) and the aqueous layer was transferred into a 
fresh RNAse free eppendorf tube and the pellet discarded. Isopropanol (500 µl) was added 
to the aqueous supernatant and samples were mixed and left at room temperature for 10 
min. The supernatant was discarded and the pellet was washed in 1 ml of 75% molecular- 
biology grade ethanol diluted in nuclease free water. Samples were centrifuged (7,000 g; 5 
min). Ethanol was removed carefully from the pellets by pipetting and samples were left to 
air dry for a few minutes. The RNA pellet was dissolved in nuclease free water (100 µl) 
and processed immediately or stored at -20°C or -80°C. 
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Spleen (BALB/c mouse) 
RNA extraction 
(Trizol method) 
RNA integrity Total RNA 
(agarose gel) 
DNA-free treatment of 
RNA 
Reverse 
cDNA 
DNA contamination 
check - Hotstart 
(PCR & E-gel) 
Hotstart -DNA ,. -. - PCR -, Gene expression detection analysis -Taqman 
Figure 2.1: Summary of the experimental process from the removal of a spleen from a 
BALB/c mouse to the final PCR product. 
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2.2.7.3 Removal of DNA contamination from RNA samples 
Following RNA extraction, DNA contamination was removed from samples using a DNA- 
freeTM kit. In an RNAse free tube, DNAse I buffer (5 µl) and DNAse 1 (2 µl) were added to 
the aqueous RNA sample (50 µl) and incubated for 30 min at 37°C. The DNAse 
inactivation reagent was vortexed to ensure mixing and 5 µl was added to samples. 
Samples were vortexed gently and incubated (2min; RT). The sample was then centrifuged 
(10,000 rpm, 1 min) to pellet the DNAse inactivation reagent. The DNA-free treated RNA 
solution was then removed to a fresh RNAse free tube without disturbing the bead pellet 
and stored at -20°C or reverse transcribed immediately. DNA-free treatment was repeated 
on RNA samples if DNA contamination was identified on an E-ge1TM following the initial 
treatment. 
2.2.7.4 Detection of RNA and DNA integrity and contamination 
To check the integrity of the RNA, a 1% agarose gel was prepared by adding agarose 
powder to a lx dilution of MOPS buffer diluted in DEPC-treated water to a volume of 
approximately 75 ml. The agarose solution was heated until the agarose dissolved 
completely during microwaving. The solution was left to cool, poured into an 8-lane gel 
system and sealed with autoclave tape. RNA samples (5 µl) and RNA millennium 
markersTM (5 µl) were mixed with 15 µl of RNA loading buffer and denatured by heating 
for 10 min at 60°C and rapidly cooling to 4°C using a Gene Amp 9700 PCR machine. A 
positive control of Total RNATM (Ambion, UK) was run on each gel. The gel was run at 70 
volts (V) using MOPS buffer for approximately one hour. HotStartTM PCR kit was used 
during method development and to assess the effectiveness of DNA-free treatment on 
RNA samples. A reaction mix of components (Table 2.5) was prepared in an RNAse free 
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Component Volume (ul) 
Buffer (10X) (Rotstart) 5 
dNTP's 1 
Taq polymerase 0.25 
Nuclease-free water 31.75 
Histone-H3 forward primer 4 
Histone-H3 reverse primer 4 
Total Volume 1 46 
Table 2.5: PCR reaction mixture using the HotstartTM kit. 
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tube to provide enough mixture for all PCR samples for each run. This reaction mixture 
(total volume 46 µl) was then aliquotted into PCR reaction tubes and cDNA or RNA 
samples (4 µl) were added to tubes as appropriate. A negative control of nuclease free 
water and a positive DNA control were run with each PCR reaction. The reaction was 
performed using the Gene Amp PCR system 9700 on programme HotStartTM 36 
(Figure2.2). DNA was detected using a 2% agarose E-gelTM. Prior to loading sample onto 
an E-gelTM, loading buffer was mixed with cDNA sample or molecular weight markers to a 
volume of 20 µl. A positive control of high molecular weight DNA was run on each gel. 
The gel was run at 70 V for 45 minutes. 
2.2.7.5 Reverse Transcription 
Reverse transcription of DNA-free treated RNA samples to produce cDNA for PCR 
analysis was performed using an OmniscriptTM Kit. A reaction mixture of components 
(Table 2.6) was prepared in an RNAse free reaction tube to provide enough mixture for all 
PCR samples during each run. This reaction mix (47.5 µl) was then aliquoted into PCR 
reaction tubes and sample (2.5 µl) was added to tubes as appropriate to a total reaction 
volume of 50 µl. The reaction was performed using the reverse transcription programme 
recommended by Qiagen, UK (Figure 2.3) on the Gene Amp PCR System 9700. cDNA 
samples were stored at -20°C or used for PCR analysis. 
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Hold 
15min 
95°C 
36 cycles 
30secs 
1 min 
94°C 30secs 
72°C 
55°C 
Hold 
10 min 
72°c 
4°C 
Figure 2.2: Hotstart 36 programme consisted of an initial HotstartTMTaq Polymerase 
activation (95°C; 15 min hold) followed by 36 cycles of denaturation (94°C; 30 sees), 
annealing (55°C; 30 secs) and extension (72°C; 1 min) followed by a final extension 
(72°C; 10 min) and rapid cooling to 4°C. 
81 
Component Volume (ul) 
Buffer (1 OX) (omniscript) 5 
dNTP's 1 
Reverse transcriptase 2.5 
Nuclease-free water 31.75 
Random Hexamers 5 
Recombinant RNAsin Ribonuclease 1 
inhibitor 
Total Volume 147.5 
Table 2.6: Reaction mixture for reverse transcription using OmniscriptTM kit. 
5 min 
4°C 
Figure 2.3: Reverse transcription reaction programme consisted of incubating the reaction 
mixture at 37°C for 60 min followed by inactivation of the reverse transcriptase by heating 
the mixture to 93°C for 5 min and rapid cooling to 4°C. 
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2.2.8 Real Time Polymerase Chain Reaction (RT-PCR) 
2.2.8.1 RT-PCR 
Real time PCR was performed using a Taqman® 7000 PCR instrument to detect cytokine 
or endogenous control gene (18sRNA) expression in cDNA samples. Pre-developed Assay 
Reagents (PDAR) and Assay-on-demand (AoD) reagents contained primers and probes 
specific for target cDNA (Table 2.7). All PDAR and AoD probes were fluorescently 
labelled with FAMTM. The 18sRNA probe was labelled with the fluorescent label VIC® 
during initial experiments and with FAMTM in further experiments. The reaction mix for 
PCR as recommended by the manufacturer is detailed in Table 2.8. A mixture of all 
components was prepared for each target gene in RNAse free tubes under sterile 
conditions. The reaction mixture (total volume 23 µl/well) was added to 96 well reaction 
plates. cDNA samples (2 µl) were then added to wells which were sealed with optical caps 
or covers. Each sample was run in triplicate. Nuclease free water (negative controls) were 
run in triplicate for each target reaction to ensure that contaminating DNA was not present 
in the reaction mixtures. Plates were then centrifuged briefly to remove any air bubbles 
from the bottom of wells and to ensure no reaction mixture or sample was left on the side 
of wells. The plate was then run on the Tagman® 7000 PCR machine using thermal cycling 
conditions recommended by the manufacturer (Figure 2.4). 
2.2.8.2 Data analysis of Real time RT-PCR results 
Data analysis was performed using ABI PRISM 7000 Analysis Software (Applied 
Biosystems, UK) using the comparative threshold cycle (Ct) method outlined below. The 
amount of cDNA expressed in each sample relative to the total amount of cDNA 
83 
Product Target 
PDAR 
Assay-on-demand 
IFN-y, IL-1p, TNFa, IL-6, IL-12p35, 
IL-12p40, IL-10, GM-CSF, 18sRNA 
IL-18, IL-27 
Table 2.7: Cytokine and endogenous control gene cDNA targets for primers and probes in 
PDAR and AoD products. 
10 min 
2 min 95°C 
50°C 
40 cycles 
15 secs 
I min 
95°C 
60°C 
25°C 
Figure 2.4: Taqman programme consisted of a step to ensure optimal AmpErase®UNG 
enzyme activity (50°C; 2 min) and a step to activate the AmpliTaq Gold® DNA polymerase 
(95°C; 10 min). This was followed by 40 cycles of a melting step (95°C; 15 sec) and an 
annealing/extension step (60°C; 1 min). 
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Component Volume (µl) 
Nuclease-free water (promega) 11.25 -x 
2X TagMan® Universal PCR 12.5 
master mix 
20X Target Primers and Probe 1.25 
cDNA sample x 
Total Volume 25 
Table 2.8: Reaction mixture for Taqman PCR reactions using PDAR and AoD products. 
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in each sample was determined. The difference between the Ct value of the endogenous 
control gene (18sRNA) and the Ct value obtained for each cytokine was calculated for 
each sample: 
Eqn 2.1: Ct cytokine - Ct 18sRNA = iCt 
This allowed normalisation of the data and a direct comparison between cytokine 
expression in different samples. In order to compare differences in cytokine expression 
between different time-points (Tx), the ACt obtained for each sample and cytokine was 
then compared with expression levels at day 0 (control sample TO): 
Eqn 2.2: ECt (sample Tx) - ACt (control sample TO) = MCt 
The standard deviation of the OCt value is numerically equal to the MCt standard 
deviation as subtraction of arbitrary values was undertaken in determination of MCt. 
To determine the relative quantification of each cytokine at each time-point the following 
value was derived: 2-AAct 
2.2.9 Constant expression of endogenous control (18sRNA) 
following S. typhimurium LPS challenge 
To ensure that the endogenous control, 18sRNA was not upregulated during infection 
Salmonella Typhimurium lipopolysaccharide (LPS), diluted in sterile PBS to 1.7 mg/ml, 
was administered to 3 female BALB/c mice intraperitoneally (100 µl). Mice were culled 
by cervical dislocation 1 hour following challenge, spleens were dissected and placed into 
Trizol (800 µl). Spleens were also removed from 3 untreated control BALB/c mice. 
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Spleens were mashed in TrizolTM using micropestles and samples were stored at -80°C 
overnight. RNA was extracted from the samples, DNA contamination was removed and 
samples were reverse-transcribed using the OmniscriptTM method and were stored at 20°C 
overnight. Prior to PCR, the concentration of cDNA in each sample was determined by 
spectrophotometry. Sample cDNA (10 µl) was added to distilled water (490 µl) in aI ml 
cuvette (dilution factor = 1: 50) and the absorbance of samples at 260 nun and 280 nm was 
measured. The amount of DNA in each sample was calculated as follows (Cavaluzzi & 
Borer, 2004): 
Eqn 2.3: A260 of 1.0 = 50µg/ml DNA 
Therefore: A260 x 50 (dilution factor) x 50µg/ml = [cDNA] 
The sample volume was limited by the amount of cDNA sample retrieved following 
reverse transcription. The maximum sample volume for the PCR reaction was 2.5 µl, 
therefore, the sample with the lowest concentration had a set volume of 2.5 µl. The amount 
of cDNA in 2.5 µl of this sample was calculated to be 81.25 ng (Eqn 2.3). The volume of 
the remaining samples required to provide 81.25 ng of cDNA was calculated and added to 
the reaction mixture. The volume of nuclease-free water in the reaction mix was adjusted 
accordingly for each sample to ensure a constant final reaction volume of 25 µl. The PCR 
reaction mix (25 µl) for 18sRNA, TNFct and IL-1ß was prepared as above (Table 2.8). All 
samples were run in triplicate and nuclease-free water controls were prepared for each 
reaction to ensure no contaminating DNA was present. 
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2.2.10 Antibody depletion experiments 
2.2.10.1 Neutrophil depletion 
2.2.10.1.1 Depleting properties of RB6-8C5 antibodies 
In order to determine the specificity and efficacy of RB6-8C5 antibodies, BALB/c mice 
(n=6) were dosed with 500 µg RB6-8C5 or isotype control (Mac5) antibodies (Table 2.1). 
Spleens were excised 24 h later, processed and spleen cell suspensions were stained for 
flow cytometric analysis using the stain combinations in Table 2.9. 
2.2.10.1.2 Role of neutrophils during B. mallei infection 
Female BALB/c mice (n=6) were injected intraperitoneally with 200 µl (2.5 mg/ml) RB6- 
8C5 antibodies or control antibodies of the same isotype (Macs; IgG2b) to give a final 
dose of 500 µg 24 h prior to infection. Mice were then dosed with antibody every 3 days. 
Animals were culled when a predetermined endpoint was reached. 
2.2.10.2 TNFa neutralisation 
2.2.10.2.1 Depleting properties of MP6-XT22 antibodies 
The specificity of the TNFa antibody was investigated in vitro under sterile conditions. 
J774A. 1 macrophages were added to 24 well plates in DMEM media, containing 10% FCS 
and L-glutamine, at a cell concentration of 2x106/ml and were incubated overnight (37°C; 
5% C02). Recombinant TNFa was diluted in media (0-50ng/ml) and was then added to 
cells in the presence or absence of 500µg/ml TNFa antibodies or Mac5 isotype control 
matched antibodies. Cells were reincubated for 24 h (37°C; 5% C02) and then harvested, 
washed and resuspended in staining buffer (100 µl) containing CD54-PE antibody. Cells 
were incubated for 30 min, resuspended in 1% paraformaldehyde and 
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Fluorochrome 
FITC PE PE-Cy5 
CDI Ic (AHIgG1) Gr-1 (rIgG2bK) B220 (rIgG2ax) 
Gr-1 (rIgG2bx) CD! lb (rIgG2b) F4/80 (rIgG2b) 
DX5 (rlgMk) Gr-1 CD3 (AHIgGIK) 
Table 2.9: Stains used for flow cytometric analysis of spleen samples. Gr-1+ populations 
were identified by specific antibodies conjugated to fluorochrome labels: FITC: 
Fluorescein Isothiocyanate; PE: Phycoerythrin; PE-Cy5: phycoerythrin-cychrome-5; CD: 
complimentarity determining. The isotypes of the antibodies are bracketed 0 next to the 
appropriate marker. AH: Armenian hamster; R: rat; IgG: immunoglobulin G. 
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macrophage activation was measured by flow cytometry. 
2.2.10.2.2 Role of TNFa during B. mallei infection 
The effect of TNFa neutralisation during B. mallei infection was assessed. TNFa 
antibodies (clone: MP6-XT22) (500 µg) were administered intraperitoneally (200 µl at 
2.5mg/ml) to BALB/c mice (n=6/group). Mice were given initial doses 24 h prior to 
infection with B. mallei, at day 1 p. i. and day 4 p. i. (Table 2.10). Mice were then re-dosed 
twice weekly (Scanga et al, 1999). An infected control group (n=6) was administered with 
the same dose of isotype control antibody (Mac49) at the same time as TNFct antibody 
dosing. Mice were culled 7 days post-infection, unless a humane endpoint was reached at 
an earlier time-point and spleens were removed for bacteriological analysis. In a further 
experiment, BALB/c mice (n=6) were infected with B. mallei and dosed intraperitoneally 
with TNFa antibodies (500 µg) at day 42 p. i. and re-dosed twice weekly. An infected 
control group (n=6) were dosed with control antibodies (Mac49) at the same timepoints. 
Mice were culled 14 days following the initial antibody dose unless a humane endpoint had 
already been reached. 
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Group I Antibody dosing regime (Days post- 
A (24 hours Pre-infection) 
B (24 hours post-infection) 
C (4 days post-infection) 
D (Isotype control: Mac49) 
infection) 
Day -1, +4 
Day +1, +5 
Day +4 
Day -1, +1, +4, +5 
Table 2.10: Description of TNFa neutralisation groups and the antibody dosing regimen 
for each group post-infection. Groups A-C were dosed with 500 µg MP6-XT22 TNFa 
antibody and Group D was dosed with 500 µg Mac49 control antibody at the timepoints 
stated post-infection 
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2.2.10.3 T cell depletion 
2.2.10.3.1 Depleting properties of T cell antibodies 
In order to determine the individual and combined effects of the antibodies YTS 191 and 
YTS169 on specific T cell subsets, BALB/c mice (n=3/group) were injected 
intraperitoneally with an initial loading dose of antibody (500 µg). An isotype control 
group (Mac5) was dosed simultaneously with 500 µg antibody. Mice were injected with a 
maintenance dose of 250 µg after 48 h and were culled by cervical dislocation the 
following day. Spleens were removed from all animals and flow cytometry was performed 
on spleen suspensions. Cytotoxic T cells were identified by staining with CD8-FITC 
(RIgG2ak) and CD3-PE (HIgGI) and T helper cells were identified by staining with CD3- 
FITC (HlgGlk) and CD4-PE (IgG2ak). 
2.2.10.3.2 Role of T cells during B. mallei infection 
T helper cells (CD4+ T cells) and/or cytotoxic T cells (CD8+ T cells) were depleted prior to 
infection with B. mallei. An initial loading dose of 500 µg CD4 (YTS 191) and/or CD8 
(YTS 169) antibodies or control antibodies (Macs) was administered intraperitoneally to 
BALB/c mice (n=6/group) 3 days prior to infection. A second dose (250 µg) of appropriate 
antibody was administered 24 h prior to infection and then every 5 days until the end of the 
experiment (Table 2.11). This dosing regimen was based on previous experimental data 
(Scanga et al, 2000)). Mice were culled 28 days p. i. unless preceded by a predetermined 
endpoint. 
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T-cell Depletion 
(Antibody Clone) 
group Antibody Dosing Regime (Days post- 
infection) 
Anti-CD8 (YTS 169) 
Anti-CD4 (YTS 191) 
Anti-CD4 and anti-CD8 (YTS 
169 + YTS 191) 
Isotype control (Mac 5) 
Day -3 (500 µg), -1 (250 µg), +5 (250 µg), 
1 +10 (250 µg), +15 (250 µg), +20 (250 µg), +25 
1 (250 µg) 
Table 2.11: Description of T cell depletion groups. The antibody dosing regimen for each 
group post-infection was the same. 
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2.2.11 In vitro stimulation of spleen cells 
2.2.11.1 Preparation and stimulation of spleen cell suspensions 
Spleens were aseptically removed from mice and placed into media (RPMI 1640 
supplemented with 10% FCS, penicillin, streptomycin and 10 mM L-glutamine). Spleens 
were mashed into media to create single cell suspensions and centrifuged (300 g, 5 min). 
Erythrocytes were lysed by adding red blood cell lysis buffer (8 ml) to cell pellets and 
incubating at room temperature for 10 min. Cell suspensions were washed in media and 
counted by trypan blue exclusion staining. Cell suspensions were adjusted to 5x106 
cells/ml by resuspending in warmed RPMI 1640 media. Cells suspensions were then plated 
at 100 µl/well in 96-well flat-bottom culture plates in triplicate wells for each mouse. Cells 
were incubated with 100 µl/well of 1x106 cfu/ml (final concentration) heat-killed B. mallei, 
IL-6 (10-200ng/ml) or medium control (5% C02; 37°C). A combination of IL-12 (5ng/ml) 
and IL-18 (5ng/ml) was added to wells in triplicate for each mouse as a positive control for 
IFN-y production. 
2.2.11.2 Intracellular IFN-y staining for flow cytometry 
Supernatants were harvested from each well after 24 h and were frozen (-20°C) prior to 
cytometric bead array analysis to detect secreted cytokines. For intracellular staining, 
Golgi plugTM (1 µl of 1: 10 dilution) was added to cultures 3.5 h prior to the end of 
stimulation and cells were harvested from wells. Cells from triplicate wells for each mouse 
were pooled for intracellular staining. Cells were washed in staining buffer and 
extracellular markers were stained using DX5-FITC (NK cells) and CD3-PC5 (T cells) and 
incubated in the dark (30 min, RT). Samples were then washed using staining buffer and 
were resuspended in 100µl LeucopermTM Reagent A (15 min, RT). Cells were washed in 
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staining buffer, resuspended in 100 µl LeucopermTM Reagent B containing IFN-y-PE 
antibody or isotype control antibody (rat IgGI-PE) and incubated in the dark (30 min, RT). 
Cells were then washed in staining buffer and resuspended in 2% paraformaldehyde 
solution prior to flow cytometric analysis. 
2.2.12 Statistical Analysis 
2.2.12.1 Analysis of temperature data 
Statistical analysis of temperature data was performed by a two-way Analysis of variation 
(ANOVA) test to determine whether infected and uninfected mice had significantly 
different temperatures over the time course of infection. The ANOVA was performed on 
the average of the uninfected and infected mice over time and F-values were calculated. 
Trendlines and correlation coefficients were determined using Microsoft Excel. 
2.2.12.2 Analysis of in vivo infection data 
Data obtained during analysis of real-time RT-PCR, serum cytokines and flow cytometry 
during infection in Immune Analysis 2 was determined to be non-parametric and, 
therefore, data is represented as median ± 99% confidence intervals. A Kruskal-Wallis Test 
was performed to determine the overall significance of the data and the significance of 
individual data points was determined using a Mann-Whitney U Test. The statistical 
significance of data obtained at each time-point during the infection was compared with 
uninfected control animals unless otherwise stated. A predetermined p-value of less than 
0.01 was deemed to indicate statistical significance (a=0.01). This lower significance level 
was chosen to reduce the chance that differences observed were due to chance because of 
the multiple comparisons made between the medians using the Mann-Whitney-U test; the 
Mann-Whitney U post-test does not automatically correct for multiple comparisons 
(Chapters 4-6). 
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2.2.12.3 Analysis of in vitro stimulation data 
Data obtained in in vitro stimulation assays was parametric and was analysed using a one- 
way ANOVA test followed by a Tukey's t-test. A p-value of less than 0.05 was deemed to 
indicate statistical significance (a=0.05). This higher significance level was chosen as the 
Tukey's post-test automatically corrects for multiple comparisons between the means and, 
therefore, the significance level did not need to compensate for the fact that multiple 
comparisons were made on the data (Chapter 7). 
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Chapter 3 
Characterisation of an intraperitoneal 
model of B. mallei infection in BALB/c 
mice. 
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3.1 Introduction 
In depth characterisation of host immune responses to pathogens is important to determine 
potential protective and detrimental aspects of the immune response. Although some work 
has been performed to characterise the pathology of disease caused by B. mallei, little work 
has been performed to investigate host immune responses to B. mallei infection. 
Intraperitoneal models of infection in both outbred (Porton) and inbred (BALB/c and 
C57BL/6) mouse strains (Fritz et al, 2000; Amemiya et al, 2002) have been used to 
describe the pathology of B. mallei infection where a non-acute, systemic infection follows 
intraperitoneal infection. Bacteria entering the peritoneal (abdominal) cavity cause 
infection and histopathological changes in several organs including the spleen, lymph 
nodes, bone marrow and liver (Fritz et al, 2000). The spleen has an important function in 
clearing the blood of circulating pathogens but may also be colonised by pathogens 
including B. mallei which targets the spleen during infection in humans (Georgiades & 
Fishman, 2001). 
In this chapter, an intraperitoneal model of B. mallei infection in BALB/c mice is 
described. The aims of this chapter were to determine: 
" The time course of bacterial colonisation of the spleen 
" Systemic changes occurring during infection by monitoring body temperature and 
signs of infection. 
This model was consequently used to investigate host immune responses to B. mallei 
infection described in chapters 4-6. 
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3.2 Methods 
In the following studies characterising temperature, signs of disease and splenic bacterial 
colonisation, female BALB/c mice were challenged i. p. with 106 cfu B. mallei (ATCC 
23344). Temperature and signs of disease were measured throughout the time course of 
infection until mice reached a predetermied endpoint and were culled. Bacterial 
colonisation in the spleen was investigated during infection at several time-points in 2 time 
course experiments: Immune Analysis (1) and Immune Analysis (2) (see Chapter 2; Table 
2.2). Immune Analysis (1) encompassed a 36-day time course of infection. Immune 
Analysis (2) repeated investigation of responses 0-7 days post-infection (p. i. ), including an 
additional time-point at 5hp. i. and higher animal numbers (n=8) in order to counter 
variation in bacterial counts observed during Immune Analysis (1). In addition to bacterial 
colonisation of the spleen, cellular responses, splenic cytokine expression and systemic 
serum cytokine production were investigated during both immune analysis experiments, 
the results of which are described in chapters 4-6. 
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3.3 Results 
3.3.1 Signs of disease and temperature changes 
Signs of disease and body temperatures were monitored for 36 days following i. p. infection 
with 106 cfu B. mallei in infected and uninfected control mice. During the 36 days of 
monitoring, none of the animals reached a humane endpoint for culling and no animal died 
as a result of the infection. Mice remained in the isolator for up to 70 days post-infection 
(Figure 3.1). After 66 days, ruffling and hunching were observed - one animal was found 
dead and another was culled 2 days later following the development of abdominal 
swelling. Once terminal signs of disease were observed in the remaining animals, mice 
were culled and the study ended. 
Infected mice were housed in two cages of 5 animals (cage A and cage B) and ruffling of 
fur was used as a consistent sign of illness in the mice. A comparison of average 
temperatures from infected mice from both cages A and B (n=10) and uninfected mice 
(n=5) over time revealed that infected mice had significantly different temperatures in 
comparison with uninfected mice (p<0.05) in both the morning and afternoon. 
Temperature in infected mice from both cages was significantly higher than controls at day 
14 p. i. (p<0.05) (Figures 3.2 & 3.3). A division in signs and temperatures was observed 
between cages of infected mice (A and B) (Figures 3.2 & 3.3). Diurnal variation in 
symptoms and temperature were also observed. Slight ruffling was observed in the 
morning on days 5-9 in both control and infected animals in cages A and B. From days 12- 
14, slight ruffling was observed in the morning in 1/5 infected animals in cage B and 2/5 
animals in cage A (Figure 3.2AM). Notable ruffling of fur was observed in all cage A mice 
in the morning and afternoon from days 22 to 36 (Figure 3.2AM & PM). This was 
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Figure 3.1: Number of BALB/c mice (n=10) surviving following intraperitoneal infection 
with 1x 106 cfu B. mallei. At 66 days post-infection, one animal was found dead. Another 
mouse was culled 2 days later following the development of abdominal swelling. Terminal 
signs of disease were observed in the remaining mice 71-72 days p. i. which were then 
culled and the study ended. 
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Figure 3.2: 'T'emperature (°C) and symptoms measured in animals from cage A (n=5) in 
the morning (AM) and the afternoon (PM). Grey bars indicate the number of infected 
animals that showed signs of ruffling and black bars indicated the number of control 
animals (n 5) showing signs of ruffling. Black lines indicate average temperatures for 
infected animals and grey lines control temperatures. Error bars represent S. D. Trendlines 
and the correlation coefficient (R2) are shown for infected animals only. Asterisk indicates 
a significant ditTerence (p<0.05) between infected and control mice. 
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Figure 3.3: Temperature (°C) and symptoms measured in animals from cage B (n=5) in 
the morning (AM) and the afternoon (PM). Grey bars indicate the number of infected 
animals that showed signs of ruffling and black bars indicated the number of control 
animals (n=5) showing signs of ruffling. Black lines indicate average temperatures for 
infected animals and grey lines control temperatures. Error bars represent S. D.. Trendlines 
and the correlation coefficient (1Z2) are shown for infected animals only. Asterisk indicates 
significant difference (p<0.05) between infected and control mice. 
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accompanied by a decreasing trend in morning temperature (R2=0.23) which was not 
observed in control animals, cage B animals or infected animals during the afternoon 
(Figure 3.2AM). Ruffling was observed only sporadically in cage B mice from days 14-36 
p. i. (Figure 3.3). 
3.3.2 Bacteriological analysis and abscess formation 
Bacteriological analysis was performed on spleens removed from BALB/c mice infected 
with 1x 106 cfu B. mallei, identified as small, smooth, distinct pinkish-white colonies on 
Congo Red plates. Splenic colonisation was investigated on days 1-7p. i. during both 
experimental time-course infections (Immune Analysis (1) and (2)) (Figure 3.4A & B). 
Similar counts were observed at days 1 and 7 p. i. in both studies although less variation 
was observed at days 3 and 5 p. i. in Immune Analysis (2). 
Uniform bacterial colonisation of the spleen occurred 5hp. i. during Immune Analysis (2) 
(Figure 3.4A). At 24 h p. i., B. mallei colonies were isolated from all mice. More than 1000 
cfu were isolated from 5/8 mice although <10 cfu were isolated from one individual. 
Spleens from all mice were colonised 3 days p. i., although bacterial burdens were variable 
(10-103 cfu). At day 5 p. i., 5/8 mice were colonised with counts ranging from 135 - 3690 
cfu. Splenomegaly was observed in some animals at day 7 p. i. and 7/8 mice were colonised 
with bacterial burdens similar to day 1. At day 14 p. i., splenomegaly and/or abscess 
formation was observed in all animals except one. Abscesses occurred in 2/10 mice at day 
14 and were characterised by yellow pus surrounded by a hard, white casing. Multiple 
small abscesses were observed in the spleens of some animals. Abscess formation 
correlated with high bacterial counts (>106 bacteria/spleen) (Figure 3.5). Splenomegaly 
was not always accompanied by high bacterial counts. At day 21,5/10 animals possessed 
abscesses accompanied by high levels of bacteria (>10v bacteria/spleen). At days 28 and 
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Figure 3.4: The number of colonies detected in the spleens of BALB/c mice infected with 
1x 106 cfu B. mallei over the first 7 days of infection during A) Immune Analysis (2) 
(n=8/timepoint) and B) Immune Analysis (1) (n=10/timepoint). Triangles represent 
individual animals. The line represents the median number of colony counts detected at 
each time-point post-infection. 
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36, abscesses were observed in 6/10 and 4/10 mice respectively, and were larger than those 
found at previous time-points. No B. mallei colonies were detected in the remaining mice 
from days 14-36 suggesting an apparent clearance or latency of infection in these animals. 
3.4 Discussion 
Intraperitoneal infection of BALB/c mice with B. mallei caused the development of a 
chronic disease to which animals succumbed several weeks after the initial observation of 
abscesses. The course of B. mallei infection could be separated into 2 phases. During the 
initial phase of infection (Days 0-7) bacterial numbers appeared to be controlled by the 
host immune system. The number of bacterial colonies did not increase but remained 
between 102 and 104 cfu during this period of infection. During the second phase of 
infection (Days 14-70), bacterial numbers rapidly expanded in the spleen, abscess 
formation occurred and overt signs of disease developed with death ensuing within 70 days 
post-infection. This suggests that B. mallei was able to overcome host immune responses 
to allow uncontrolled bacterial replication leading to a systemic, fatal disease. 
A heterogeneous infection, characterised by variable bacterial numbers, signs of disease 
and temperature changes was observed. This variability became more apparent after the 
first week of infection when animals either developed abscesses or appeared to clear the 
infection. Heterogeneity in BALB/c mice was also observed in another model of B. mallei 
infection (Fritz et al, 2000) and exists in cases of human glanders where a variety of 
symptoms are observed between infected individuals (Bernstein & Carling, 1909). The 
spleens of individual mice were colonised uniformly at 5h p. i.. This suggests that variation 
in bacterial colonisation of the spleen from day 1 following infection was not due to a 
variation in challenge dose and that mice were infected with the same initial loading dose. 
The cause of variable bacterial colonisation during the remainder of the infectious time 
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course in an inbred mouse strain is unknown. However, bacteria can undergo 
transformation during infection leading to the development of a chronic, latent strain. Loss 
of the capsular structure of B. mallei has been observed in experimental murine glanders 
(Fritz et al, 2000). This may have implications in the development of latent infection as the 
capsule is an important virulence factor (DeShazer et al, 2001; Popov et al, 2002). Latent 
B. mallei infection is present in natural populations (Bernstein & Carling, 1909) and the 
absence of splenic colonies in some individuals during the second phase of infection 
suggests that a latent infection may exist in these animals. 
Multiple body-wide abscess formation is a common feature of human glanders (Srinivasan 
et al, 2001). Splenic abscess formation was observed in this model of B. mallei infection. 
Capsular polysaccharide structures appear to be important in the formation of abscesses 
during infection with B. fragilis. Interaction of the polysaccharide capsule of this bacterium 
with T cells is responsible for abscess formation during infection (Tzianabos et al, 1994). It 
would be interesting to determine whether the B. mallei capsular polysaccharide is 
important for abscess formation in vivo. 
In recorded human cases of glanders, symptoms accompanied by fever and pyrexia 
normally occur in the afternoon (Howe et al, 1947). Temperature differences between 
control and infected animals were more marked in the morning in mice with overt signs of 
disease in comparison with afternoon temperatures in the same mice. Diurnal variations in 
mouse species means that they are normally more active at night and less active during 
daytime - the opposite to human activity, suggesting that these temperature changes may 
be analogous to human glanders. Temperature spiking also occurs throughout the day in 
human glanders with temporary, short-lived periods of pyrexia (Howe & Miller, 1947). 
The occurrence of temperature spiking during B. mallei infection in the mouse is not 
known, however, more regular monitoring (e. g. hourly) of core body temperature using an 
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implanted temperature probe may identify any temperature spikes occurring in the mouse 
model of B. mallei infection. This would prevent exclusion of temperature elevations 
occurring in between temperature monitoring in the morning and afternoon. 
Periodic symptoms were observed in mice during the first three weeks of infection, 
however, this developed into continuous ruffling in half the mice from day 21 p. i.. During 
this period temperatures dropped below those of control values only in animals that were 
ruffled. Hypothermia, is a marker in acutely ill BALB/c mice during lipopolysaccharide- 
induced shock (Vlach et al, 2000) and the trend towards hypothermia in overtly ill mice in 
this study suggests that a drop in temperature may be indicative of the severity of illness. 
However, in order to substantiate this, a more sensitive technique (e. g. implanted 
temperature probe) could be used to measure core body temperature rather than peripheral 
temperature in a manner which is not subject to user variation. 
Ruffling occurred occasionally in some control mice from days 5-9 p. i.. This may have 
been due to differential assessment of signs of disease by different investigators in the 
early part of the study, however, the reason for this should be more fully investigated in 
future studies. The distinct difference between the two separate cages of infected mice 
(cages A&B) in terms of signs of disease could also not be explained: both cages were 
challenged with the same dose of B. mallei from the same culture; signs of disease were 
recorded by the same operators at each time-point; all mice (from both cages) developed 
terminal signs of disease within days of each other. Variation was apparent in this model of 
B. mallet infection in terms of splenic bacterial colonisation, however, the clear cage- 
specific signs of disease would not be expected and should be investigated in further 
studies. 
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A heterogeneous model of chronic, i. p. B. mallei infection has been described in this 
chapter, characterised by abscess formation. Host immune responses occurring during 
infection in this model, and the immunological consequences of heterogeneity of disease, 
are described in Chapters 4-6. 
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Chapter 4 
Characterisation of neutrophil and 
macrophage responses during B. mallei 
infection in BALB/c mice. 
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4.1 Introduction 
Neutrophils and macrophages are immune cells important in innate defence against 
infection. They are involved in pathogen recognition and killing by a number of 
mechanisms including release of reactive oxygen and nitrogen species. They are also 
involved in the production of cytokines (eg. IL-12 and IL-18) involved in IFN-y production 
and development of type 1 immunity. Neutrophils are essential for protection against 
infection with a number of intracellular pathogens including L. monocytogenes (Conlan & 
North, 1994), S. typhimurium and Y. enterocolitica (Conlan, 1997) and their protective role 
during M. tuberculosis infection has also been established (Pedrosa et al, 2000). 
Macrophages can be infected by a number of intracellular pathogens including B. 
pseudomallei (Harley et al, 1998) and F. tularensis (Clemens et al, 2005). Although 
macrophages instigate a number of bacterial killing mechanisms following infection, 
including the production of nitric oxide and pro-inflammatory cytokines, many 
intracellular pathogens are able to subvert these processes to enable survival and 
propagation within the macrophage (Jones et al, 1996). 
Histopathological analysis has identified that neutrophils and macrophages infiltrate 
several organs during B. mallei infection (Fritz et al, 2000). However, the activation status 
and role of these cells in the progression of disease has not been characterised. Therefore, 
the aims of this chapter were to determine: 
" The effect of B. mallei on host neutrophil and macrophage responses by measuring 
the infiltration and activation profiles of these cells during infection. 
9 The effectiveness of host neutrophil responses in protecting against B. mallei using 
depleting antibodies. 
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4.2 Methods 
Neutrophil and macrophage responses were measured by flow cytometry following 
staining with lineage markers and markers of activation. Data described from the first 7 
days of B. mallei infection were predominantly derived during Immune Analysis (2). 
However, where possible, this data was compared with data derived from Immune 
Analysis (1). Data relating to days 14-36 of infection were observed during Immune 
Analysis (1) (Table 2.2). 
Gr"1+ cell populations were depleted 24 h prior to infection following intraperitoneal 
injection with RB6-8C5 depleting antibodies or Mac5 isotype-matched control antibodies 
and mice were re-dosed every 3 days p. i.. BALB/c mice were infected with 106 cfu B. 
mallei. The specificity of Gr-1+ antibodies was assessed following depletion with RB6-8C5 
or Mac5 antibody in naive BALB/c mice. Gr-1+ populations were identified in the spleen 
by flow cytometry. 
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4.3 Results 
4.3.1 Neutrophil responses during B. mallei infection 
4.3.1.1 Splenic Neutrophil infiltration 
During the first 7 days of infection in Immune Analysis (2) and Immune Analysis (1) 
(Table 2.2), the number of neutrophils was investigated in the spleens of infected BALB/c 
mice. During Immune Analysis (2), neutrophils were identified by their forward 
scatter: side scatter profiles (size and granularity) (Figure 4.1) and by examining the 
expression of high intensity Gr-1 on these cells (Figure 4.2A). In this experiment, the 
percentage of neutrophils within the spleen increased at 5hp. i. (p<0.01) and remained 
elevated 24 h p. i. (p<0.01) returning to control levels 3 days p. i. (Figure 4.3). The 
percentage of neutrophils became elevated above control values again 7 days p. i. (p<0.01) 
(Figure 4.3). The number of neutrophils in the spleen at day 5 p. i. was related to bacterial 
colonisation with comparatively low neutrophil numbers present in spleens colonised by 
<10 cfu. 
During Immune Analysis (1), the neutrophil marker (Clone: 7/4) was used and was found 
to have very low expression in BALB/c mice. Therefore, neutrophils were identified solely 
on their forward scatter: side scatter (FS: SS) profiles. In order to provide a relevant 
comparison, neutrophil data obtained during Immune Analysis (2) was further analysed 
and neutrophils were identified solely on their FS: SS characteristics. A similar proportion 
of neutrophils per sample were observed in uninfected BALB/c mice in both Immune 
Analysis (1) and (2) with 2-4% of cells having neutrophil size and granularity (Figure 4.4). 
At days I and 3 p. i., 6-8% of cells had neutrophil FS: SS properties in both experiments. At 
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Figure 4.1: Representative splenic cell populations in a naive and an infected BALB/c 
mouse. Forward scatter (FS): side scatter profiles (SS) of lymphocytes, 
macrophages/monocytes and neutrophils identified in A) a naive and B) a B. mallei 
infected BALB/c mouse spleen. FS represents cell size and SS represents cellular 
granularity. 
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Figure 4.2: Representative flow cytometry histograms to indicate positive staining profiles 
of' neutrophils during B. mallei infection. Splenic cells obtained from BALB/c mice 
following infection with B. mullei during Immune Analysis (2) were identified by staining 
with A) Gr-1 and co-stained with antibodies specific for 13) Cl)54; C) CDllb and ll) 
CD621,. Blue plots indicate negative staining determined using appropriate isotype 
controls and red plots indicate positive fluorescence staining. 
Gr-1 
116 
N 
CO^^ S4 
'0 MN M' 
C0Oy" 
6 
0 
U5 
CC 
4 
ä 
03 
.r 
c2 
t7 
0 
0 
Days post-infection 
Figure 4.3: Splenic Gr-1+ neutrophil populations during the first 7 days post-infection with 
B. mallei. The median percentage of Gr-1H` neutrophils detected as a proportion of total 
cells collected per sample (n=8/timepoint) during Immune Analysis (2). Error bars 
represent 99% confidence intervals. Asterisk(s) indicate statistical significance (p<0.01) in 
comparison with day 0 (uninfected). 
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Figure 4.4: Splenic neutrophil populations during the first 7 days post-infection with B. 
mulled during Immune Analysis (1) and Immune Analysis (2). The median percentage of 
neutrophils (identified by FS: SS profiles alone) as a proportion of total cells collected per 
sample during Immune Analysis I (IA 1) (n=5/timepoint) or Immune Analysis 2 (IA 2) 
(n=8/timepoint). Error bars represent 99% confidence intervals. 
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day 5, the proportion of neutrophils increased in Immune Analysis (1) although in Immune 
Analysis (2) neutrophil percentages remained at similar levels to days I and 3. At day 7 
p. i., neutrophil percentages remained elevated above control levels and were 10-12% of 
total cells per sample in both experiments (Figure 4.4). 
4.3.1.2 Splenic Neutrophil activation 
Cell surface markers involved in inflammation (CD54, CD1 lb and CD62L) were identified 
using plots displayed in Figure 4.2 and were investigated on Gr-1+ neutrophils at 5h and 
days 1,3,5 and 7 p. i. during Immune Analysis 2. A significant increase in CD11b 
expression (p<0.01) on Gr-1+ neutrophils (Figure 4.5A) was accompanied by a significant 
decrease in CD62L expression (p<0.01) 5hp. i. (Figure 4.5B). The increase in CD1lb and 
decrease in CD62L expression was observed on approximately the same percentage (30%) 
of neutrophils. Expression of both markers returned to levels observed in uninfected mice 
24 h p. i.. CD11b expression remained constant until an increase in expression was 
observed again at day 7 p. i. (p<0.01). A large decrease in CD62L expression (50% lower 
than control values) occurred at day 3 p. i. (p<0.01). Expression of CD62L recovered to 
control levels at days 5 and 7 p. i.. The percentage of neutrophils expressing both markers 
(CD62L+CD11b) remained within control values until day 3 p. i. when the percentage of 
CD62L+CD11b+ neutrophils decreased significantly below control levels (p<0.01) (Figure 
4.5C). An increase in neutrophils expressing both CD62L and CD11b occurred at day 5 
and was higher than control values 7 days p. i. (p<0.01). 
The activation marker CD54 (ICAM-1) was also investigated on neutrophils during B. 
mallei infection. Less than 2% of Gr-1+ neutrophils expressed CD54 in uninfected mice 
(Figure 4.6). Within 5hp. i., expression of CD54 on Gr-1+ neutrophils increased to 24 ± 
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Figure 4.5: Activation status of splenic Gr-l+ neutrophils during the first 7 days of B. 
mallei infection in Immune Analysis (2). Percentage of neutrophils expressing A) CDI Ib; 
B) CD62L; C) both CD62L and CDI1b. Line indicates median. Individual points at each 
time-point represent individual BALB/c mice (n=8/timepoint). Boxes indicate animals with 
<10cfu /spleen. Circled asterisks indicate that activation is significantly elevated in 
comparison with day 0 (uninfected) (p<0.01). 
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Figure 4.6: Activation status of splenic Gr-1+ neutrophils during the first 7 days of B. 
mallei infection in Immune Analysis (2). Percentage of neutrophils expressing CD54 
during the first 7 days post-infection. Line indicates median. Individual points at each 
time-point represent individual BALB/c mice (n=8/timepoint). Boxes indicate mice with 
<10 cfu /spleen. Circled asterisks indicate that activation is statistically elevated (p<0.01) 
in comparison with day 0 (uninfected). 
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4% (p<0.01) and remained elevated 24 h p. i. (17 ± 6%) (p<0.01). CD54 expression 
returned to control levels 3 days p. i. but increased significantly above controls at days 5 
and 7 p. i. (p<0.01) (Figure 4.6). CD54 expression at days 1 and 7 p. i. was related to 
bacterial colonisation of the spleen (Figure 4.6). Neutrophil responses characterised during 
Immune Analysis 1, revealed that on days 21-28 p. i., CD54 expression on neutrophils was 
elevated only in mice with splenic abscesses and high bacterial loads (Figure 4.7A & B). 
4.3.1.3 Characterisation of splenic Gr-1+ populations 
The neutrophil population (Gr-1"1) during B. mallei infection comprised the majority of 
splenic Gr-1+ cells. Further characterisation of Gr-1"1 cells with neutrophil forward 
scatter: side scatter properties demonstrated that they also co-expressed CDl lb but did not 
express the macrophage marker F4/80 (Figure 4.8A). Other splenic cell populations also 
expressed Gr-1. These included a small Gr-1+F4/80+ population (Figure 4.8B), a Gr-1+ 
CD3+ T cell population and a rare population of Gr-1+CD11c+B220+ cells which expressed 
markers characteristic of plasmacytoid dendritic cells. No Gr-1+ NK cells were identified. 
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Figure 4.7: CD54+ neutrophils are associated with abscessed spleens. The absolute 
number of CD54+ neutrophils (7/4) and bacterial colonies identified in the spleens of 
individual BALB/c mice (n=5/timepoint) infected with B. mallei at A) 21 days post- 
infection and B) 28 days post-infection during Immune Analysis (1). Diamonds represent 
individual BALB/c mice. 
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Figure 4.8: Gr-l " neutrophil and macrophage populations identified in the spleens of naive 
FALB/c mice. Gr-l and CDllb expression on A) F4/80- (neutrophils); E3) F4/80+ 
(macrophages) identified in splenic cell suspensions extracted from naive BALB/c mice. 
This data is representative of splenic cell populations from 6 BALB/c mice. 
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4.3.1.3 Depletion of Gr-1+ populations during B. mallei infection 
The role of neutrophils and other Gr-1+ cells during B. mallei infection was investigated 
using depleting antibodies. The majority of Gr-1+ cell populations identified in the spleen 
were depleted by Gr-1 (RB6-8C5) antibodies but not Mac5 isotype-matched control 
antibodies (p<0.05) (Figure 4.9). Following B. mallei infection of BALB/c mice 
administered with Gr-1 antibodies 24 h prior to infection, all animals died within 5 days 
p. i. (Figure 4.10). Infected animals administered with isotype control (Mac5) antibodies 
did not die as a result of the infection. 
4.3.2 Macrophage responses 
4.3.2.1 Splenic Macrophage infiltration 
Splenic macrophage numbers and their activation status were investigated during the first 7 
days of infection (Immune Analysis 2). Macrophages were identified by their size and 
granularity (Figure 4.1) and their expression of F4/80, a macrophage lineage marker. The 
number of macrophages in the spleen increased significantly within 5hp. i. continuing to 
increase by 24 h p. i. (p<0.01) (Figure 4.11). The number and percentage of macrophages 
remained significantly elevated from days 1-5 p. i. (p<0.01) (Figure 4.11) and macrophage 
numbers increased further 7 days p. i. in comparison with control mice (p<0.01) (Figure 
4.11). 
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Figure 4.9: Splenic Gr-1+ cell populations depleted by RB6-8C5 antibodies. Mean 
numbers of Gr-1+ populations in the spleens of BALB/c mice (n=6/group) treated with 
either 500 µg RB6-8C5 depleting antibodies or isotype-matched Macs antibodies. A) Gr- 
1+ CD11b+F4/80" neutrophils and Gr-1+ F4/80+ macrophages; B) Gr-1+CD3+T cell and Gr- 
1+ CD1lc+B220+ plasmacytoid dendritic cell populations. Error bars indicate standard 
deviation. 
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Figure 4.10: Survival of BALB/c mice following depletion of Gr-1+ cells with 500 µg of 
Gr-1 (RB6-8C5) antibody during B. mallei infection. Groups of BALB/c mice (n=6) were 
dosed with Gr-1 or isotype-control matched (Mac5) antibodies 24 hours prior to infection 
with B. mallei. 
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Figure 4.11: Splenic F4/80+ macrophage populations during the first 7 days of B. mallei 
infection in Immune Analysis (2). The median percentage of F4/80+ macrophages detected 
in spleens extracted from BALB/c mice (n=8/timepoint) over the time course of infection 
as a proportion of total cells collected per sample. Error bars indicate 99% confidence 
intervals. Asterisk(s) indicate statistical significance (p<0.01) in comparison with day 0 
(uninfected). 
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4.3.2.2 Splenic Macrophage activation 
Expression of the activation markers CD54, MHCII and CD11b on macrophages were 
investigated during B. mallei infection. Between 50 and 60% of resting macrophages in 
uninfected mice expressed CD54 at intermediate intensity whereas less than 10% 
expressed CD54 at high intensity. Increases in high intensity expression of CD54 (CD54h`) 
were investigated to measure changes in the activation status of the macrophage population 
i. e. increases in the percentage of macrophages with high numbers of CD54 molecules per 
cell (Figure 4.12A). Significant increases in the percentage of CD54h` macrophages 
occurred 5h p. i. (p<0.01) with further increases 24 h p. i (p<0.01) (Figure 4.12A). A 
decrease in the percentage of CD54h` macrophages occurred at day 3 p. i. to uninfected 
levels and then increased in number again at days 5 and 7 p. i. (p<0.01). The expression of 
MHCII was also investigated on macrophages by measuring expression of IA/IE, a 
haplotype of MHCII expressed in BALB/c mice. In resting macrophages, approximately 
90% expressed IA/IE at intermediate levels although less than 20% expressed IA/IE at 
high levels. The number of macrophages expressing IA/IE at high levels (IA/I&) was 
investigated during infection (Figure 4.12B). The percentage of IA/IEh' macrophages 
increased above control values 24 h p. i. (p<0.01). The percentage of IA/I& macrophages 
decreased at day 3 p. i. but was elevated 5 days p. i. (p<0.01) and remained elevated 7 days 
p. i. in 7/8 mice although this was not significant. The expression of CD11b on 
macrophages did not increase above control levels until 5 days p. i. (p<0.01) (Figure 
4.13C). 
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Figure 4.12: 1`4/80 macrophage populations expressing different levels of CD54 and 
Mi ICIL Flow cytometry plots showing high (hi) and intermediate (int) levels of expression 
of A) CD54 and B) MI ICII in splenic F4/80' macrophages from uninfected BALB/c mice 
(0 h) and mice infected with B. mullei 24 h p. i. (24 h) during Immune Analysis 2. This data 
is representative of individual 13ALI3/c mice (n=8/timepoint). Dotted line represents the 
fluorescence intensity of the F4/80 isotype control. Data to the right of this line indicates 
F4/80} cells. 
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Figure 4.13: Activation status of splenic F4/80+ macrophages during the first 7 days of B. 
mallei infection in Immune Analysis (2). Percentage of macrophages expressing A) high 
intensity CD54; B) high intensity IA/IE (MHC II); C) CD11b. Line indicates median. 
Individual points at each time-point represent individual BALB/c mice (n=8/timepoint). 
Boxes indicate animals with <10cfu /spleen. Circled asterisks indicate that activation is 
statistically elevated (p<0.01) in comparison with day 0 (uninfected). 
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4.4 Discussion 
Characterisation of neutrophil and macrophage responses in the spleen was performed in 
order to investigate the host's innate cellular immunological response to B. mallei 
infection. The spleen is composed of a number of resident cell populations including a 
small percentage of neutrophils and macrophages. Within 24 hours following infection, the 
number of Gr-1+ neutrophils and macrophages in the spleen had doubled. Influx of 
neutrophils and macrophages into the spleen has previously been reported during B. mallei 
infection following histological examination (Fritz et al, 2000) and also occurs during 
infection with other intracellular bacteria including S. typhimurium (Kirby et al, 2002) and 
L. monocytogenes (Conlan, 1997). Infiltration of these phagocytic cells into the spleen 
suggests that they are involved in the host immune response to B. mallei at this site of 
infection. 
Gr-1 is commonly used as a marker for identification of neutrophils (Tateda et al, 2001), 
however, another antibody (7/4) may also be used for identifying neutrophils. This 
antibody was found to have very low expression in BALB/c mice in Immune Analysis (1), 
therefore, Gr-1 was used in Immune Analysis (2) to refine the analysis of the neutrophil 
population. Examination of the size and granularity of neutrophils alone lead to a higher 
percentage of neutrophils being identified in comparison with those identified using Gr-1. 
A number of other cells including some monocytes, eosinophils and blasting T cells share 
the same FS: SS characteristics as neutrophils which may have lead to a higher percentage 
of neutrophils being identified using their size and granularity alone. Comparison of the 
neutrophil population between Immune Analysis 1 and 2 was performed using FS: SS 
characteristics alone. A comparable proportion of neutrophils were identified in the two 
experiments showing reproducibility of the analysis at each timepoint except day 5 p. i. 
when a higher proportion of neutrophils were identified in Immune Analysis 1. This 
132 
discrepancy could be addressed in future studies, although the use of Gr-1 should be used 
to identify the neutrophil population. 
Analysis of the macrophage/monocyte population could not be compared between Immune 
Analysis (1) and (2). In Immune Analysis (1), CD14 (Lipopolysaccharide receptor) was 
used, however, this was found to be weakly expressed on macrophages and did not provide 
a coherent picture of the macrophage population. Use of the antibody for F4/80 allowed a 
better defined macrophage population to be discerned in Immune Analysis (2). A 
comparison of the macrophage/monocyte population between the 2 experiments, based on 
FS: SS profile alone, was not possible as the size and granularity of this cell type is more 
diffuse. F4/80 should be used in future studies to identify the macrophage population and 
provide further evidence for reproducibility of the macrophage data discerned in Immune 
Analysis (2). 
Neutrophils infiltrate tissues from the blood using cell-cell interactions between adhesion 
molecules on the neutrophil and the endothelial lining of blood vessels. CD62L (L- 
selectin) is involved in adhesion of neutrophils to epithelial surfaces and rolling across the 
surface of blood vessels. CD62L expression on neutrophils decreased dramatically 5h p. i.. 
Loss or `shedding' of CD62L during infection occurs following neutrophil migration into 
the tissue possibly to capture migrated cells (Kishimoto et al, 1989) and to limit leukocyte 
aggregation in the tissues (Walcheck et al, 1996). The loss of CD62L expression coincides 
with neutrophil influx into the spleen 5hp. i.. By 24 h p. i., CD62L expression returned to 
control levels. Neutrophil numbers did not change significantly between 5 and 24 h p. i. 
suggesting that the neutrophils entering the spleen 5hp. i. remained in situ. Concurrent 
increases in CD11b expression were also observed 5hp. i.. CD11b is also involved in 
neutrophil migration by interacting with CD54 on endothelial cells allowing migration 
from the blood vessels into the tissues (Agace et al, 1995). Concurrent increases in CD1lb 
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expression with decreased CD62L expression have also been observed during infection 
(Wang et al, 1998) possibly highlighting the differing roles of these receptors in neutrophil 
adhesion and migration during B. mallei infection. CD11b is also the receptor for the C3 
component of the complement cascade aiding neutrophil (Egan & Gordon, 1996) and 
macrophage (Clemens et al, 2005) phagocytosis by complement mediated fixation of 
bacteria. Upregulation of CD1lb may also aid uptake of B. mallei into these cells early in 
infection. A loss of CD62L expressing neutrophils was again observed 3 days p. i. although 
the percentage of neutrophils and activated CD11b (and CD54) expression returned to 
control levels. The reason for the loss of CD62L+ neutrophils is unknown, although it may 
be a mechanism for retaining neutrophils with the spleen to aid the fight against infection. 
Upregulation of CD54 (ICAM-1) on both macrophages and neutrophils 5hp. i. 
demonstrated that these cells had become activated as a result of the infection. CD54 is an 
adhesion molecule involved in inflammatory responses. Upregulation of CD54 on 
neutrophils (Wang et al, 1998) and macrophages (Ghosh & Saxena, 2004) occurs during 
inflammation and infection. CD54 may be involved in aggregation of neutrophils during 
the inflammatory response (Wang et al, 1997) although its role on macrophages within 
hours of infection is uncertain. The recognition of bacterial components by pattern 
recognition receptors on macrophages and neutrophils allows them to respond to infection 
immediately following contact with the pathogen. The receptors involved in recognition of 
B. mallei are unknown, however, the early (5 h p. i. ) activation of macrophages and 
neutrophils suggests that these cells interact directly with the bacillus. CD54 expression 
was also upregulated on neutrophils during the later stages of infection and was associated 
with abscesses. This suggests that an ongoing inflammatory response is occurring in 
abscessed tissue although it appears to be ineffective in controlling bacterial growth. 
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In addition to their role in innate responses, macrophages are also involved in the 
development of adaptive immune responses by presenting processed antigen (in 
association with MHCII on the macrophage surface) to CD4+ T cells (Neild et al, 2005). 
IFN-? is a potent macrophage activator that specifically initiates gene expression of MHCII 
through signalling via the IFN-y receptor on the macrophage surface (Schroder et al, 
2004). Increased macrophage MHCII expression, observed 24 h p. i., may signify the 
involvement of early IFN-y responses during B. mallei infection. Increased expression of 
macrophage MHCII was also observed 5 and 7 days p. i.. Increased expression of MHCII 
suggests that B. mallei infected macrophages are capable of presenting antigen to T cells 
and stimulating cell-mediated immunity. CD54 expression was also upregulated at days 5 
and 7 p. i. suggesting a potential role for CD54 in antigen presentation during B. mallei 
infection. Macrophage CD54 acts as a costimulatory molecule during MHC I presentation 
of antigen (Lebedeva et al, 2005) to CD8+ T cells. These cells are cytotoxic for host cells 
infected with intracellular pathogens and may therefore be involved in protective responses 
during B. mallei infection. 
Macrophage activation and influx to the spleen during infection suggests that macrophages 
may play a role in B. mallei-mediated immunity. Studies involving inducible nitric oxide 
synthase (iNOS) knockout mice revealed that nitric oxide was not important for survival or 
control of bacterial replication during B. mallei infection (Lukaszewski, 2004). Nitric oxide 
is one of a number of mechanisms of macrophage-mediated pathogen killing. B. 
pseudomallei, a close relative of B. mallei, is able to subvert macrophage-mediated killing 
by nitric oxide to survive and multiply inside macrophages (Utaisincharoen et al, 2001). 
Macrophage (and neutrophil) responses were downregulated 3 days p. i. suggesting that B. 
mallei may be modulating the host immune response and, therefore, the relationship 
between B. mallei and macrophages during infection should be investigated further. 
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The antibody RB6-8C5 (anti-Gr-1) has been used during infection studies to demonstrate 
the role of neutrophils in protection against infection with intracellular pathogens including 
L. pneumophila (Tateda et al, 2001), F. tularensis (Sjostedt et al, 1996) and S. 
typhimurium (Vassiloyanakopoulos et al, 1998). Therefore, these antibodies were used in 
this study to determine the role of neutrophils during B. mallei infection. An essential role 
for Gr-1+ cells was demonstrated during innate responses to B. mallei infection following 
treatment with RB6-8C5 antibodies. The predominant population depleted by RB6-8C5 
antibody were neutrophils and, therefore, their contribution to Gr-l-mediated immunity to 
B. mallei is likely to be important. However, examination of spleen cells from naive mice 
found that a number of Gr-1+ cell types were depleted. These included Gr-1+ T cell, 
macrophage and plasmacytoid dendritic cell (pDC) populations. Gr-1 is expressed on a 
subset of memory CD8+ T cells which can be depleted by RB6-8C5 treatment (Matsuzaki 
et al, 2003). Memory CD8+ T cells can respond to cytokines released very early in 
infection to produce IFN-y and other cytokines to aid the innate immune response in 
response to B. pseudomallei (Lertmemongkolchai et al, 2001). Recruitment of Gr-1+ 
macrophages into the tissues during T. gondii infection has also been found to be important 
in protective immunity by secreting type 1 cytokines (Robben et al, 2005) Murine pDCs 
express Gr-1 and are rapidly able to recognise and respond to bacterial components 
(Nakano et al, 2001), initiating innate immune responses by activating NK cells and 
macrophages. Consequently depletion of all these Gr-1+ populations by RB6-8C5 may 
affect the outcome of B. mallei infection and their role requires further examination. 
In this chapter, activation and infiltration of neutrophils and macrophages was identified in 
the spleen, demonstrating that these cells are responding to B. mallei infection. Gr-1+ cells 
were found to be essential for protection in innate responses during B. mallei infection, 
although the contribution of neutrophils to this effect was likely to be important, it could 
not be characterised. 
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5.1 Introduction 
T and B cells are involved in both innate and adaptive responses to infection and have a 
range of functions in immunity. T cells differentiate in response to cytokines secreted 
during innate immune responses to polarise the immune response towards type 1 (IL-12, 
IFN-y) or type 2 (IL-4) immunity depending on the infective pathogen. CD8+ T cells and 
CD4+ Thl cells are particularly important in immunity to intracellular pathogens through 
cytotoxic killing and secretion of IFN-y, respectively. Some T cell subsets are able to 
secrete cytokines non-specifically in response to bacterial components and cytokines, thus 
contributing to innate immune responses (Kambayashi et al, 2003). The interaction of T 
cells with B cells and other antigen presenting cells, including macrophages and dendritic 
cells, allows the development of effector and antigen-specific T cell populations (Constant 
et al, 1995). Antigen-specific responses are important for killing pathogens not cleared by 
the initial, innate responses and in the development of memory responses to protect against 
further challenge with the pathogen. 
B cells are involved in the processing and presentation of antigen to T cells in the 
formation of specific, adaptive immune responses. B cells secrete opsonising antibody in 
response to type 1 cytokines early in infection to enhance the phagocytosis of pathogens by 
neutrophils and macrophages (Kozel et al, 2004). The clonal expansion of plasma cell 
populations which secrete specific antibody to neutralise pathogens during extracellular 
stages of infection is supported by the presentation of processed antigen by B cells to T 
cells. The aims of this chapter were to determine: 
" The effect of B. mallei on host T and B cell responses by measuring the infiltration 
and activation profiles of these cells during infection. 
" The effectiveness of host T cell responses in protecting against B. mallei using 
depleting antibodies. 
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5.2 Methods 
T and B cell responses were measured by flow cytometry following staining with lineage 
markers and markers of activation. Data described from the first 7 days of B. mallei 
infection was derived predominantly during Immune Analysis (2) and where possible, this 
data was compared with data derived from Immune Analysis (1). Data relating to 14-36 
days of infection was determined during Immune Analysis (1) (Table 2.2). 
CD4+ and CD8+ T cell populations were depleted 72 h and 24 h prior to infection 
following i. p. injection with YTS 169 and/or YTS 191 depleting antibodies or Mac5 
isotype-matched control antibodies. Mice were then re-dosed with antibodies every 5 days 
following infection. BALB/c mice were then infected with 106 cfu B. mallet. The 
specificity of CD4 and CD8 antibodies was assessed following depletion with YTS169 
and/or YTS 191 antibodies or Mac5 control antibody in naive BALB/c mice. T cell 
populations were identified in the spleen by flow cytometry. 
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5.3 Results 
5.3.1 Lymphocyte responses 
The responses of lymphocytes (T cells and B cells) were investigated. Distinct lymphocyte 
populations share similar size and granularity profiles (Figure 4.1) and were identified as 
individual populations by their exclusive expression of CD3 (T cells) (Figure 5.1A) and 
CD19 (B cells) (Figure 5.1B). 
5.3.1.2 T cell and B cell infiltration 
In Immune Analysis (2), CD3+ T cells comprised 30% of the lymphocyte population in 
uninfected mice and this percentage of T cells remained at control levels 5 h, 24 h and 72 h 
p. i. (Figure 5.2). At days 5 and 7 p. i, the percentage of T cells was significantly decreased 
below control levels (p<0.01) (Figure 5.2). A similar kinetic profile of the T cell 
population as a percentage of total splenic cell composition during B. mallei infection was 
observed during both Immune Analysis (1) and Immune Analysis (2) (Figure 5.3): In 
uninfected mice CD3+ T cells comprised 30% of the total splenic cell composition, 
however, by day 7 p. i., less than 20% of total splenic cells were CD3+ (Figure 5.3). 
In Immune Analysis (2), B cells comprised 50% of splenic cell composition in uninfected 
mice and almost 50% of the total lymphocyte population (Figure 5.2). The B cell 
population reduced by almost 50% within 5hp. i. compared with uninfected mice (p<0.01) 
although it returned to control levels 24 h p. i. and remained at control levels 72 h p. i. 
(Figure 5.2). A further comparable reduction in the percentage of B cells occurred 5 days 
p. i. and the B cell population remained diminished 7 days p. i. (p<0.01) although the B cell 
population appeared to be recovering at this timepoint (Figure 5.2). 
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Figure 5.1: Representative flow cytometry histograms to indicate positive staining, profiles 
of CU3' 'I' and CI)l9' 13 cells during B. mallei infection. Splenic lymphocytes obtained 
from [3A1, ß/c mice Following infection with B. mullei during Immune Analysis 2 were 
stained with antibodies specific for A) CD3; [3) C[)19; and appropriate isotype-matched 
control antibodies. Blue plots indicate negative staining determined using appropriate 
isotype controls and red plots indicate positive fluorescence staining. 
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Figure 5.2: Splenic C IV l' cell and CD l9' B cell populations during B. mallei infection 
(immune Analysis (2)). The median percentage of splenic T cells and 13 cells within the 
lymphocyte population collected per sample. Spleens were extracted from BAL13/c mice 
(n=8/timepoint) over the time course of infection. Error bars indicate 99% confidence 
intervals. Asterisk(s) indicate statistical significance (p<0.01) in comparison with day 0 
(uninfected). 
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Figure 5.3: A comparison of the splenic Cl)3' T cell population in BALB/c mice during 
B. mallei infection in Immune Analysis (1) and Immune Analysis (2). The median 
percentage of splenic T cells detected as a proportion of total cells collected per sample. 
White bars indicate data collected from Immune Analysis (1) (IA 1) (n=5/timepoint) and 
grey bars indicate data collected from Immune Analysis (2) (IA 2) (n=8/timepoint). Error 
bars indicate 99% confidence intervals. Asterisk(s) indicate statistical significance 
(p<0.01) in comparison with day 0 (uninfected). 
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5.3.1.3 T cell activation 
T cell activation was measured by cell surface expression of CD25, CD54 and CD44 on 
CD3+ T cells (Figure 5.4). In Immune Analysis (2), the percentage of CD25+ T cells 
decreased below uninfected control levels 5hp. i. (p<0.01) (Figure 5.5A). The CD25+ 
population returned to control levels 24 h p. i. and became significantly elevated 3 days p. i. 
(p<0.01) returning to control levels at days 5 and 7 p. i. (Figure 5.5A). A similar profile of 
CD25 expression on T cells during the first 7 days of B. mallei infection was also 
determined in data derived during Immune Analysis (1) although the overall percentage of 
T cells expressing CD25 was lower and CD25 expression was not higher than control 
levels 3 days p. i. (Figure 5.5B). 
In Immune Analysis (2), CD54 expression on T cells was elevated above control levels 24 
h p. i. (p<0.01) but was not different from control values at any other timepoint (Figure 
5.6A). In Immune Analysis (1), CD54 expression was also elevated 24 h p. i. and was 
maximally elevated above control values 5 days p. i. (p<0.01) (Figure 5.6B). CD54 
expression on CD3+ T cells was associated with splenic abscesses from days 21-36 during 
Immune Analysis (1) and abscessed mice expressed higher levels of CD54 on T cells than 
non-abscessed mice (Figure 5.7). 
The activation status of individual T cell subsets in Immune Analysis (2) was measured by 
high intensity expression of CD44 (CD44H') on CD3+CD4+ and CD3+CD8+ T cells. The 
proportion of CD4+ T cells expressing CD44H' increased above control levels 24 h p. i. and 
remained elevated at days 3 and 7 p. i. (p<0.01) (Figure 5.8A). Expression of CD44H' on 
CD8 T cells was significantly lower 5hp. i. (p<0.01) but returned to control levels 24 h 
p. i.. CD441i' expression on CD8 T cells decreased again 7 days p. i. (p<0.01) (Figure 5.8B). 
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Figure 5.4: Representative flow cytometry histograms indicating positive staining profiles 
of 'I' cell activation markers during B. mallei infection. Splenic CD3+ 'F cells obtained from 
I3ALB/c mice following infection with B. mallei during Immune Analysis (2) were co- 
stained with antibodies specific for A) CD25; B) CD54 and C) CD44. Blue plots indicate 
negative staining determined using appropriate isotype controls and red plots indicate 
positive fluorescence staining. 
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Figure 5.5: CD25 expression on splenic CD3+ T cells during the first 7 days of B. mallei 
infection in Immune Analysis (1) and Immune Analysis (2). Percentage of T cells 
expressing CD25 during A) Immune Analysis (2) (n=8/timepoint); B) Immune Analysis 
(1) (n=5/timepoint). Line indicates median and individual points at each time-point 
represent individual BALB/c mice. Circled asterisks indicate statistical significance 
(p<0.01) in comparison with day 0 (uninfected). 
146 
01234567 
Days post-Infection 
01234567 
Days post-infection 
A 40 
35 
30 
N 
25 V 
+ 20 
V 15 
OR 10 
5 
0 
0 
B 40 
35 
30 
N 
25 
20 
v 15 
10 
5 
A 
Figure 5.6: CD54 expression on splenic CD3+ T cells during the first 7 days of B. mallei 
infection in Immune Analysis (1) and Immune Analysis (2). Percentage of T cells 
expressing CD54 during A) Immune Analysis (2) (n=8/timepoint); B) Immune Analysis 
(1) (n=5/timepoint). Line indicates median and individual points at each time-point 
represent individual BALB/c mice. Circled asterisks indicate statistical significance 
(p<0.01) in comparison with day 0 (uninfected). 
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Figure 5.7: CD54 expression on splenic T cells from 21-36 days post-infection with B. 
mallei during Immune Analysis (1). The percentage of T cells expressing CD54+ on 
individual BALB/c mice (n=5/timepoint). Boxes indicate mice with splenic abscesses. 
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Figure 5.8: High intensity expression of CD44 on T helper and cytotoxic T cell subsets 
during the first 7 days of B. mallei infection during Immune Analysis 2. Percentage of A) 
CD3+CD4+ T cells; B) CD3+ CD8+ T cells expressing CD44 at high intensity (CD44H`). 
Line indicates median and individual points at each time-point represent individual 
BALB/c mice (n=8/timepoint). Circled asterisks indicate statistical significance (p<0.01) in 
comparison with day 0 (uninfected). 
149 
1234567 
Days post-infection 
1234567 
Days post-infection 
5.3.2 The role of T cells during B. mallei infection 
The progression of B. mallei infection in the absence of CD8+ and CD4+ T cells was 
assessed using depleting antibodies. The specificity of anti-CD4 and anti-CD8 antibodies 
was assessed prior to infection of antibody-treated mice. 
5.3.2.1 Specificity of anti-CD4 and CD8 antibodies 
The efficacy of anti-T cell antibodies was assessed using flow cytometry to detect T cell 
subsets in the spleens of treated mice. No CD4+ T cells were detected in the spleens of 
mice dosed with anti-CD4 (YTS191) antibodies (Figure 5.9A). The number of CD8+ T 
cells present in the spleens of mice dosed with anti-CD4 (YTS191) antibodies was not 
significantly different from mice treated with control (Mac5) antibodies (p<0.05) (Figure 
5.9B). This demonstrates that anti-CD4 (YTS191) antibodies specifically deplete CD4+ T 
cells without affecting the CD8+ T cell population. In the spleens of mice treated with anti- 
CD8 antibodies (YTS169), no CD8+ T cells were detected (Figure 5.9B) and CD4+ T cell 
numbers were not significantly different from mice treated with control antibodies 
(p<0.05) (Figure 5.9A) demonstrating the specificity of depletion with YTS 169. When 
both YTS 191 and YTS 169 were administered simultaneously neither CD4+ T cells nor 
CD8+ T cells could be detected (Figure 5.9 & B). A population of CD3+CD4-CD8" T cells 
was detected following treatment with a combination of both antibodies (Figure 5.9C). 
5.3.2.2 T cell depletion during B. mallel infection 
The effects of T cell depletion on survival of BALB/c mice following infection with B. 
mallei were assessed. CD4+ T helper cells or CD8+ cytotoxic T cells were depleted from 
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Figure 5.9: Splenic T cell populations in BALB/c mice identified by flow cytometry 
following administration of CD4 (YTS 191) and/or CD8 (YTS 169) or isotype control 
antibodies (Mac5) to BALB/c mice (n=3/group). A) Mean absolute number of CD4+ T 
cells; B) Mean absolute number of CD8+ T cells; C) Mean absolute number of CD3+ T 
cells identified in the spleens of BALB/c mice. Error Bars represent standard deviation. 
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BALB/c mice prior to infection with B. mallei using the antibodies YTS 191 and YTS169 
respectively. The effect of removing both T cell subsets was assessed by administering 
both YTS 191 and YTS 169 antibodies in combination. Depletion of the CD4+ T cell 
population caused 3/6 animals to die 21 days p. i. (Figure 5.10). Following depletion of the 
CD8+ T cell population, 2/6 animals died at day 14 p. i.. Mice (4/6) died 14 days p. i. 
following depletion of both T cell subsets simultaneously and a further animal died 23 days 
post-infection (Figure 5.10). Infected animals treated with isotype-matched control 
antibodies (Mac5) did not die as a result of the infection (Figure 5.10). 
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Figure 5.10: Survival of BALB/c mice following depletion of T cell populations during B. 
mallei infection. Groups of mice (n=6) were dosed with CD4 antibodies (YTS169), CD8 
antibodies (YTS 191), both CD4 and CD8 antibodies (YTS 169 + YTS 191) or isotype- 
matched control antibodies (Mac5) 24 hours prior to infection with 106 cfu B. mallei. 
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5.4 Discussion 
The work presented in this chapter further aimed to characterise the cellular mechanisms 
involved in the host immune response to B. mallei by examining lymphocyte responses 
during infection. In uninfected, immunocompetent BALB/c mice, lymphocytes comprised 
the majority of spleen cells. A significant decrease in the B cell population occurred 5h 
p. i., recovering to normal levels within 24 h. Splenic B cell depletion within hours of 
infection has been observed in response to the supertoxins of S. aureus caused by a 
combination of trafficking and apoptosis of specific B cell populations (Goodyear & 
Silverman, 2004). However, it is unknown whether a B. mallei `superantigen' exists or is 
released during infection. The recovery and maintenance of the B cell population 24 h p. i. 
to 72 h p. i. suggests that B cells are migrating into the spleen from the blood or lymphatic 
circulation. However, further work is required to establish the reasons for these changes in 
the B cell population. 
The functional contribution of B cells in protective immunity to B. mallei infection was not 
investigated, however, previous studies involving infection of B cell knockout mice 
showed that removal of B cells did not affect survival or bacterial proliferation during B. 
mallei infection (Lukaszewski, 2004). This suggests that antibody-mediated immunity is 
not essential for control of B. mallei infection in vivo. This was also observed in a non- 
human primate model of infection where humoral immunity was not found to be protective 
during re-infection with B. mallei in monkeys with high titres of antibody (Manzeniuk et 
al, 1997). 
Decreases in the percentage of activated CD25+ T cells and CD8+ T cells with a CD441" 
memory phenotype occurred 5hp. i. while T cell numbers remained constant. T cell 
populations continually move between the blood and tissues in surveillance for pathogens 
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(Butcher & Picker, 1996). Movement of cell populations between the blood and the spleen 
allows mixing of activated T cells, which have been presented with antigen, with naive T 
cells. This suggests that an increase in naive T cells in the spleen, causes dilution of these 
activated splenic T cell populations during B. mallei infection. However, the actual 
mechanisms involved in lymphocyte trafficking during B. mallet infection are unknown. 
An increase in the percentage of CD54+ T cells and CD4+ T cells with a CD44Hi memory 
phenotype was observed 24 h p. i., although the number of T cells in the spleen remained 
constant. This suggests that local activation of T cells is occurring within the spleen in 
response to B. mallei. CD54 is upregulated on T cells during infection with M. tuberculosis 
(Mitra et al, 2005) and expression of CD54 on T cells may be important in the 
differentiation of naive CD4+ T cells into Thl cells in response to IL-27 (Owaki et al, 
2005) suggesting the development of type 1 immunity during B. mallei infection. Memory 
CD4+ T cells are able to respond to cytokines and proliferate independently of antigen 
(Eberl et al, 2000) suggesting that these cells may be responding during B. mallei 
infection. The discrepancy in CD54 expression between Immune Analysis (1) and (2) at 
day 5 p. i. should be investigated in further studies. 
The number of T cells and B cells in the spleen remained at control levels 72 h p. i. but 
diminished 5-7 days following infection. Histopathological analysis of the spleen during B. 
mallei infection in BALB/c mice revealed lymphoid depletion of the white pulp between 
days 3-7 post-infection (Fritz et al, 2000). The white pulp is composed mainly of T cells 
and B cells and it is possible that destruction of the splenic architecture is responsible for 
the decrease in lymphocyte numbers observed during B. mallei infection. During infection 
with other pathogens, antigen-specific T cell responses develop around 5-7 days p. i.. 
Selective depletion of non-specific T cell populations or circulation of antigen-specific T 
cell populations may also lead to decreased T cell numbers observed in the spleen. 
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Neither CD4+ T helper cells nor CD8+ cytotoxic T cells were important for survival during 
the initial phases of B. mallei infection although they were both essential for survival 2-3 
weeks following B. mallei infection. This suggests that T cells may play a role in 
controlling the infection by adaptive immune mechanisms (Haque et al, 2005). Adaptive 
immunity develops following antigen presentation to T cells in the presence of polarising 
cytokines, allowing the development of antigen-specific T cells to specifically target the 
infective pathogen. CD8+ T cells are important in cytotoxic killing of infected host cells 
and, therefore, may be important in killing macrophages (or other cells) presenting B. 
mallei antigen. The importance of both CD4+ and CD8+ subsets in B. mallei mediated- 
immunity is highlighted by the decreased survival time in the absence of both subsets, 
suggesting that a mixed antigen-specific response is required for protection against B. 
mallei infection. 
Following treatment with both CD4 and CD8 antibodies some CD3+ (CD4"CD8") T cells 
were not depleted. T cells may be important in innate responses to intracellular infection 
by producing IFN-y in response to proinflammatory cytokines and bacterial components 
(Lertmemongkolchai et al, 2001; Kambayashi et al, 2003). Subsets of CD3+CD4'CD8' T 
cells exist which are involved in innate immune responses to infection with F. tularensis 
(Cowley et al, 2005). It is possible that this subset and other CD4'CD8' subsets including 
yS T cells (Kawakami, 2004) may constitute part of the CD3 population remaining 
following depletion of CD4 and CD8 subsets and may provide protection against early B. 
mallei infection. 
In immunocompetent mice, splenic abscesses are prevalent within 2 weeks following B. 
mallei infection. CD4+ T cells are known to be important for abscess formation following 
infection with B. fragilis (Tzianabos et al, 2000; Chung et al, 2003). The role of T cells in 
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abscess formation during B. mallei infection is unknown; however, CD54 expression was 
elevated on T cells in abscessed mice suggesting an active role for T cells within abscessed 
tissue. In addition to this, mice begin to die 21 days p. i. following depletion of CD4+ T 
cells when abscesses are known to have formed in the spleens of immunocompetent 
animals. Disruption in the formation or maintenance of abscesses could lead to systemic 
release of bacteria leading to sepsis and death. 
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Chapter 6 
Characterisation of cytokine responses 
during B. mallei infection in BALB/c mice. 
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6.1 Introduction 
Cells communicate and propagate immune responses by releasing a range of proteins with 
a diverse range of functions allowing appropriate immune responses to develop. TNFa, IL- 
6 and IL-10 are pro-inflammatory cytokines released during early infection and are 
involved in inducing innate, bactericidal mechanisms in neutrophils, macrophages and DCs 
and propagating inflammatory reactions. Chemokines (e. g. MCP-1) and colony stimulating 
factors (e. g. GM-CSF) are involved in the recruitment, development and maintenance of 
cellular inflammatory responses. IFN-y is produced in the early stages of infection and is 
involved in development of type 1 immune responses in conjunction with a number of 
other cytokines including IL-27, IL-18 and IL-12. Type 1 responses are important for 
killing intracellular pathogens by activating the cytotoxic responses of macrophages and T 
cells and killing host cells infected with intracellular pathogens. 
In order to complement investigation of the cellular mechanisms involved in the immune 
response to B. mallei, this chapter describes splenic and systemic cytokine responses 
occurring during B. mallei infection. The aims were to determine: 
" The effect of B. mallei on type 1 and proinflammatory cytokine host responses by 
measuring splenic cytokine mRNA and serum cytokine protein during infection. 
Type I and proinflammatory cytokines were chosen to provide a comparison 
between B. mallei and the cytokines responses important during infection with 
other intracellular pathogens. 
The effectiveness of the type 1 cytokine IFN-y and proinflammatory cytokine TNF- 
a in protection against B. mallei infection using knockout mice and depleting 
antibodies respectively. 
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6.2 Methods 
Expression (mRNA) of a range of cytokines involved in pro-inflammatory responses and 
type 1 immunity were investigated in the spleen using RT-PCR. In addition to this, 
cytokine protein levels in the serum were investigated using a flow cytometric assay to 
determine systemic responses during B. mallei infection. Data retrieved during the first 7 
days of infection in Immune Analysis (2) is described in detail (Chapter 2; Table 2.2). 
Trends in cytokine responses and their relationship to bacterial colonisation and abscess 
formation were observed in Immune Analysis (1). 
In order to assess the role of IFN-y in immunity to B. mallei infection, IFN-y KO mice on 
both BALB/c and C57BL/6 backgrounds were infected with 106 cfu B. mallei (ATCC 
23344). Mice were also infected with other doses stated in the results (section 6.3.5.1). The 
effects of TNFa were assessed in BALB/c mice dosed i. p. with 500 µg TNFa antibodies 
(MP6-XT22) or 500 µg control (Mac49) antibodies at several time-points during and prior 
to infection. Mice were again challenged i. p. with 106 cfu B. mallei. 
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6.3 Results 
6.3.1 Validation of endogenous control (18sRNA) 
Analysis of cytokine expression was investigated by real-time RT-PCR in the spleens of 
BALB/c mice. The use of 18sRNA as an endogenous control was validated in order to 
ensure that 18sRNA expression remained constant and was not upregulated in response to 
the inflammatory stimulus, lipopolysaccharide (LPS), a component of Gram-negative 
bacterial cell walls. Expression of 18sRNA was not upregulated one hour following 
administration of LPS, in comparison with control animals, although the expression of 
inflammatory cytokines (TNFa and IL-10) was significantly elevated as expected (p<0.05) 
(Figure 6.1). Therefore, 18sRNA was determined to be a suitable endogenous control for 
cytokine expression during RT-PCR analysis. 
6.3.2 Splenic cytokine mRNA responses 
Expression of a range of cytokines TNFa, IL-Iß, IL-12p35, IL-12p40, IL-6, IFN-y, GM- 
CSF, IL-18, IL-27 and IL-10 was investigated during two time course experiments of B. 
mallei infection (Immune Analysis 1& 2) by comparing cDNA produced from the spleens 
of infected and uninfected animals. Background levels of all cytokines investigated were 
detected in control animals. Comparable trends in cytokine expression were observed 
during both time course studies during the first 7 days of infection (Figure 6.2). The 
predominant cytokines in both studies, peaking at 24 h p. i., were IFN-y, IL-6 and IL-27. 
Differential results existed for IL-10 which was elevated in the initial time course study 
within 24 h p. i. but not in the repeated study. 
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Figure 6.1: Mean threshold cycle (Ct) values for 18sRNA, TNFa and IL-lß in the spleens 
of BALB/c mice (n=3) following LPS challenge or saline-control mice. Error bars indicate 
standard deviation. Asterisks indicate statistical significance (p<0.05) between control and 
LPS treated mice. 
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6.3.3 Splenic cytokine expression during B. mallei infection 
The data shown below was retrieved from Immune Analysis (2). Splenic cytokine 
expression was investigated in BALB/c mice (n=8/timepoint) during the first 7 days of 
infection. Data could not be retrieved from all samples taken due to RNA degradation or 
bacterial contamination, therefore, analysis of the data was performed initially using a 
Kruskal-Wallis test followed by a Mann-Whitney Test to account for variation in results 
obtained from differing numbers of animals at each time-point. RT-PCR was performed on 
a minimum of 4 samples per time-point. 
Five hours post-infection with 106 cfu B. mallei, a significant increase in IL- 18 and IL-lß 
expression was observed (p<0.01) in comparison with uninfected control levels (Figure 
6.3). An increase in TNFa also occurred although this was not significant (p=0.0124) 
(Figure 6.4). Increases in cytokine expression were accompanied by a decrease in GM-CSF 
expression 5hp. i. (p<0.01) (Figure 6.4). At 24 h p. i., IL-lß expression remained elevated 
(p<0.01) and IL-18 expression returned to control levels (Figure 6.3). Large, increases in 
IFN-y (27-fold) and IL-27 (10-fold) expression (p<0.01) occurred 24 h p. i., accompanied 
by a 19-fold increase in IL-6 expression (p=0.0124) (Figure 6.5). A significant increase in 
GM-CSF at 24 h p. i. infection (compared with expression at 5hp. i. ) also occurred 
(p<0.01) (Figure 6.4). IL12p35 (but not IL12p4O) and TNFa expression was significantly 
higher than control values over the 7 day time course of infection as determined by 
Kruskal-Wallis analysis (p<0.01). Significant differences at individual time-points could 
not be elucidated, possibly due to the variation in IL12p35 and TNFa expression in control 
mice (Figure 6.6). 
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Figure 6.3: Splenic expression of IL-18 and IL-lß during B. mallei infection of BALB/c 
mice (Day 0: n=7; 5 h: n=6; Dayl: n=6; Day 3: n=6; Day 5: n=5; Day 7: n=4). (A) Relative 
fold increase in expression of IL-18 and IL-lß compared with uninfected mice; (B) 
Median delta threshold cycle (Ct) values for IL-18 and IL-1ß over the time course of the 
infection. Error bars indicate 99% confidence intervals. Asterisks (*) indicate statistical 
significance (p<0.01) in comparison with day 0 (uninfected). 
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Figure 6.4: Splenic expression of TNFa, GM-CSF and IL-10 during B. mallei infection of 
BALB/c mice (Day 0: n=7; 5 h: n=6; Dayl: n=6; Day 3: n=6; Day 5: n=5; Day 7: n=4). 
(A) Relative fold increase in expression of TNFa, GM-CSF and IL-10 compared with 
uninfected mice; (B) Median delta threshold cycle (Ct) values for TNFa, GM-CSF and IL- 
10 over the time course of the infection. Error bars indicate 99% confidence intervals. 
Circled asterisks (*) indicate statistical significance (p<0.01) in comparison with day 0 
(uninfected); * * indicates statistical significance in comparison with 5hp. i.. 
166 
01234567 
Days post-Infection 
A 100 
z 
E 
d 
C 
0 ýd 
VN 
O 
pC lo 
0 
C 
aT 
27 
d 
I 
B 11 
13 
d 15 
17 
m 
0 19 
21 
  IFNy 
23 +TI 
01234567 
Days post-infection 
Figure 6.5: Splenic expression of IFN-y, IL-6 and IL-27 during B. mallei infection of 
BALB/c mice (Day 0: n=7; 5 h: n=6; Dayl: n=6; Day 3: n=6; Day 5: n=5; Day 7: n=4). 
(A) Relative fold increase in expression of IFN-y, IL-6 and IL-27 compared with 
uninfected mice; (B) Median delta threshold cycle (Ct) values for IFN-y, IL-6 and IL-27 
over the time course of the infection. Error bars indicate 99% confidence intervals. Circled 
asterisks (*) indicate statistical significance (p<0.01) in comparison with day 0 
(uninfected). 
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Figure 6.6: Splenic expression of 1L-12p35 and II, -12p40 during B. mullei infection of 
BALB/c mice (Day 0: n=7; 5 h: n=6; 1)ay l: n-6; Day 3: n=6; Day 5: n=5; Day 7: n=4). 
(A) Relative fold increase in expression of II, -12p35 and ll, -12p40 compared with 
uninfected mice; (13) Median delta threshold cycle (Ct) values for IL-12p35 and II, -12p40 
over the time course of the infection. Error bars indicate 99% confidence intervals. 
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Cytokine expression was related to splenic bacterial burdens for most, but not all 
cytokines, 24 h p. i.. One individual mouse with low splenic bacterial colonisation (<10 
cfu) had higher threshold cycle (Ct) values (and therefore lower cytokine expression) for 
IL-6, IL-27, IFN-y, TNF-a, IL12p35, GM-CSF and IL-10 (Figure 6.7A & B) but not IL-18, 
IL-lß and IL12p40 (Figure 6.8) at 24 h p. i. in comparison with the remaining individuals 
in the group. A notable decrease in the expression of all cytokines, in comparison to the 
peak in cytokine expression observed 24 h p. i., occurred 72 h p. i.. Expression of IL-27 
(p=0.0124), IFN-y and IL-6 remained slightly elevated above control values 72 h p. i. 
although this was not significant (Figure 6.4 & 6.5). Expression of all other cytokines 
returned to control levels. At days 5 and 7 p. i., no significant deviation from control values 
for any cytokine was observed although elevation of IL-27 (p=0.0182) and TNFa 
(p=0.028) expression was observed 7 days p. i.. 
Examination of mRNA expression in spleens of individual mice at day 14 p. i. during 
Immune Analysis (1), revealed elevated expression of TNFa, IL-10, IL-6, GM-CSF and 
IL-10 in abscessed animals in comparison with control values and non-abscessed animals 
(Figure 6.9A). At day 21 p. i., increased expression of TNFa, IL-10, IFN-y, IL-6, GM-CSF, 
IL12p35 and IL-18 and decreased expression of IL 12p40 were observed in abscessed mice 
in comparison with non-abscessed mice (Figure 6.9B). 
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Figure 6.7: Comparison of bacterial colonisation and cytokine expression in the spleen 24 
h post-infection. Delta Threshold cycle (Ct) values for A) IFN-y, IL-6, IL-27 and TNFa; 
B) IL-12p35, GM-CSF and IL-10 in individual BALB/c mice (n=6) from Immune 
Analysis 2 are plotted against the number of bacterial colonies (cfu) detected in each 
individual spleen. 
170 
13 
15 
U 
17 
0 
0 
19 
1 10 100 1000 10000 
B. mallei (cfu) 
Figure 6.8: Comparison of bacterial colonisation and cytokine expression in the spleen for 
IL12p40, IL-18 and IL-lß 24 h post-infection. Delta Threshold cycle (Ct) values for 
IL12p40, IL-18 and IL-lß in individual BALB/c mice (n=6) from Immune Analysis 2 are 
plotted against the number of bacterial colonies (cfu) detected in each individual spleen. 
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Figure 6.9: Splenic cytokine expression is related to abscess formation during B. mallei 
infection. Delta Threshold cycle (Ct) values for cytokine mRNA expression from 
individual BALB/c mice (n=5) investigated during Immune Analysis I at A) Day 14 and 
B) Day 21 post-infection with B. mallei. Boxes indicate mice with splenic abscesses. 
172 
6.3.4 Systemic cytokine responses 
The presence of the cytokines (IFN-y, IL-6, IL-12p70, TNFa, IL-10) and the chemokine, 
monocyte chemoattractant protein (MCP)-1, were examined in serum from infected and 
control animals in the first 7 days of infection during Immune Analysis (2). Within 5hp. i., 
increases in IFN-y, MCP-1 and IL-6 were detected in the serum of infected animals 
compared with uninfected controls (p<0.01) (Figure 6.10). At 24 h p. i., circulating IFN-y, 
MCP-1 and IL-6 peaked at maximum levels (p<0.01) (Figure 6.10). At 72 h p. i. serum 
levels of IL-6, MCP-1 and IFN-y had returned to control levels and remained at control 
levels until day 7. No significant changes in serum levels of TNFa, IL-12p70, IL-10, IL-2, 
IL-4 and IL-5 were detected at any time-point during infection. 
During Immune Analysis (1), similar profiles were observed during the first 7 days of 
infection in comparison with Immune Analysis (2) with the predominant mediators being 
IFN-y, IL-6 and MCP-1 24 h p. i. (Figure 6.11A). From days 14-36, median expression 
levels of all cytokines was low. At day 14 p. i., MCP-1 and IL-6 were detected only in 
abscessed mice and serum IFNy was detected in 3/5 animals - two of which possessed 
abscesses. At day 36 p. i., MCP-1 and IL-6 were present only in the serum of animals that 
possessed splenic abscesses (Figure 6.11B). 
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Figure 6.10: Systemic cytokine responses during B. mallei infection. Median IL-6, MCP-1 
and I IF N-y production in the serum of BALB/c mice (n=8) 0-7 days post-infection with B. 
mallei in Immune Analysis 2. Error bars indicate 99% confidence intervals. Asterisks (*) 
indicate statistical significance (p<0.01) in comparison with day 0 (uninfected). 
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Figure 6.11: Systemic cytokine responses during 36 days of B. mallei infection (Immune 
Analysis 1). A) Median IL-6, MCP-1 and IFN-y production in the serum of BALB/c mice 
(n=5) 0-36 days post-infection with B. mallei in Immune Analysis 1. Error bars indicate 
standard deviation. B) Relationship between splenic bacterial colonisation and systemic 
IL-6 and MCP-1 from individual mice (n=5) 14 and 36 days post-infection. 
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6.3.5 The role of IFN-y during B. mallei infection. 
The importance of the IFN-y peak observed 24 h following B. mallei infection, both in the 
spleen and serum of BALB/c mice, was investigated in IFN-y knockout (KO) mice. 
6.3.5.1 Infection of IFN-y knockout mice with B. mallei 
IFN-y KO mice on both BALB/c and C57BL/6 backgrounds were used to assess IFN-y- 
mediated immunity during B. mallei infection. BALB/c IFN-y KO mice (9/10) died 2 days 
post-infection following challenge with a high dose (1 x 106 cfu) of B. mallei (Figure 
6.12A). IFN-y KO mice on a C57BL/6 background also died 2 days following challenge 
with a high dose (4.1 x 104 cfu) of B. mallei (Figure 6.12B). Challenge with a low dose (1 
x 102 cfu) of B. mallei caused 6/7 IFN-y KO (BALB/c) mice to die within 5 days p. i. 
(Figure 6.12A) and IFN-y KO C57BL/6 mice challenged with a low dose of B. mallei (41 
cfu) died within 3 days p. i. (Figure 6.12B). Wild-type BALB/c and C57BL/6 mice 
challenged with both low and high doses survived for the duration of the experiment 
(Figure 6.12). 
6.3.6 The role of TNFa during B. mallei infection 
The effect of the pro-inflammatory cytokine TNFa on the progression of B. mallei 
infection was assessed by depleting TNFa from mice using TNFa antibodies. The 
specificity of TNFa antibodies was assessed in vitro prior to infection of antibody-treated 
mice. 
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Figure 6.12: IFN-y is essential for protection against B. mallei infection. The percentage 
survival of A) IFN-y (BALB/c) knockout mice (n=6/group) challenged with 1x 106 cfu 
(high) or 1x 102 cfu (low) B. mallei and wild type BALB/c mice (n=6) challenged with 1x 
106 cfu. B) IFN-y (C57BL/6) knockout mice (n=6/group) challenged with 4.1 x 104 cfu 
(high) or 41 cfu (low) B. mallei and wild type C57BL/6 mice (n=6) challenged with 4.1 x 
104 cfu. The data from this experiment was supplied by R. Lukaszewski, Dstl, UK. 
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6.3.6.1 Specificity of TNFa antibodies 
CD54 expression on J774A. 1 macrophages was significantly reduced in the presence of 
TNFa antibodies at a range of TNFa concentrations following stimulation for 24 h (Figure 
6.13). No significant reduction in CD54 expression was observed in the presence of 
isotype-matched control antibodies in comparison with cultures containing TNFa alone 
(Figure 6.13) demonstrating that TNFa antibodies were able to neutralise TNFa-specific 
macrophage activation. 
6.3.6.2 Depletion of TNFa during B. mallei infection 
The role of TNFa during early infection with B. mallei was assessed by administering 
TNFa antibodies to BALB/c mice at several time-points during the first 7 days of 
infection. Treatment with TNFa antibodies 24 h prior to infection, 24 h p. i. and 4 days p. i. 
did not result in mortality during the first 7 days of infection regardless of when the first 
dose of antibody was administered. No mortality was observed in mice treated with control 
antibodies. Bacteriological analysis of spleens obtained 7 days p. i. from all anti-TNFa 
dose groups revealed a 100 to a 1000-fold increase in bacterial counts in comparison with 
infected animals treated with control antibodies (Figure 6.14A & B). Mice treated with 
TNFa antibodies developed overt signs of disease (measured by ruffling of fur during the 
7 days of infection) and abscesses had developed by 7 days p. i.. 
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Figure 6.13: TNFa antibodies reduce TNFa-mediated macrophage activation. The mean 
fluorescence intensity (MFI) of CD54 expression in a J774A. 1 macrophage cell line 
stimulated in vitro with a range of doses of TNFa in triplicate for 24 hours in the presence 
of isotype-matched control antibody (control Ab), TNFa (MP6-XT22) antibody (anti- 
TNFa Ab) or TNFa alone (no Ab). 
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Figure 6.14: Bacterial counts detected in the spleens of BALB/c mice 7 days following 
infection with B. mallet treated with control or TNFa antibodies. Mice (n=6) were treated 
with control or TNFa (MP6-XT22) antibodies A) 24 hours prior to infection and B) 24 
hours post-infection (24h p. i. ) or 4 days post-infection (4 days p. i. ). Mice (n=6) were dosed 
with control antibodies at the same time-points as mice treated with TNFa antibodies. 
Asterisks indicate statistical significance following treatment with TNFa antibodies 
compared with mice dosed with control antibody (p<0.05). 
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Abscesses did not develop 7 days p. i. and overt signs of disease were not observed in 
infected control animals. The role of TNFa during the late stages of B. mallei infection 
was investigated by administering TNFa antibodies to BALB/c mice 42 days following 
infection (Figure 6.15). At day 38 p. i., 1/6 mice in the control group died prior to antibody 
dosing and at day 41 p. i. 2/6 mice in the anti-TNFa dosing group died prior to 
administration of the antibody. Following treatment with TNFa antibodies the remaining 
mice (4/6) died within 3 days. Infected control mice (5/6) did not die as a result of the 
infection following administration of isotype control antibodies. 
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Figure 6.15: Survival of BALB/c mice (n=6/group) treated with TNFct antibodies or 
control antibodies 6 weeks following infection with B. mallei. 
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6.4 Discussion 
Characterisation of splenic and systemic cytokine responses during B. mallei infection 
revealed the induction of a range of inflammatory and type 1 cytokines. Expression of 
splenic IL-1 P and IL-18 was enhanced very early (5 h p. i. ) in the immune response. IL-1 ß 
is a proinflammatory cytokine and acts both locally and systemically in the induction of 
fever (Lee et al, 2004). It is important in host defence against L. monocytogenes infection, 
possibly by modulating neutrophil responses and upregulating MHCII expression on 
macrophages (Rogers et al, 1994). IL-lß can be induced in neutrophils by granulocyte 
macrophage-colony stimulating factor (GM-CSF) (Fernadez et al, 1996) during infection 
(Hartung et al, 2001) linking the observed increased expression of GM-CSF and IL-1I 24 
h p. i. in this study. IL-18 is important in host defence against infection for a number of 
intracellular pathogens including B. pseudomallei (Santanirand et al, 1999), Y. 
enterocolitica (Bohn et al, 1998) and L. major (Ohkusu et al, 2000). It exerts its effects 
either via the induction of IFN-y or in an IFN-y-independent manner by inducing bacterial 
killing mechanisms of macrophages eg. nitric oxide and TNFa production (Neighbors et 
al, 2001). This implicates IL-18 in the induction of IFN-y early in B. mallei infection. 
Both IL-10 and IL-18 are members of the IL-1 family of ligands (Lee et al, 2004) and 
require proteolytic cleavage by caspase-1 for their activation. Bacteria are able to activate 
caspase-1 to induce the death of infected macrophages. B. pseudomallei (Sun et al, 2005) 
and F. tularensis (Mariathasan et al, 2005) induce caspase-l-dependent cell death leading 
to the release of IL-1ß and IL-18. The mRNA expression of either of these cytokines was 
not related to bacterial colonisation 24 h p. i., although significant increases in their 
expression were observed over the first 24 h p. i.. This suggests that processing the protein 
form of these cytokines by caspase-1 is important in immunity to B. mallei infection. 
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High levels of splenic IFN-y mRNA expression and systemic IFN-y were detected within 
24 h p. i. implicating it in immunity to B. mallei infection. IFN-y is a cytokine essential for 
type 1 responses and is important for host protection against a number of intracellular 
pathogens including B. pseudomallei (Santanirand et al, 1999), M tuberculosis (Cooper et 
al, 1993) and C. trachomatis (Perry et al, 1997). IFN-y was found to be essential for 
protection against B. mallei infection. Disruption of the IFN-y gene in IFN-y KO mice 
rendered mice highly susceptible to B. mallei infection with death occurring 2-3 days post- 
infection. Removing this rapid, innate IFN-y response early in infection demonstrates the 
critical nature of this response for survival against B. mallei infection. It is also critical in 
defence for a number of other intracellular pathogens including the closely related 
bacterium B. pseudomallei (Santanirand et al, 1999) and Listeria monocytogenes (Huang et 
al, 1993). 
IFN-yKO mice on both a BALB/c and C57BL/6 background succumb to the disease within 
the early stages of infection. This demonstrated that IFN-y is essential for immunity to B. 
mallei infection in both mouse strains suggesting that genetic background does not affect 
the host's response to IFN-y mediated immunity. In addition to this, immunocompetent 
mice on either a BALB/c or a C57BL/6 background died several weeks following B. mallei 
infection. This suggests that both mouse strains have a similar disease progression in 
response to B. mallei infection. In infection with other pathogens including B. 
pseudomallei, differences in resistance to infection occur between BALB/c and C57BL/6 
mice. Infection of BALB/c mice with B. pseudomallei leads to an acute disease whereas 
C57BL16 mice are relatively resistant to B. pseudomallei infection (Leakey et al, 1998). In 
both mouse strains IFN-y is important for immunity to B. pseudomallei although 
differences in susceptibility appear to be related to the balance in production of other 
cytokines during infection (Ulett et al, 2000). 
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Increased expression of other cytokines involved in type 1 immunity was also observed 
during B. mallei infection. IL-27 mRNA expression was elevated 24 h p. i. following B. 
mallei infection. IL-27 is a heterodimeric cytokine that binds to the receptor WSX-1 and is 
involved in development of type 1 responses during infection. It is produced by activated 
antigen-presenting cells during infection and plays a role in IFN-y production from naive 
mouse CD4+ T cells and human NK cells in vitro (Pflanz et al, 2002). It is expressed 
during M tuberculosis infection (Pearl et al, 2004) and is important in vivo in L. major 
infection as impaired IFN-y production and increased susceptibility to infection occurs in 
WSX-1-/- (IL-27 Receptor KO) mice (Yoshida et al, 2001). The concurrent expression of 
IL-27 and IFN-y during B. mallei infection implicated IL-27 as a potential inducer of IFN-y 
production. 
Increased expression of IL12p35, a cytokine involved in instigation of type 1 responses, 
was observed over the first 7 days of B. mallei infection. IL-12 is a cytokine critical in 
guiding type 1 responses during intracellular infection (Gazzinelli et al, 1994), is produced 
by macrophages and acts on naive T cells and NK cells to stimulate IFN-y production 
(Yoshimoto et al, 1998). IL-12 is composed of two subunits, p35 and p40. Increased 
expression of IL12p35 but not IL12p4O was observed and IL12p35 expression (but not 
p40) was associated with bacterial colonisation of the spleen 24 h p. i. suggesting that the 
p35 subunit is upregulated in response to the infection. Other studies have revealed that the 
IL-12p40 subunit is important for survival following the first week of B. mallei infection 
(Lukaszewski, 2004) and, therefore, has a role in controlling the infection although mRNA 
expression of IL12p4O was not detected. IL12p40 is homologous to a subunit from the 
cytokine IL-23 (Oppmann et al, 2000) whereas the IL12p35 is specific for IL-12. Higher 
levels of IL12p35 expression suggests that IL-12 and not IL-23 may have a more important 
role in the spleen during B. mallei infection although this requires further investigation. 
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IL-6 is a multi-functional cytokine and high levels of this cytokine both in the spleen and 
systemically 24 h p. i. suggest it may be important in immune responses to B. mallei. IL-6 
is essential for surviving infection with L. monocytogenes (Dalrymple et al, 1995), M 
tuberculosis (Ladel et al, 1997) and Escherichia coli (Dalrymple et al, 1996) although it is 
not important for immunity to L. major infection (Moskowitz et al, 1997). It exerts its 
activity during the innate immune response by aiding and allowing appropriate neutrophil 
responses to develop during infection (Dalrymple et al, 1995; Romani et al, 1996). In 
addition to this, IL-6 has also been shown to induce IFN-y during infection with the 
intracellular bacteria M. tuberculosis (Saunders et al, 2000) and L. monocytogenes (Guilera 
& Pollard, 2001) as well as following BCG inoculation (Luo et al, 2003). High levels of 
IL-6 and IFN-y co-expression and production suggested that IL-6 may be involved in IFN- 
y responses during B. mallei infection. Upregulation of IL-6 in the serum also coincided 
with high levels of MCP-1. MCP-1 (CCL2) is a chemokine involved in the 
chemoattraction of monocytes (Lu et al, 1998) and T cells (Carr et al, 1994) to sites of 
infection. It is important in protective immune responses during bacterial infection by 
recruiting cells to the site of infection (Chae et al, 2002; Guilera & Pollard, 2001). 
Following B. mallei infection, IL-6 may be inducing MCP-1 which in turn may induce 
recruitment of monocytes into the spleen as has been observed in other bacterial infections 
(Bohn et al, 1998). In addition to this, detection of systemic IL-6 and MCP-1 responses in 
the serum of abscessed animals at days 14 and 36 p. i. were associated, suggesting the 
combined release of these mediators from infected tissues during infection. 
The strong immune responses elicited by the host in the first 24 h p. i. represented a peak in 
cytokine responses. Decreased splenic expression of IFN-y, IL-10, IL-6, GM-CSF and 
IL12p35 occurred 3 days p. i.. This was complemented by decreased serum production of 
IFN-y, IL-6 and MCP-1 to control levels. This suggests that B. mallei may be modulating 
host immunity after the first 24 h p. i. by interfering with cytokine responses. IL-6 is 
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important in protective immune responses during bacterial infection, however, it is a 
multifunctional cytokine that is also able to downregulate protective immune responses 
during M tuberculosis infection to allow pathogen survival. IL-6 acts to reduce 
macrophage responsiveness to IFN-y, causing down regulation of MHCII expression on 
macrophages (Nagabhushanam et al, 2003). The high levels of IL-6 observed 24 h p. i. with 
B. mallei, in addition to a potential role in protective immunity, implicate it in the 
downregulation of cytokine responses. IL-10 is an anti-inflammatory cytokine that acts as 
a negative regulator of the inflammatory response by instigating processes required for 
down-regulating proinflammatory responses (Weissman, 2001). Although increases in IL- 
10 24h p. i. were not significant during Immune Analysis 2, IL-10 expression was related to 
bacterial colonisation of the spleen suggesting that its expression is influenced by the 
infection. In addition to this, IL-10 expression levels were raised 24 h p. i. in Immune 
Analysis 1. IL-10 is able to down-regulate the expression of GM-CSF (Lenhoff et al, 1998) 
and may be involved in suppressing expression of the macrophage activators, GM-CSF 
and IFN-y, during B. mallei infection. Although most responses examined were 
downregulated by 3 days p. i., IL-27 expression remained elevated suggesting that IL-27 
may be important in controlling bacterial numbers which remained constant in the spleen 
over the first 7 days of infection. 
TNFa is involved in protection against a number of intracellular pathogens including M. 
tuberculosis (Scanga et al, 1999) and S. typhimurium (Kirby et al, 2002). TNFa expression 
was significantly higher than control expression throughout the first 7 days of B. mallei 
infection and was related to bacterial colonisation 24 h p. i. suggesting a role for TNFa in 
immunity to B. mallei infection. Antibody treatment demonstrated that TNFa played an 
important role in innate immunity to B. mallei infection by controlling expansion of 
bacterial populations in the spleen. Control of bacterial replication was independent of 
when TNFa was depleted. This suggests that TNFa maintained continual control of 
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bacterial replication during the early stages of infection, although it was not critical 
for 
survival during early infection. TNFa may mediate its effects by a number of mechanisms 
including upregulation of adhesion molecules including CD54 on the surface of 
neutrophils, macrophages and endothelial cells to aid migration of cells into the site of 
infection (Gibson III et al, 1998). Early abscess formation occurred 7 days p. i. in the 
absence of TNFa, suggesting that TNFa may delay abscess formation during infection of 
immunocompetent mice, possibly by controlling bacterial proliferation. TNFa is 
implicated in abscess formation and controls the number of abscesses observed during C. 
albicans infection by enhancing the killing capacity of granulocytes (Vonk et al, 2002). In 
a S. aureus abscess formation model, TNFa antibodies prevented the formation of 
abscesses (Song et al, 2002) and administration of TNFa antibodies during B. fragilis 
infection also prevented the formation of abscesses (Gibson III et al, 1998) suggesting that 
TNFa has a role in prevention and control of abscess formation for different pathogens. 
Increased splenic expression of TNFa and other proinflammatory cytokines including IL- 
I ß, IL-6 and GM-CSF were associated with abscessed mice at 14 and 21 days p. i.. During 
this chronic phase of infection, TNFa was also found to be involved in controlling B. 
mallei infection since death occurred rapidly following depletion of TNFa 6 weeks 
following infection. At this stage of infection, large abscesses existed within the spleen. 
TNFa appeared to maintain protective responses in the host, possibly by controlling 
bacterial growth in localised areas of infection in abscesses. In the absence of TNFa, 
bacteria may have been released into the circulation from the organs leading to a rapid and 
fatal outcome. 
In summary, the expression and production of a number of cytokines was observed during 
B. mallei infection. Pro-inflammatory cytokines were induced 5hp. i. followed by a strong 
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splenic and systemic cytokine response, mediated predominantly by IFN-y, IL-6 and the 
chemokine, MCP-1 24 h p. i.. This was followed by a decrease in cytokine responses 72 h 
p. i.. The IFN-y response was found to be essential for protection against B. mallei 
infection. TNFa was also important in controlling bacterial proliferation in the spleen 
during innate responses and was involved in protective immunity during the chronic stages 
of infection. 
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Chapter 7 
Induction and production of IFN-y 
response to heat-killed B. mallei in vitro. 
in 
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7.1 Introduction 
The work presented so far in this thesis has demonstrated the essential nature of IFN-y in 
the innate immune response to B. mallei infection in mice. Therefore, the role of cytokines 
and cells involved in the IFN-y response was investigated in more detail. IFN-y is an 
essential component of the innate immune response to a number of intracellular pathogens 
including B. pseudomallei (Haque et al, 2005) and L. monocytogenes (Berg et al, 2005). 
The main cellular sources of innate IFN-y during infection with B. pseudomallei and L. 
monocytogenes are NK cells and T cells (Lertmemongkolchai et al, 2001; Berg et al, 2005) 
although other cell types, including macrophages, are involved in production of IFN-y in 
vivo (Haque et al, 2005). IFN-? is induced by a range of cytokines during infection, which 
are mainly associated with type 1 immunity to intracellular pathogens, including IL-12, IL- 
18, IL-23 and IL-27. Other cytokines, including IL-6, have also been implicated in 
induction of IFN-y in vivo during infection (Guilera & Pollard, 2001). In Chapter 6, 
upregulated expression of IL12p35, IL-18, IL-27 and IL-6 was described during the first 
24 h following B. mallet infection. This corresponded with a strong IFN-? response 
suggesting a link between IFN-y production and these cytokines. The aims of this chapter 
were to determine: 
The role of type 1 cytokines, upregulated early during B. mallef infection, in 
induction of IFN-y in vitro in response to heat-killed B. mallei. 
9 The role of T cells and NK cells in IFN-y production in vitro in response to heat- 
killed B. mallet to provide a comparison with other intracellular pathogens. 
9 The role of Gr-1+ cells in IFN-y production in vitro in response to heat-killed B. 
mallei due to the importance of both IFN-y and Gr-1+ cells in protection during the 
early phases of B. mallei infection. 
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7.2 Methods 
The secretion of IFN-y and other cytokines (TNFa, IL-10, MCP-1, IL-6 and IL-12p70) was 
detected in spleen cell culture supernatants from wild type and knockout mice, with or 
without antibody treatment, following stimulation with 106 cfu/ml heat-killed B. mallei 
(Table 7.1). This allowed investigation of the contribution of ILI2p35, ILI2p40, IL- 18, IL- 
6, IL-27 and Gr-1+ cells to the IFN-y response in vitro. 
Intracellular IFN-y was detected in CD3+ T cell and DX5+ NK cell populations by flow 
cytometry in response to heat-killed B. mallei in vitro. Splenic cell cultures were 
stimulated with 106 cfu/ml heat-killed B. mallei and IFN-y secretion was prevented 3h 
prior to intracellular staining using Brefeldin A. Intracellular IFN-y was assessed in spleens 
from wildtype (C57BL/6 and BALB/c) mice in the presence or absence of anti-IL-18R 
antibodies and IL-12KO mice to determine the effects of IL-12 and IL-18 on IFN-y 
production from different cell types. 
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Mouse strain Antibody treatment Stimulant 
IL-6 Knockout C57BL/6 - Heat-killed B. mallei 
WSX-1 (IL-27R) Knockout - Heat-killed B. mallei 
C57BL/6 
IL12p35 Knockout C57BL/6 - Heat-killed B. mallei 
IL12p40 Knockout C57BL/6 - Heat-killed B. mallei 
C57BL/6 ± IL-I 8R or Mac5 Heat-killed B. mallei 
antibody 
(in vitro) 
BALB/c Gr-1 (RB6-8C5) or Heat-killed B. mallei 
Mac5 antibody 
(in vivo) 
Table 7.1: Summary of the mouse strains and antibodies used to determine the role of IL- 
6, IL-27, IL12p35, IL12p4O, IL-18 and Gr-1+ cells on IFN-y production in response to 
heat-killed B. mallei in vitro. 
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7.3 Results 
7.3.1 Induction of IFN-y in response to B. mallei in vitro 
The role of the cytokines IL12p35, IL12p40, IL-18, IL-27 and IL-6 in inducing IFN-y 
production was investigated to determine the significance of the elevation and co- 
expression of these cytokines with IFN-y during the first 24 h of B. mallei infection. 
7.3.1.1 IL12p35 and IL12p40 
Following stimulation of splenic cultures from wildtype C57BL/6 mice with heat-killed B. 
mallei, 3-5ng/ml of IFN-y was detected. In response to stimulation with heat-killed B. 
mallei, no IFN-y was detected in splenic cultures from either IL12p35 or IL12p4O KO 
mice (Figure 7.1A). In wildtype cultures, significantly higher amounts of IL-12p70 were 
detected in response to heat-killed B. mallei in comparison with IL12p35KO and IL12p4O 
KO spleen cultures (p<0.05) (Figure 7.1B). A reduction in IL-6, MCP-1 and IL-10 was 
also observed in both IL-12K0 mouse strains in comparison with wildtype cultures 
(p<0.05) (Figure 7.1 A&B). 
7.3.1.2 IL-18 
Following stimulation of spleens from wild-type C57BL/6 mice treated in vitro with 
neutralising antibodies against the IL-18 receptor, a 3-fold reduction in IFN-y production 
compared with wild-type mice (without antibody) was observed (p<0.05) 
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Figure 7.1: Mean cytokine production in cell culture supernatants following in vitro 
stimulation of spleens from 1L12p35KO, l1,12p4OKO or control C57I3I. /6 mice with heat- 
killed B. mal/ei (ß. m. ) or media for 24 hours. A) Mean amount (pg/ml) of 11, N-y, 'l'NF(x 
and 1L-6; ß) Mean amount of MCP-l, [L-l0 and IL-12p70 detected in culture 
supernatants. l; rror bars indicate standard deviation. Asterisks represent statistical 
significance (p<0.05) in comparison with IL12p35 and 11,12p40 spleen cultures stimulated 
with 13. m.. This data is representative oftwo experiments with groups of 4 mice. 
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(Figure 7.2A). No differences between wild-type and treated cultures in IL-12p70, TNFa, 
MCP-1, IL-10 or IL-6 production occurred (Figure 7.2A&B). 
7.3.1.3 IL-27 
No significant differences in IFN-y secretion in cell culture supernatants from WSX-1 (IL- 
27 Receptor) KO mice occurred in comparison with control mice following stimulation 
with heat-killed B. mallei (Figure 7.3A). Decreased MCP-1 and IL-10 production was 
observed in wildtype cultures in comparison with WSX-1KO cultures (p<0.05) (Figure 
7.3A&B). 
7.3.1.4 IL-6 
No differences in IFN-y secretion were observed between IL-6KO or wildtype cultures in 
response to heat-killed B. mallei in vitro (Figure 7.4A). Decreased production of TNFct, 
IL-10 and MCP-1 occurred in IL-6KO cultures in comparison with wildtype cultures 
(Figure 7.4A). IL-6 could not be detected in cultures from IL-6K0 mice although it was 
detected in wildtype cultures in response to heat-killed B. mallei. Statistical analysis could 
not be performed on this data as only two IL-6KO mice were available for this 
experimental procedure. To determine whether IL-6 could alone induce IFN-y in vitro in 
spleen cultures, recombinant IL-6 was added to cultures at a range of concentrations (0- 
40ng/ml). No IFN-y was detected in cell culture supernatants at any dose of IL-6 in either 
BALB/c or C57BL/6 mice, although addition of IL-12 and IL-18 to cultures induced a 
strong IFN-y response (Figure 7.5). 
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Figure 7.3: Mean cytokine production in the supernatant following in vitro culture of 
spleens from WSX-1 KO (IL-27 receptor) mice (n-5) or control C57BL/6 mice (n=5) 
stimulated with heat-killed B. mullei (B. m. ) or media for 24 hours. Error bars indicate 
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spleens from II, -6KO mice (n=2) or control C57I3L/6 mice (n=5) stimulated with heat- 
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Figure 7.5: Mean IFN-y production in the supernatant following in vitro stimulation of 
splenic cell cultures from C57BL/6 (n=3) and BALB/c (n=3) mice with IL-6. IFN-y 
production in response to recombinant IL-6 (10-40 ng/ml), a combination of IL-12 (5 
ng/ml) and IL-18 (5 ng/ml) or media alone for 24 hours. 
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7.3.2 Cellular sources of B. mallei-induced IFN-yin vitro 
The lymphocyte populations responsible for IFN-y production in vitro were examined by 
intracellular flow cytometry. The predominant producers of IFN-y in wildtype C57BL/6 
mice in response to B. mallei in vitro were DX5+ NK cells with CD3+ T cells also 
contributing to the IFN-y response (Figure 7.6). Of the NK cell population, 12-22% were 
IFN-y+ and 1-2% of the T cell population were IFN-y+ (Figure 7.7). 
Intracellular analysis of IFN-y production following B. mallei stimulation of IL12p35KO 
and IL12p40 KO confirmed the absence of an IFN-y response in cell culture supernatants. 
Intracellular IFN-y was not detected in either T cells or NK cells in the absence of IL-12 
(Figure 7.8). The viability of spleen cell suspensions from IL12p35KO and IL12p4OKO 
mice was examined by adding a combination of IL-12 and IL-18 to splenic cultures. IFN-y 
was produced from both T cells and NK cells in spleens from both KO mice in response to 
IL-12/IL-18 demonstrating their ability to respond under these experimental conditions 
(Figure 7.9). The reduced IFN-y response observed in cell culture supernatants in the 
absence of the IL-18R was investigated further by intracellular analysis of IFN-y. A 
decrease in IFN-y production from the NK cell population was observed in cell culture 
supernatants treated with IL-18R antibody in vitro (Figure 7.10). 
In order to determine whether genetic background affected the cellular source of IFN-y, 
IFN-y production was assessed in splenic NK and T cells from BALB/c mice and like 
C57BL/6 mice NK cells were the predominant producers of IFN-y in response to heat- 
killed B. mallei with 2.5 - 4.5% of NK cells producing IFN-y (Figure 7.11). The CD3+ T 
cell 
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Figure 7.6: Intracellular IFN-y production in T cells and NK cells in response to heat- 
killed B. mullei or media in vitro. Intracellular IFN-y detected in NK (I)X5') cells and T 
(CI)3+) cells following stimulation of spleens from wild type C57B116, in vi! ro with heat- 
killed B. mallei (13. m. ) or media alone. Percentage or IFN-y-positive NK cells or T cells is 
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Figure 7.7: Mean percentage of IFN-y+ T cells and NK cells produced in response to heat- 
killed B. mallei or media in vitro. Intracellular IFN-y detected in A) NK (DX5) cells and 
B) T (CD3+) cells following stimulation of spleens from wildtype C57BL/6, IL12p35KO 
or IL12p4OKO mice in vitro with heat-killed B. mallei (B. m. ) or media alone. Error bars 
indicate standard deviation. This data is representative of two experiments with groups of 4 
mice. 
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Figure 7.9: Intracellular IFN-y production in NK cells in response to a combination of IL- 
12 and IL-18 in vitro. Intracellular IFN-y detected in NK (DX5) cells following 
stimulation of spleens from IL12p35KO mice (n=3) and ILI2p4OKO mice (n=3) in vitro 
with IL-12 and IL- l8. 
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Figure 7.10: Percentage of IFN-y+ NK cells detected in response to heat-killed B. mallei 
following IL-I 8R neutralisation in vitro. Intracellular IFN-y detected in NK (DX5) cells 
following stimulation of spleens from wildtype C57BL/6 mice (n=3) in vitro with heat- 
killed B. mallei with (B. m. + anti-IL-18R) or without (B. m. ) IL-18R antibody 
neutralisation or media alone. Data points represent spleen cultures from individual mice. 
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population also contributed to this response with between 0.4-0.6% T cells producing IFN- 
y (Figure 7.11). 
7.3.2.1 Effects of Gr-1 depletion on B. mallei induced IFN-y 
The role of Gr-1+ cells in IFN-y production in vitro was assessed due to the essential 
requirement for Gr-1+ cells in protection against B. mallei infection in vivo. IFN-y 
production was significantly reduced in spleen cell suspensions from RB6-8C5 depleted 
mice in comparison with Mac5-treated control spleens (p<0.05) (Figure 7.12A). IFN-y was 
produced in all Macs treated control spleen suspensions in response to heat-killed B. mallei 
although inter-individual variability existed in the strength of this response (Figure 7.12A). 
Production of IL-6, TNFa and IL-10 was significantly lower in RB6-8C5 treated mice than 
Mac5 treated controls (p<0.05) and MCP-1 levels were comparable with Mac5 controls in 
spleens from RB6-8C5 depleted mice (Figure 7.12B). 
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Figure 7.12: The role of Gr-l+ cells in cytokine production in response to heat-killed B. 
mallei in vitro. A) IFN-y production in spleen cell suspensions from individual mice; B) 
Mean cytokine production of TNFa, MCP-1, IL-10 and IL-6 in the supernatant following 
in vitro culture of spleens from BALB/c mice (n=6) treated with Gr-1 (RB6-8C5) antibody 
or control (Mac5) antibody (n=6) and heat-killed B. mallei (B. m. ) or media for 24 hours. 
Error bars indicate standard deviation. Asterisks indicate statistical significance (p<0.05) in 
comparison with RB6-8C5 spleen cultures stimulated with B. m.. 
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7.4 Discussion 
The aim of this chapter was to investigate the cytokine-mediated induction of IFN-y in 
response to heat-killed B. mallei and to determine which cell types are involved in IFN-y 
production in vitro. IL12p35 and IL12p4O were found to be essential for IFN-y production 
in the presence of heat-killed B. mallei in vitro. IL-12 is essential for development of type 
1 responses during intracellular infection and is involved in IFN-y production during 
infection with M. tuberculosis (Nolt & Flynn, 2004) and C. trachomatis (Perry et al, 1997). 
IL-23 may also be involved in production of IFN-y responses during infection in the 
absence of IL-12 (Khader et al, 2005). The requirement of both the p35 and p40 subunits 
for IFN-y production suggests that IL-12 (p35 + p40) itself and not IL-23 (p40 but not p35) 
is responsible for the IFN-y response. 
IL-18 was found to be involved in IFN-y production in response to B. mallei. IL-18 is 
important in host defence against intracellular infection with B. pseudomallei (Haque et al, 
2005) and L. monocytogenes (Neighbors et al, 2001) by inducing IFN-y, in synergy with 
IL-12, from T cells (Yoshimoto et al, 1998) and NK cells (Garcia et al, 1999). IL-18 is 
known to induce IFN-y production from NK cells during infection with Cryptococcus 
neoformans (Kawakami et al, 2000) and was involved in production of IFN-y from NK 
cells in response to B. mallei in vitro. IL-12 was absolutely required for IFN-y production 
in vitro although both IL-12 and IL-18 were involved in IFN-y production from NK cells 
suggesting a synergistic effect of these 2 cytokines on IFN-y induction. However, in the 
absence of IL-12, the IFN-y response from both NK cells and T cells is eradicated 
suggesting that IL-12 may act independently as well as in synergy with IL-18 in IFN-y 
induction. 
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IL-27 was implicated as a potential inducer of IFN-y production during B. mallei infection 
due to their co-expression 24 h p. i.. IL-27 plays a role in IFN-y production from naive 
mouse CD4+ T cells and human NK cells in vitro (Pflanz et al, 2002) and is also important 
in vivo in L. major infection as impaired IFN-y production occurs in WSX-1-/- (IL-27 
Receptor) mice (Yoshida et al, 2001). Other studies with intracellular pathogens eg. T. 
gondii suggest that IL-27 is not required for the development of IFN-y mediated immunity 
(Villarino et al, 2003). The discrepancy between the requirement for IL-27 in development 
of IFN-y mediated immunity appears to be due to the production of IL-4 during infection. 
High levels of IL-4 are produced early during L. major infection where IL-27 appears to be 
important in IFN-y production, however, in infections with low IL-4 involvement (eg. T. 
gondii, T. cruz), IL-27 is not important during the developmental phases of a Thl response 
(Artis et al, 2004). IL-4 was not detectable during the early stages of B. mallei infection 
suggesting that IL-27 may have an independent role in Thl mediated immunity during B. 
mallet infection. In vitro studies suggested that IL-27 was not involved in IFN-y production 
in response to B. mallei. However, lower levels of IFN-y were found in control mice in 
these studies in comparison with control mice in IL-12KO and IL-18R neutralisation 
studies. Therefore, it would be useful to repeat these studies to determine whether the 
similar IFN-y responses observed between control and IL-27K0 mice were a valid finding. 
IL-6 plays a role in IFN-y production during M tuberculosis infection (Saunders et al, 
2000a) and is also important in inducing IFN-y responses during L. monocytogenes 
infection, possibly in synergy with IL-12 (Guleria & Pollard, 2001). In other studies IL-6 
was found to have immunosuppressive effects by suppressing IFN-y-mediated responses 
during M. tuberculosis infection (Fortune et al, 2004). The co-expression and production 
of IL-6 and IFN-y during the early stages of B. mallei infection suggested a link between 
the two cytokines. In the limited studies performed, IL-6 was found not to be responsible 
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for IFN-y production in response to heat-killed B. mallei in vitro and the role of IL-6 in 
induction or suppression of IFN-y-mediated responses during B. mallei infection requires 
further investigation. 
Previous studies with heat-killed B. pseudomallei demonstrated that IFN-y is produced by 
NK cells and CD8+ memory T cells in vitro (Lertmenmongkolchai et al, 2001). Therefore, 
the contribution of these cell types to IFN-y production in response to heat-killed B. mallei 
was investigated. NK cells and CD3+ T cells were found to provide most of the IFN-y in 
response to B. mallei. NK cells are essential in host defence against a number of 
intracellular pathogens through their production of IFN-y e. g. L. major (Scharton & Scott, 
1993) and B. pseudomallei (Haque et al, 2005) and, as the main contributors of IFN-y in 
response to B. mallei in vitro, these cells may be important in the generation of type 1 cell- 
mediated immune responses to B. mallei. T cells also produced IFN-y in a non-antigen 
specific manner in response to B. mallei although the subset responsible for this production 
was not identified in these studies. In other studies performed with heat-killed B. mallei, 
CD8+ T cells and y8 T cells were the main T cell contributors to the antigen-independent 
IFN-y response, however, CD4+ T cells did not contribute to this response 
(Lertmemongkolchai, 2005; Personal communication). 
Gr-1+ cells were also involved in the secretion of IFN-y in response to heat-killed B. 
mallei. Gr-1+ cells are implicated in IFN-y production as a direct source of IFN-y or by 
producing the cytokines (i. e. IL-12 and IL-18) responsible for induction of IFN-y. Certain 
Gr-1+ cell types are able to produce IFN-y in response to bacteria. Neutrophils secrete IFN- 
y during infection with S. typhiumurium (Kirby et al, 2002) and in response to cytokines 
and LPS (Yeaman et al, 1998) and Gr-1+ T cells also secrete IFN-y (Matsuzaki et al, 
2003). Neutrophils (Bliss et al, 2000) and Gr-1+ macrophage populations (Mordue & 
Sibley, 2003) secrete IL-12 during T. gondii infection suggesting that they may play an 
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indirect role in induction of IFN-y responses. Other cells types may also contribute to the 
IFN-y response during B. mallei infection. During B. pseudomallei and S. typhimurium 
infection, macrophages are important in providing a protective IFN-y response (Haque et 
al, 2005; Kirby et al, 2002). Therefore, the role of other cell populations in IFN-y 
production during B. mallei in vivo cannot be discounted and should be investigated 
further. 
In summary, IL-12 was found to be essential for IFN-y production from NK cells and T 
cells in vitro in response to heat-killed B. mallei. IL-18, but not IL-27 or IL-6, was also 
involved in this response. Gr-1+ cells also played a role in IFN-y production although the 
mechanism for this induction is unknown. 
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Chapter 8 General Discussion 
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8.1 Introduction 
Burkholderia mallei is a pathogen which is currently considered to be a bioterrorism threat 
(Bossi et al, 2004) and has historically been used in biological warfare (Christopher et al, 
1997). No post-exposure therapies or vaccines are currently available for B. mallei and, 
therefore, the development of such treatments is important in protecting against this threat. 
Previous research on B. mallei has been limited to a few studies investigating the 
pathogenesis of disease in several animal species. Limited examination of immune 
responses has focused on histopathological investigation of tissue, however, the cellular 
and cytokine responses involved in immunity to B. mallei infection have not previously 
been investigated. Characterising cellular and cytokine responses allows the protective 
aspects of the immune response to be identified thus leading to the development of 
appropriate immunotherapies and vaccines. The work presented in this thesis has 
characterised the host immune response over the first five weeks of infection in BALB/c 
mice, providing valuable information into the interactions of B. mallei with the host 
immune system. 
8.2 The early, innate response to B. mallei infection: 5-24h p. i. 
The spleen was colonised by B. mallei 5h following i. p. infection. This was accompanied 
by activation and influx of neutrophils and macrophages and increased expression of the 
pro-inflammatory cytokines IL-lß and IL-18 demonstrating a rapid response to the 
infection. Potential infection of macrophages by B. mallei may cause activation and 
caspase-l-dependent release of IL-18 (and IL-lß) known to be important in induction of 
IFN-y in response to B. mallei. Low levels of serum IL-6, IFN-y and MCP-1 were also 
present suggesting systemic immune responses were active. Both splenic and serum 
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cytokine responses peaked 24 h p. i. and were accompanied by increased macrophage 
activation. These responses were initially able to control, but not eradicate, bacterial 
colonisation in the spleen and are illustrated in Figure 8.1. 
IFN-y was found to be essential in controlling the innate response to B. mallei infection. 
IFN-y is essential in immunity to a number of intracellular pathogens including B. 
pseudomallei (Santinarand et al, 1999) and L. monocytogenes (Portnoy et al, 1993) and is 
key in the development of type 1 immune responses. IL-12 was found to be essential for 
IFN-y production (in vitro) and IL-18 was involved in the induction of IFN-y in response 
to B. mallei. IL-12 is essential in guiding the differentiation of Thl subsets (Heinzel & 
Rerko, 1999) and can work independently or in synergy with IL-18 to stimulate IFN-y 
during infection (Garcia et al, 1999). The requirement for IFN-y, IL-12 and IL-18 
demonstrates that type 1 immune responses are mounted in response to B. mallei infection 
and are characteristic of those required to fight infection with intracellular pathogens. 
IL-27 is a recently discovered cytokine involved in the development of type 1 immunity 
and its expression in vivo has only previously been described during M tuberculosis 
infection (Pearl et al, 2004). High levels of IL-27 expression occurred in response to B. 
mallei infection, although it was not responsible for IFN-y production in vitro. The 
upregulation of CD54 on T cells 24 h p. i. corresponded with elevated IL-27 expression in 
the spleen. IL-27 can induce CD54 on naYve T cells which is important in Thl 
differentiation (Owaki et al, 2005) suggesting that IL-27 may have IFN-y-independent 
effects in inducing type 1 immune responses to B. mallei infection. 
TNFa is important in protection against infection with M. tuberculosis (Scanga et al, 1999) 
and B. pseudomallei (Santanirand et al, 1999) and was important in maintaining control of 
bacterial replication over the first 7 days of B. mallei infection. TNFa may mediate its 
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Figure 8.1: Summary of host immune responses occurring in the spleen during the first 24 
hours of R. mullei infection in BAE, E3/c mice. 
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protective effects during infection by aiding the development of type 1 responses by 
stimulating CD8+ T cells and NK cells to produce IFN-y (Lertmemongkolchai et al, 2001). 
TNFa can also activate neutrophils and macrophages causing upregulation of CD54 
(Mandi et al, 1997; Tomioka et al, 2000) and may be important for establishing 
macrophage-lymphocyte interactions in a pro-inflammatory environment during infection 
(Ulett et al, 1998). TNFa was also produced by Gr-1+ neutrophils in response to B. mallei 
suggesting that TNFa may be involved in Gr-l-mediated immunity to B. mallei infection. 
In the absence of TNFa, abscesses developed several days early during B. mallei infection 
suggesting that TNFa played a role in the control of abscess formation. TNFa mRNA 
expression and macrophage CD54 expression were elevated 7 days p. i., possibly at a time 
when the process of abscess formation was beginning. CD54 and TNFa expression was 
also associated with abscessed spleens in the later stages of infection. TNFa and CD54 
have been implicated in the development of abscesses in other bacterial infections (Gibson 
III et al, 1998) and maybe involved in the development or propagation of abscesses during 
B. mallei infection. 
Macrophage activation is important in immunity to intracellular pathogens. Macrophages 
are stimulated by type 1 cytokines secreted following the interaction of pathogens with NK 
cells and T cells. Macrophage activation during early B. mallei infection suggested that 
IFN-y may mediate its protective effects in part by activating macrophage responses. IFN-y 
is a potent macrophage activator that can specifically initiate gene expression of MHCII by 
signalling via the IFN-y receptor on the macrophage surface (Schroder et al, 2004). High 
levels of MHCII expression on macrophages observed 24h p. i. corresponded with a peak in 
splenic and serum IFN-y production. This suggests that IFN-y can induce macrophages to 
initiate bacterial killing mechanisms for intracellular bacteria including the induction of IL- 
12 (Yoshida et al, 1994) and nitric oxide production (Dalton et al, 1993). The high levels 
of MHCII expression also suggests that macrophages are presenting antigen to T cells and 
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are thus involved in the development of adaptive immune responses. In addition to 
IFN-y, 
increases in GM-CSF expression also coincided with increased macrophage activation 24h 
p. i.. GM-CSF is an effective macrophage activator and controls infection with T. cruzi 
(Reed et al, 1987) and P. Carinii (Paine III et al, 2000) suggesting it may have a similar 
role in macrophage activation during B. mallei infection. Macrophages also migrated to the 
spleen within the first 24h p. i. coinciding with elevated serum levels of the macrophage 
chemoattractant, MCP-1 (Lu et al, 1998), suggesting that this chemokine is involved in 
macrophage migration during B. mallei infection. Macrophages, therefore, are implicated 
in both pathogen killing and development of antigen-specific responses during B. mallei 
infection. The development of antigen-specific responses in a milieu of type 1 cytokines 
(IFN-y, IL-27, IL-12 and IL-18) suggests that T cell mediated immunity is likely to be 
driven by ThI and Tcl subsets. 
NK cells are important in the development of type 1 immune responses by secreting IFN-y 
in the innate response to infection. This allows activation of macrophages and the 
development of type 1T cell subsets. The main cellular sources of IFN-y in response to B. 
mallei in vitro were NK cells. Although it was not possible to study the role of NK cells in 
vivo during B. mallei infection, they are likely to be important in the development of cell- 
mediated immune responses to B. mallei. Differentiated T cell subsets are also able to 
secrete IFN-7 during innate responses and contributed to the IFN-y response in vitro in a 
non-specific fashion. However, removal of T cells during innate responses to B. mallei 
infection did not affect survival. This suggests that CD4+ and CD8+ T cell subsets were not 
required for the essential, innate IFN-y response observed in vivo during B. mallei 
infection. A similar scenario has been found to exist for B. pseudomallei infection where in 
vitro data suggested a requirement for T cells (and NK cells) in innate IFN-y production. 
However, in vivo studies suggested that this requirement was dispensable and may be due 
to compensatory IFN-y production by other cell types including macrophages (Haque et al, 
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2005). The contribution of CD4-CD8- T cell subsets, remaining following depletion by 
CD4 and CD8 antibodies, requires further investigation. These cells potentially include 
yET cells which have been found in vitro to produce IFN-y in response to B. mallei and 
may be important in innate immune responses to infection. 
Neutrophils are important in innate immunity to pathogens including B. pseudomallei 
(Easton & Bancroft, 2005). Neutrophils became activated early in B. mallei infection, 
migrated into the spleen and were the major Gr-1+ population depleted following anti-Gr-1 
treatment. Therefore, it is likely that they played a major role in protection in early 
immunity to B. mallei infection. It is possible that neutrophils were involved in protection 
as sources of IFN-y, the IFN-y inducing cytokines IL-12 and IL-18 or TNFa and, therefore, 
were important in contributing to the development of type I immunity during B. mallei 
infection. The effect of neutrophils in Gr-1 mediated immunity may have been 
complimented by the production of IL-12 by Gr-1+ macrophages and pDCs. However, Gr- 
1+ T cells and NK cells did not contribute to Gr-l-mediated immunity as T cells were not 
responsible for early protection against B. mallei infection and NK cells did not express 
Gr-l. 
8.3 Downregulation of immune responses: Day 3 p. i. 
The strong immune responses elicited by the host 24 h p. i. represented a peak in cytokine 
responses and the end of an initial peak in neutrophil and macrophage activation. A notable 
decrease in the immune response occurred 3 days p. i. which did not result from decreased 
bacterial numbers reducing stimulation of immune responses. A reduction in IFN-y (and 
other type 1 cytokines), essential for controlling early B. mallei infection, was observed. 
220 
Macrophage and neutrophil activation was also diminished and was associated with 
reduced expression of cytokines involved in their activation (IL-1 P and GM-CSF). 
Phagocytic cells such as macrophages and neutrophils are vital in protection against 
intracellular infections, however, some bacteria including B. pseudomallei have evolved 
mechanisms to modulate host immune responses to allow them to survive and multiply 
within these cells (Pruksachartvuthi et al, 1990). CD1lb upregulated on neutrophils and 
macrophages during the first 24h p. i. may provide an entry route for complement-fixed B. 
mallei into host cells to allow it to survive and replicate intracellularly (Egan & Gordon, 
1996; Clemens et al, 2005). The capsule of B. mallei is a known virulence factor 
(DeShazer et al, 2001) and although its mechanism of interference with host immune 
responses is unknown, the capsular protein from another pathogen, B. fragilis, impairs 
phagocytic killing and bacterial clearance during infection (Onderdonk et al, 1990). B. 
mallei also expresses a type III secretion system which may contribute to its pathogenicity 
(Ulrich & DeShazer, 2004). This type III secretion system is also a virulence determinant 
of B. pseudomallei and acts in vitro by allowing replication of the bacterium within 
macrophages (Stevens et al, 2002). B. pseudomallei is also able to multiply within resting 
or unactivated macrophages, in the absence of IFN-y (Utaisincharoen et al, 2001). The 
increased presence of unactivated macrophages and the lack of macrophage activating 
cytokines (IFN-y and GM-CSF) 3 days p. i., may allow intracellular B. mallei to replicate 
thus shielding the infection from host immune responses. 
Bacteria can also affect host immunity by interfering with cytokine responses. During M. 
tuberculosis infection, IL-6 is able to downregulate protective immune responses to allow 
pathogen survival. IL-6 acts on macrophages to reduce their responsiveness to IFN-y, 
causing down regulation of MHCII expression on macrophages (Nagabhushanam et al, 
2003). The high levels of IL-6 observed 24 h p. i. and the decrease in MHCII expression 
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observed 72 h p. i. implicate this cytokine in the downregulation of B. mallei-induced 
immune responses. IL-10 is an anti-inflammatory cytokine that acts as a negative regulator 
of the inflammatory response by instigating processes required for down-regulating 
proinflammatory responses (Weissman, 2001). IL-10 is able to down-regulate the 
expression of GM-CSF (Lenhoff et al, 1998). Correlation of its expression with bacterial 
colonisation of the spleen and upregulated expression during Immune Analysis 1, implicate 
IL-10 in suppressing GM-CSF and IFN-y expression during B. mallei infection. 
8.4 The intermediate phase of infection: Days 5-14 p. i. 
B. mallei infection was controlled by the immune response over the first 7 days of 
infection, however, by day 14 p. i. high bacterial loads were observed in the spleens of 
infected mice suggesting that host immunity was compromised. Host immune responses 
appeared to enter a new phase 5-7 days p. i. with increased macrophage and neutrophil 
numbers accompanied by renewed macrophage and neutrophil activation, in contrast to the 
downregulation observed 3 days p. i.. This suggests that the interaction between the host 
and the pathogen changed during this period. B. mallei was potentially taken up into, and 
replicated in, host cells over the first 5 days p. i., as occurs in B. pseudomallei infection. 
The potential release of intracellular B. mallei from host cells may cause the increase in 
macrophage and neutrophil activation observed 5-7 days p. i.. The absence of serum MCP- 
1 also suggests that increasing splenic macrophage numbers may be a result of local 
proliferation within the spleen rather than continuing migration. Other systemic cytokine 
responses from day 3 p. i. were also absent suggesting that the infection is contained, and 
that cytokine responses are compartmentalised, within the tissues. 
It is likely that antigen-specific T cell responses are also developing at this stage of 
infection. Increased expression of macrophage CD54 and MHCII, both involved in 
interactions with effector or naive T cells during antigen presentation, suggests that 
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antigen-specific immune responses are being propagated. However, the potential 
destruction of the white pulp in the spleen observed during previous analyses of 
intraperitoneal infection in BALB/c mice (Fritz et al, 1999) may be responsible for the 
decrease in T cell and B cell numbers observed 5-7 days p. i.. This has obvious implications 
for the development of protective adaptive immune responses and may be crucial in the 
breakdown of immunity to B. mallei infection within the spleen. 
The pathogenesis of disease between 7 and 14 days is unknown; however, interactions 
between the immune response and bacteria during this time period appear to be essential 
for determining the course of infection. During this period, bacterial numbers grow 
uncontrollably within the spleens of infected mice, abscesses form and death ensues or 
mice are able to apparently able to clear the infection. Although infection could not be 
detected in these spleens, it is possible that latent infection exists with very low numbers of 
bacteria surviving. However, the immune mechanisms for this divergence in control of 
infection are as yet unknown. 
8.5 The chronic phase of infection: Days 14-36 
In diseases with certain intracellular pathogens, including B. pseudomallei and M. 
tuberculosis, the early immune response may not be adequate to clear the initial infection. 
The disease progresses into a chronic phase, where the infection is contained within the 
tissues and may eventually overcome the host or remain latent for many years prior to 
reactivation. During M. tuberculosis infection, granulomas form in the tissues which 
contain the bacteria, thus preventing the spread of infection systemically (Saunders & 
Cooper, 2000b). In other infections with pathogens including B. pseudomallei (Leakey et 
al, 1998) and anaerobic bacteria (Finlay-Jones et al, 1999), abscesses form which contain 
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bacteria in localised areas during infection. During B. mallei infection, abscesses formed in 
the tissues. In addition to confining infection, abscesses appeared to provide a 
microenvironment for bacterial growth, as bacterial numbers were very high in abscessed 
spleens. The persistence of high bacterial loads within the spleen (and probably other 
organs) means that the host could become overwhelmed with the infection leading to 
bacteria `leaking' from abscesses to cause a systemic and ultimately fatal infection. This 
may explain why mice survive for several weeks following the development of large 
abscesses before developing a fatal systemic illness. 
Active inflammatory responses occurred both in the spleen and systemically during this 
phase of infection and were related to bacterial colonisation of the spleen. Splenic 
expression of proinflammatory cytokines, including TNFa and IL-6, and neutrophil and T 
cell activation were related to abscess formation from days 14 - 28. TNFa and T cells were 
important in controlling B. mallei infection following the formation of abscesses although 
this was not effective in preventing high bacterial loads or eventual lethality of infection. 
The importance of T cells in adaptive immune mechanisms during this phase of infection 
suggest they may be involved in killing infected host cells or producing IFN-y to try and 
maintain control of the infection. This demonstrates that although B. mallei is able to 
override host immune responses, some immune mechanisms still exist which are able to 
delay lethality for several weeks. 
Systemic production of IL-6 and MCP-1, only in abscessed animals, suggested the release 
of mediators from infected tissues. IL-6 is one of the main activators of acute phase 
responses in the liver causing release of acute phase proteins (Kopf et al, 1994) which are 
involved in fever and sickness behaviour (van der Poll & van Deventer, 1999). This 
corresponds with the ruffling that was observed in some animals at day 14 and all animals 
from day 21 onwards suggesting that IL-6 may be responsible for overt symptoms of 
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sickness observed in these animals. Serum levels of IL-6 have also been shown to be a 
good predictor of severe bacterial infection in human patients (Groenveld et al, 2001) 
suggesting that IL-6 serum levels may also be related to the severity of B. mallei infection. 
IL-6 may also be involved in the induction of MCP-1 observed (Bohn et al, 1998). The 
presence of MCP-1 in the blood suggests that monocytes are still being recruited into sites 
of infection possibly in an attempt to control bacterial replication in abscessed spleens. The 
systemic release of these mediators appears to be implicated in instigating development of 
systemic inflammatory responses which may eventually lead to uncontrolled inflammation 
or sepsis causing death of the host. 
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8.6 Conclusions 
The protective immune responses identified during early B. mallei infection suggest that 
type 1 immunity is essential for protection against infection as summarised in Figure 8.2. 
Following intraperitoneal infection, B. mallei enters the spleen and interacts with 
neutrophils and macrophages leading to their activation. Induction of cytokine expression, 
principally IFN-y, IL-6 and IL-27, occurs and MCP-1 is released to further propagate 
macrophage responses. IFN-? is fundamental for survival against B. mallei infection, 
possibly by activating macrophages to kill intracellular B. mallei bacilli. Gr-l+ cells, 
predominantly neutrophils, are also involved in protective B. mallei immunity and the 
induction of IFN-y and TNFa responses. These cells potentially mediate their protective 
effects by producing the type 1 cytokine IL-12 essential for IFN-y production by T and NK 
cells, in conjunction with IL-18. TNFa, is involved in controlling bacterial replication, 
possibly by activating neutrophil and macrophage responses, and containing the infection 
within abscesses. IL-27 is also implicated in the development of type I immunity by 
potentially upregulating CD54 expression on T cells. T cells are important in adaptive 
immune responses and may exert their effects by killing infected host cells or maintaining 
type 1 immune responses by producing IFN-y. 
The requirement of IFN-y for innate survival of B. mallei infection suggests that any 
potential vaccine or immunomodulatory therapy should preferentially stimulate type 1 cell- 
mediated immune responses. By maintaining the type 1 cell-mediated immune responses 
initially instigated, and then downregulated during natural infection, the immune system 
may be modulated to overcome B. mallei infection. Immunomodulation of innate 
responses may be mediated by bacterial components or cytokines including synthetic 
bacterial DNA sequences (CpGs) or treatment with exogenous IFN-y. CpGs have been 
used effectively during B. pseudomallei infection in vivo (Wongratanacheewin et al, 2004). 
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Preliminary studies with B. mallei have also shown that some CpGs are able to provide 
protection against B. mallei infection (Lukaszewski, 2004) by upregulating macrophage 
and neutrophil responses (data not shown). 
In conclusion, the work presented in this thesis provides valuable information on host 
immune responses to B. mallei infection that contributes to the field of immunity to 
intracellular pathogens. The immune response to B. mallei shows many similarities with 
that of other intracellular pathogens including its close relative B. pseudomallei. The 
similarities in immunity to infection with these two pathogens may lead to the 
development of a vaccine and/or an immunomodulatory therapy that targets type 1 
responses and is able to treat both B. mallei and B. pseudomallei infection. 
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